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SUMMARY
The work reported in this thesis deals with mathematical 
model studies on the optimal scheduling of treatment of 
systemic malignant disease by radiation. To provide the 
necessary background to the original aspects of the work 
reviews of several fields are required. Chapter 1 is a 
general review of normal tissue radiobiology. Chapter 2 is 
a review of human tumour radiobiology. Chapter 3 focusses 
on one particular isoeffect model, the linear-quadratic or 
LQ model, which is employed throughout this thesis to 
describe the effects of radiation on normal tissues. These 
basic radiobiological principles are applied to the 
clinical modalities of total body irradiation ( TBI ) and 
biologically targeted radiotherapy ( BTR ). Chapter 4 
reviews the principles of TBI. Chapter 5 is a review of 
published data on the in-vitro radiosensitivities of human 
leukaemia/lymphoma and neuroblastoma, two conditions which 
require a systemic approach to treatment. Chapter 8 is a 
review of the principles of BTR.
The original work is contained in the appendix to chapter 
3, which examines the correspondence between the LQ model 
and CRE models for continuous radiation exposures with 
constant and exponentially decaying dose-rates; chapter 6, 
Which examines the question of whether fractionated or low 
dose-rate TBI is the superior method of treatment; chapter 
7, where the optimal scheduling of fractionated TBI is 
investigated; chapter 9, where the LQ isoeffect model and 
a dosimetric approach is used for the evaluation of
alternative therapeutic strategies for the treatment of 
widespread micrornetastatic disease by BTR. Finally, in 
chapter 10 a simple model is used to investigate optimal 
scheduling of BTR, TBI and marrow rescue.
CONCLUSIONS
1/ Comparison of the LQ model and the CRE model for 
continuous radiation exposures: for constant dose-rates it 
is found that, when late-effect parameter values are used 
in the LQ model, there is a correspondence between the 
models' predictions. There is no correspondence between 
models when acute-effect parameter values are used in the 
LQ model. In the case of exponentially decaying dose-rates 
the predictions of the CRE and LQ models appear more 
divergent, although again the use of late rather than 
acute-effect parameter values in the LQ model gives a 
closer match to the CRE.
2/ Fractionated TBI is predicted to be preferable to low 
dose-rate TBI treatment. Although theoretically the 
methods can be equivalent, low dose-rate treatments would 
have to be over impractically long treatment times.
3/ In the case of external beam TBI, fractionated low 
dose-rate treatments do not appear to offer a significant 
improvement over fractionated high dose-rate treatments. 
This is because in order to achieve a significant increase 
in dose or reduction in toxicity impractically long 
exposure times are required. It is expected that this 
finding will be true in general for external beam 
radiotherapy, not just in the case of TBI.
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4/ Optimal fractionation schedules for the treatment of 
leukaemia/lymphoma and neuroblastoma by TBI are predicted 
to be accelerated and hyperfractionated. It is suggested 
that a two fraction per day schedule of 10 fractions of 
1.3-1.5 Gy is a suitable candidate for clinical 
evaluation.
5/ It is concluded that knowledge of ratios for
tumours and normal tissues is, by itself, insufficient 
information to enable prediction of optimal schedules.
6/ In the case of BTR, dose-rate effects are predicted to 
be important for late-responding tissues. Tolerance doses 
may be greater or less than those for fractionated 
radiotherapy depending on the effective radionuclide 
half-life.
7/ When injected activities of targeted radionuclide are 
restricted by haemopoietic tolerance, curative therapy is 
unlikely. 131-1 appears to be a better radionuclide 
warhead for therapy of micrometastases than 90-Y.
8/ The use of bone marrow rescue in conjunction with BTR 
seems to offer curative potential, however reasons are 
presented why a combined strategy using BTR, TBI and 
marrow rescue is likely to be preferable.
9/ For optimal scheduling of BTR, TBI and marrow rescue, 
the main characteristics of BTR which determine curative 
potential are its specificity and sensitivity. Specificity 
is defined here as the ratio of initial dose-rate at the 
tumour cells to that in the dose-limiting tissue. 
Sensitivity is inversely related to the proportion of
10
tumour cells which escape targeting. Where biological 
targeting is highly specific but some tumour cells escape, 
a phenomenon of "overkill" will largely determine the 
optimal schedules. It is predicted that these are likely 
to consist of combinations of BTR and external beam TBI 
with the TBI component being the greatest in terms of 
radiation dose to the whole body.
11
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1.0 NORMAL TISSUE RADIOBIOLOGY
The major object of radiotherapy is to sterilize tumour 
cells. In general, greater radiation doses produce greater 
levels of tumour cell sterilization. In principle, any 
tumour of any size can be sterilized if a high enough dose 
is given. However, it is not possible to irradiate tumour 
cells without, simultaneously, irradiating non-tumour 
normal tissues and it is the capacity of these to 
withstand radiation insult which provides the limitation 
on the dose which can be given. Limiting doses are 
dependent on the types and proportions of normal tissues 
and organs irradiated. Most radiotherapeutic practice is 
based on the principle of "treat to tolerance" i.e. give 
as much dose as the relevant normal tissues can be 
expected to tolerate. As the probability of tumour cure is 
dependent on dose, the knowledge of allowable doses to 
normal organs and how these change as the parameters of 
the radioth-Jire.peutic technique changes is of vital 
importance. This chapter consists of a brief description 
of isoeffect models, a historical overview of how they 
have developed and an account of the relevant underlying 
biological processes involved.
1.1 ISOEFFECT MODELS IN CLINICAL RADIOBIOLOGY
An isoeffect model is basically a method of predicting how 
the parameters of a radiotherapy schedule influence the 
dose of radiation which brings about a specific biological 
endpoint. This may be a certain level of functional 
impairment of an organ or tissue, alternatively it may be
13
a probability of survival of a whole animal or patient. 
Isoeffect relationships are arrived at by, in effect, 
specifying a number of dose schedules which are all judged 
to be "biologically equivalent". They may exist in the 
form of graphs or nomograms, as simple or complex 
mathematical formulae and as the intuition, based on 
clinical experience, of a radiotherapist. Some data upon 
which isoeffect relationships are based are derived from 
clinical practice and usually involve the ranking of 
radiation effects on some semi-quantitative scale of 
damage. The work of Turesson and Notter( 1988 ) on the
acute and late effects on skin of radiotherapy for breast 
cancer is a particularly good example of this. Information 
may also be accumulated through studies of organ function 
( Depledge et al, 1983 ), radiographic examination ( Mah 
et al, 1987 ) and mortality ( Fryer et al, 1978 ) Animal
experiments provide an additional source of data which is 
becoming more important as information about individual 
organs is required. These in-vivo assays may be on a 
semi-quantitative scale similar to the clinical case ( 
Fowler et ; al, 1965; Turesson and Notter, 1979 (a) ) but 
other methods are also available such as LD50 assays (
Lehnart and Rybka, 1985; Cardoso et al, 1985; Vegnesa et
al, 1985 ) colony counting assays ( Withers and Elkind, 
1970; Huczowski and Trott, 1987 ) and assays of organ
function ( Travis et al, 1979; Williams and Denekamp,
1983; Stewart et al, 1984 & 1987 ).
From the earliest days of radiation biology it has been 
recognised that radiation effects on biological systems
14
are highly dependent on the pattern of exposure. For
example in any one particular tissue or organ using
several small radiation doses enables a larger total dose 
to be given for an equivalent observed biological effect 
compared to one single big dose. Alternatively if the same
total dose is given in small fractions the biological
effect will be less. Another important consequence of the 
pattern of radiation exposure from the point of view of
cancer therapy is the dissociation of responses in 
different tissues or organs, each having their own
individual behaviour, when the pattern of radiation
exposure changes. The earliest reference to this 
phenomenon is in the work of Regaud ( 1922 ) on the
sterilization of the testes of rats by radiation. In order 
to effect sterilization with a single dose, significant
damage was caused to the surrounding skin. When 
fractionated radiation was used, sterilization could be 
accomplished without the same degree of skin damage. This 
experiment demonstrated that the relative sensitivities of 
two tissues were not invariant but could be changed by 
manipulating the treatment structure. The dissociation of 
radiation effects in tissues composed of different cell 
populations provides the ultimate raison d'etre of 
isoeffect models i.e. their use in the attempt to increase 
the therapeutic ratio between damage to tumours and damage 
to normal organs and tissues. The subject of radiation 
effects on neoplastic cells is considered in the next 
chapter. This chapter will deal with the development of 
mathematical descriptions of isoeffect relationships for
normal tissues.
Radiation therapy can be given in one of two ways :
1/ In the form of multiple high dose-rate exposures e.g. 
external beam fractionated treatment.
2/ As a single continuous treatment at a low doserate e.g. 
interstitial implant of radioactive sources 
If one had to specify what qualities an "ideal" isoeffect 
model should have then one important feature would be 
applicability to both of the above situations. Another 
would be the ability to express any differences between
different biological systems. Yet another would be to
account specifically for every variable of importance. At 
present there is no isoeffect model which embodies this 
combination of properties; some come closer than others
however. The next section deals with the history of 
isoeffect models in which can be seen the development of 
successively closer approaches to the ideal.
1.2 HISTORICAL DEVELOPMENT OF ISOEFFECT MODELS
The first -isoeffect rule for fractionated radiotherapy, 
the "cube root law" was purely empirical and stated that 
the total dose for a given biological effect should be 
proportional to the cube root of the number of fractions, 
i.e.
D - k A/ 75 0 - 0
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This meant that if it were desired to change a 
fractionation schedule of total dose Dj given in N4 
fractions to a "biologically equivalent" schedule 
consisting of fractions, the new total dose was given
Strandqvist in 1944 published a curve of isoeffective 
total dose versus duration of treatment based on many 
years’ experience in the treatment of carcinoma of the 
skin and lip. By finding the curve which most effectively 
divided patients into cures and failures he found a 
relationship.
When expressed on a log-log plot this relationship was 
represented by a straight line. This method of expressing 
total dose for a tissue isoeffect became known as a 
Strandqvist plot. Alternatively total dose may be plotted 
against fraction number in a Fowler-Stern plot (Fowler and 
Stern, 1963).
The next development in the history of isoeffect models 
was due to Ellis and co-workers in the late 1960’s ( 
Ellis, 1969; Winston et al, 1969 ). Ellis reasoned from 
consideration of isoeffect curves for skin tolerance, 
erythema and squamous carcinoma cure that the effects of 
fraction size and overall time could be separated. This 
led to the concept of nominal standard dose, NSD. NSD and 
its derivatives proved to be very influential in the 
historical development of radiotherapy. It is instructive 
to examine the assumptions underlying this approach.
by
p.
Briefly, Ellis’s reasoning went as follows : the main 
factor in the healing of skin epithelium is the condition 
of the underlying connective tissue. By and large, 
connective tissue is similar throughout the body including 
the vicinity of tumours. Both cutaneous tolerance and 
erythema have the same slope on a Strandqvist plot, i.e. 
0.33, suggesting that the same mechanisms are responsible 
for the expression of and recovery from radiation damage. 
As squamous carcinoma is not subject to homeostatic 
control of growth the radiation effect depends only on 
fractionation and not on temporal factors. The slope of 
the isoeffect curve for cure of squamous carcinoma is 
0.22. Therefore the effects of time can be represented by 
the difference between the slopes, i.e. 0.11. As the 
i;adiotherapeutic schedules represented by the curves used 
5 fractions per week, the regression coefficient with 
respect to number of fractions was modified to become 
0.24. This was summarised in the equation
the parameter NSD representing connective tissue 
tolerance. For schedules which did not result in 
tolerance, the concept of partial tolerance (PT) was 
introduced.
where N was the number of fractions of a specified dose 
and frequency which produced tolerance and n was the 
actual number of fractions in the schedule. Regimes 
consisting of a series of sub-tolerance schedules could be 
represented by a PT value which was the sum of the partial
PT
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tolerances of the schedules.
p r  r prk + F tx + •••• 6-t>
In retrospect Ellis's reasoning1 was flawed. He was not
justified in assuming that fractionation had the same 
effect on normal connective tissue and tumour. Another 
conceivable interpretation would be that the slope of 
connective tissue tolerance was entirely due to
fractionation with effectively no time dependence whilst
that for tumour cure was composed of a small fractionation 
effect and also a factor due to time. The alternative 
interpretation is what would be expected for a normal 
tissue having a slow turnover time and a proliferating 
tumour cell population. The problem was further 
complicated by the fact that epithelial tissue ( Potten, 
1986 ) and vascular endothelium ( Withers et al, 1980 ),
which are both important in the context of tolerance, 
represent distinct cell populations. Whilst separation of 
the fractionation and time components may have led to 
negligible clinical consequences for epithelial tissue
this was not so for the critical cells of the vascular 
endothelium. Needless to say, this was not evident at the 
time.
The NSD formula gave rise to the derivatives of cumulative 
radiation effect, CRE, and time, dose and fractionation 
factors, TDF. As the fractionated versions of these 
models are based on the original Ellis equation, and 
thereby the same biological reasoning, they suffer from 
the same flaws. The CRE model for fractionated
radiotherapy ( Kirk et al, 1971 ) used the regression
19
factors of Ellis for normal connective tissue to establish 
a scale of radiation damage. Kirk et al reasoned that 
Ellis's NSD parameter defined a particular value of a more 
general function which, as it took on different values, 
corresponded to different levels of sub-tolerance 
radiation damage
The CRE value at tolerance was equal to the NSD parameter. 
In the CRE approach, instead of having an analogue of 
partial tolerance, schedules which did not result in 
tolerance were represented by values of the CRE function. 
The overall effect of a series of sub-tolerance schedules 
was found by applying equivalence conditions at the 
junctions between schedules. In a series of papers the CRE 
concept was extended to describe continuous radiation 
therapy with long-lived ( Kirk et al,• 1972 ) and
short-lived radionuclides ( Kirk et al, 1973 ), volume 
effects ( Kirk et al , 1975(a) ) and the consequences of 
gaps in treatment ( Kirk et al, 1975(b) ).
Although the same name was used for both the fractionated 
and continuous isoeffect models, the clinical databases 
and mathematical interpretations were totally different. 
In the continuous case the clinically derived isoeffective 
dose curves of Paterson and Green ( referred to by Kirk et 
al, 1972 ) for radium treatments were used. Kirk et al 
reasoned that the CRE for continuous radiation at a 
constant dose-rate could be expressed as
F
c
where D was the total dose given in time T
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r was the dose-rate ( = D/T )
q was a factor accounting for differences in the relative
biological effectiveness (RBE) of different radiations
and k was a normalising constant which was required to
ensure that the same value of CRE described the same level
of biological effect for both continuous and fractionated
o>*C
radiation. The value of k was estimated to be 0.53 (day) 
from comparisons of fractionated and continuous 
treatments which were said to achieve tolerance.
The extension of the CRE to continuous radiation had a
dual purpose, firstly to compare continuous radiation 
treatment at differing dose-rates and secondly to relate 
fractionated treatments at high dose-rate to continuous
treatment at low dose-rate. In the first of these
applications the continuous CRE formula was successful, 
not surprisingly as it was simply the expression in 
mathematical terms of a clinically observed isoeffect 
relationship uncomplicated by attempts to separate the 
effects of time and dose-rate, in contrast to the case of 
the fractionated CRE. The application of the CRE formulae 
to comparisons between fractionated and continuous 
radiation was less successful ( Liversage, 1980 ). It is
tempting to suggest that the whole idea of relating the 
fractionated to the continuous CRE was flawed due to the 
different biological databases used. An alternative method 
of extending the NSD concept to sub-tolerance radiotherapy 
schedules was provided by the time, dose and fractionation 
factor ( TDF ) approach ( Orton and Ellis, 1973 ). This
procedure enables the effects of sub-tolerance schedules
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to be added, and had practical advantages over the NSD and 
PT approach. TDF was extended to continuous radiation with 
the aid of Patersons data on isoeffective doses for 
different radium dose-rates ( Orton, 1974 ). The
oontinuous versions of the CRE and TDF are thus, to all 
intents and purposes, identical. The inadequacies of the 
Ellis equation and its derivatives have been exposed by 
accumulating clinical evidence and animal studies 
(Arcangeli et al, 1974; Bates and Peters, 1975; Singh,
1978; Berry et al, 1974; Turesson and Notter, 1979(b); 
Overgaard et al, 1987 ). The biological basis of the
failure of NSD is well established. It is a direct
consequence of the dissociation of radiation responses in 
different tissues and organs. The general concept of
normal connective tissue tolerance appears to be no longer 
a useful one and tissues and organs require to be studied 
on an individual basis. There have been a variety of
attempts to modify the basic N/T exponent equation of
Ellis for use with specific tissues like lung ( Wara et
al, 1973 ) and brain ( Pezner and Archambeau, 1981 ). This 
may be done by changing the exponents for individual 
tissues. For example, increasing the exponent of N and 
decreasing that for T will describe a tissue with a
greater fraction size dependence and a lesser dependence 
on time. An alternative method of modifying the Ellis 
equation has been used by Turesson and Notter ( 1979 ).
This approach involves the use of fraction size dependent 
correction factors evaluated through experiments on
delayed radiation effects in pigs' skin. Even with these
attempts to extend the usefulness of the Ellis equation it 
is difficult to avoid the conclusion that the stage of its 
clinical relevance is over. It is perhaps unfortunate that 
the fractionated and continuous isoeffect formulae are 
described by the same name and thus tend to be condemned 
together. There is no evidence which casts doubt on the 
continuous versions of the CRE and TDF and these empirical 
relationships appear to be as valid now as they were when 
proposed.
Computer based isoeffect models have been described by 
Cohen ( Cohen and Creditor, 1983(a); Cohen and Creditor, 
1983(b); Cohen, 1987 ). These are based on the multitarget 
two component (TC) or linear^quadratic cell survival 
curves ( see next chapter) and estimates of parameters 
such as cell cycle time and the maximum number of 
compensatory cell doublings allowed. Cohen has derived 
parameter values by computer-aided statistical analyses of 
clinical data and has produced isoeffective dose curves 
for different organs with various fractionation patterns. 
Cohen’s work represents the most developed form of 
isoeffect model for normal tissues. However, it suffers 
from the disadvantages of being not easily accessible and 
inconvenient to apply in a clinical setting. The years 
since 1982 have seen the rapidly increasing application of 
the linear quadratic or LQ equation which is now the 
normal tissue isoeffect formalism most widespread in use. 
The LQ model will be employed throughout this thesis and 
is described in detail in chapter 3.
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1.3 BIOLOGY OF RADIATION DAMAGE TO NORMAL TISSUES
Although individual normal tissues probably have 
individual radiobiological properties, it has been found 
useful to classify them into two general types, acute 
responders and late responders ( Thames et al, 1982; 
Fowler, 1984). Barendsen ( 1982 ) has suggested that three 
distinct classes may usefully be identified, however here 
only two groups will be considered :
1/ Acute or early responders where the time required for 
the expression of radiation damage can be measured in days 
or weeks
2/ Late responders in which the time to expression of 
radiation damage is a matter of months or even years. 
Haemopoietic tissues and intestinal, skin and testicular 
epithelium ware all acute responders. In general these cell 
lines have a dependence on fraction size, and by 
implication a capacity to repair radiation damage, which 
is less than that of late responding tissues. However, 
there are . also variations within the acute responding 
category, as indeed there are within the late responding 
category, e.g. the fraction size dependence of skin 
epithelium appears to be greater than that of the 
haemopoietic system. Conventionally changes occurring two 
to three months or longer after the end of radiation 
therapy are considered as "late effects". However, there 
is no general "late effect" syndrome. It has been 
suggested ( e.g. Duncan and Nias, 1977; Hopewell et al, 
1986 ) that the vascular system may be the main target, 
damage to which would result in late radiation effects. In
24
contrast, the following three arguments have been cited 
against the origin of late effects being due to vascular 
damage and instead being directly attributable to 
depletion of parenchymal cells ( Withers et al, 1980 ) :
1/ The doses which may be given safely to different organs 
( i.e. tolerance doses) are different.
2/ Different radiations vary in their RBE values from one 
organ to another.
3/ The times required for the expression of functional 
impairment are different.
Kidney, spinal cord, lung and vascular endothelium are all 
late responding organs.
The time required for the manifestation of radiation 
damage is dependent on the kinetics of tissue renewal and 
the organisational structure of the tissue. Acute 
responders, such as intestinal epithelium and haemopoietic 
tissues, have what has been described as a "hierarchical" 
or H-type organisation ( Michalowski, 1981 ), meaning a
relatively small compartment of clonogenic but 
functionally incompetent stem cells feeding into a 
maturing compartment with limited proliferative ability 
and also a limited functional capacity, finally feeding a 
fully functional compartment with no ability for division 
and from which cells are lost through "wear and tear" or 
programmed ageing. The functional lifetime of a cell in an 
acute responding tissue is dependent on type but may 
typically be from days to weeks. The transit time from 
stem cell to functional cell is typically a few days. 
Radiation damage is also carried through the different
25
compartments. Initially stem cells are sterilized but the 
damage is not seen till functional cells are lost in the 
normal way without being replaced. The behaviour of acute 
responding tissues following radiation insult is 
characterized by a progressive diminution of functional 
cell number followed, after a time lag, by compensatory 
accelerated proliferation. This would mean, from the 
perspective of an isoeffect model, that the time during 
which radiation exposure takes place is irrelevant when it 
is less than the delay period and of great importance when 
it is longer. It therefore implies that the sort of time 
function used in the Ellis equation cannot be correct, as 
this has most effect for short times. However taking 
account of the. time factor in acute tissue isoeffect 
models is not a simple process ( Wheldon and Amin, 1988 ) 
and remains an unsolved problem to the present day.
Late reponding organs, such as kidney, liver and nervous 
tissue, do not have the same kinetic structure as the 
acutely reacting tissues, but instead appear to consist of 
a population of stable, functionally competent cells. 
Replacement of functional cells lost through "wear and 
tear" processes may be achieved by division and 
differentiation of stem cells or by division of 
functionally competent cells. In normal circumstances 
cells are not noticeably involved in proliferation and the 
existence of a separate compartment of clonogenic stem 
cells is not established. Isoeffect curves of total dose 
versus dose per fraction are steeper for late responses 
than for acute reactions. It has been suggested ( Thames
et al, 1982 ) that this is a consequence of an intrinsic 
difference in the shapes of the clonogenic survival curves 
of the target cells responsible for these effects ( i.e. 
the intrinsic radiosensitivities ) and the delayed 
response of these organs to radiation insult simply 
reflects the slow kinetics of renewal of parenchymal cells 
( Withers et al, 1980 ). On the basis of this hypothesis 
one would expect the time for development of functional 
impairment to be dose-independent.
The viewpoint that the differences in fractionation
reponse between acute and late responders are due to 
differences in the intrinsic radiosensitivities of target 
cells has been challanged by Zeman and Bedford ( 1984 ).
These authors have suggested that cell cycle 
redistribution may be a major contributory factor. The 
radiosensitivity of a cell depends on which point in the 
cell cycle it is in. For instance, cells in the mitotic or 
M phase are more sensitive to radiation than those in the 
DNA synthetic S phase. Following irradiation of a
population of cells the "survivors" ( i.e. those fully 
clonogenic ) will contain a higher proportion of cells in 
resistant phases than the original sample. However over a 
period comparable with the cell cycle time the synchrony 
of the cell population is lost due to variations in cycle 
times. A cell population actively involved in 
redistribution would be expected to display an enhanced 
radiosensitivity relative to what it would be like if 
redistribution did not occur. The effects of
redistribution would be expected to be greater in acute
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effects -target cells than late responding ones due to the 
shorter cell cycle durations of the former. Another 
hypothesis to explain the differences between acute and 
late responders has been advanced by Schultheiss et al ( 
1987 ). These authors suggest that the greater the amount 
of heterogeneity in cellular radiosensitivity parameter 
values the more apparently "flat" the response curve for 
tissue function will be. This could distinguish two 
different cell lineages even if the average 
radiosensitivity parameter values are the same. The 
apparently flatter dose-response curves for acute 
responding tissues may therefore be due to a greater 
amount of heterogeneity.
An alternative suggestion is that the late response is 
governed by the "flexible" or F-type organizational 
structure of the target cell lineage ( Michalowski, 1981 
). On the basis of this hypothesis the behaviour of a late 
responding tissue following radiation insult may be 
summariz.ed as follows Cells capable of both division 
and physiological function will die and be removed at the 
end of their lifetime. A dose-dependent proportion of the 
remaining cells will have been rendered non-viable by 
radiation. On receiving a homeostatic signal for 
compensatory proliferation these will attempt to divide in 
order to restore tissue function. In this way latent 
radiation damage may be expressed as an "avalanche" of 
abortive mitoses, driven by the increasing strength of the 
signal for cell recruitment generated in response to the 
dwindling population size. Post irradiation stimulation of
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proliferation would lead to a potentially catastrophic 
failure of mitoses. This is in contrast to an H-type 
tissue where stimulated proliferation would be beneficial. 
For a F-type tissue the behaviour of cells rendered 
incapable of full clonogenicity but with a limited
division potential will be an important factor in the 
functional dose response curve. "Doomed" cell 
proliferation of only one or two generations following 
irradiation may preserve the functional integrity of the 
tissue. There will consequently be a dissociation between 
clonogenic and functional endpoints. The functional 
dose-response curve will be "curvier" than for an H-type
tissue, even if the underlying intrinsic clonogenic
radiosensitivity of the constituent cells are the same.
For an F-type organ the time to expression of radiation 
damage will be inversely dose-dependent ( Michalowski, 
1981 ). This was illustrated by the mathematical model
study of Wheldon et al ( 1982 ). Wheldon and Michalowski ( 
1986 ) have suggested that a spectrum of proliferative 
organizations may occur in different organs from pure 
H-type to pure F-type and HF hybrids between these 
extremes. HF hybrids will also possess some of the pure 
F-type characteristics such as the "avalanche" effect and 
the dose-dependent latency of radiation damage.
Inversely dose-dependent times to functional impairment 
have been observed clinically and experimentally in 
animals ( Focht et al, 1966; Phillips and Roth, 1973; van 
der Kogel and Barendsen, 1974; Madrazo and Churg, 1976; 
White and Hornsey, 1978; Masuda et al, 1980; Schultheiss
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et al, 1984, Lebesque et al, 1986 ). However Thames et al 
( 1986 ) concluded that differences in post irradiation
proliferative behaviour could not explain the differences 
in fractionation sensitivity between acute and late 
responding tissues. Presently there is no conclusive proof 
of the correctness of any of the theories of why acute and 
late responding tissues differ in their fractional 
dose-dependence. The HF approach appears to be most 
amenable to experimental testing and conceivably this may 
be the first hypothesis to be accepted or rejected.
1..4 ACCELERATED AND HYPER-FRACTIONATION
From the perspective of isoeffect models, late responses 
have an increased dependence on the size of dose fractions 
in comparison with acute reactions, and have little 
dependence on the timescale of a radiotherapy treatment 
for all reasonable durations. Lung is, to some extent, 
exceptional in that a phenomenon called "slow repair" has 
been observed ( Field et al, 1976 ). The nature of this is 
uncertain. It appears to be different from the 
compensatory proliferation seen in acute tissues, although 
it may be a protracted form of this. In clinical practice 
late effects are generally dose-limiting. This is because 
acute effects can usually be seen developing and 
fractionation schedules modified ( e.g. by inserting a 
break in treatment) to limit them. Conversely, late 
effects are not apparent sometimes for years and their 
severity cannot be predicted by the severity of acute 
effects. With isoeffect models like the linear-quadratic ( 
see Chapter 3 ) late effects can be anticipated and
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attempts have been made to improve the therapeutic ratio 
between radiation effects on tumours and those on late 
responding normal tissues. Hyperfractionation, or using a 
schedule with a large number of small fractions enables 
higher doses to be given for the same late toxicity ( 
Douglas, 1982; Thames et al, 1983 ). It has been suggested 
that tumours have less fraction size dependence ( Williams 
et al, 1985 ) and consequently will be damaged more by 
hyperfractionation. Accelerated fractionation, or giving 
the treatment in a shorter time than conventional, has 
also been suggested as a possible way to increase the 
therapeutic ratio ( Thames et al, 1983 ). This is because 
tumour cells are expected to have short intermitotic 
intervals ( Steel, 1977; Trott and Kummermehr, 1985 ).
Shortening the treatment time may thus . enable fewer 
potential tumour doublings. These arguments are largely 
qualitative and open to criticism on the grounds that 
tumours are not all similar. In a later chapter 
information for specific normal tissues and tumour types 
is used to derive optimal fractionation schedules. Some of 
these schedules have elements of both accelerated and 
hyper-fractionation.
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2.0 HUMAN TUMOUR RADIOBIOLOGY
For the vast majority of mammalian cells the ability to 
replicate through mitotic division is the function most 
sensitive to radiation dose. This property can be 
permanently lost by otherwise apparently normal, intact 
cells which remain capable of protein synthesis. The 
ability of tumours to proliferate indefinitely, without 
reference to homeostatic control, provides one of their 
main life-threatening qualities. The aim of radiotherapy 
is to remove the ability of tumour cells to replicate i.e. 
to sterilize them. In clinical radiotherapy, it has long 
been common knowledge that different human tumours respond 
very differently to the same treatment strategy. In part, 
this could be ascribed to differences of tumour cell 
kinetics and architecture, leading to different rates of 
cell removal and hence visible tumour shrinkage ( Steel, 
1977; Stephens and Steel, 1980 ). However clinical
observation also extends to the variation which exists in 
"radiocurability” or "local controlabi1ity" ( Rubin et al, 
1974 ) irrespective of the rate of tumour shrinkage 
following treatment ( Suit et al, 1965 ); although there 
may be an inverse correlation between regression and the 
probability of recurrence ( Barkley and Fletcher, 1977 ). 
For several decades, this variable radiocurability, 
presumably reflecting differences in clonogenic cell 
survival in different tumours, has been attributed to 
mechanisms which are based on the relative radioresistance 
of hypoxic cells. A major part of applied radiobiology has 
been devoted to the search for ways of overcoming or
circumventing the "hypoxic cell problem" in radiotherapy ( 
Adams, 1973’; Duncan, 1973; Watson et al, 1978 ).
Undoubtedly, the upsurge of interest in the radiobiology 
of hypoxic cells owed much to the seminal observations of 
Gray et al ( 1953 ) and Thomlinson and Gray ( 1955 ) and 
their conclusions on the likely existence of hypoxic cells 
in human tumours. However, one component in the collective 
decisions of radiobiologists to focus on hypoxia was the 
lack of evidence for any convincing differences in the 
radiosensitivities of tumour cells in vitro ( e.g. Nias, 
1974; Weichselbaum et al, 1980 ). This perhaps made it 
seem unlikely that the variability of tumour response in 
the clinic reflected a corresponding variability in the 
"intrinsic" radiosensitivity of clonogenic cells.
In recent years, several lines of investigation have 
resulted in new evidence which justifies reconsideration 
of the extent to which variation in radiocurability might 
be ascribed to variations in the sensitivities of 
clonogenic cells in different tumour types. Fertil and 
Malaise in 1981, reviewed the available evidence on the 
intrinsic radiosensitivities of human tumour cells in 
vitro, demonstrating that the cell survival curves 
reported differed significantly from one tumour line to 
another (this being especially true of the low dose region 
of the survival curve) and that the estimated survival 
following a dose of 2 Gy correlated well with clinical 
radioresponsiveness. Recently they have confirmed and 
extended these observations ( Fertil and Malaise, 1985 ).
Deacon et al ( 1984 ) have come to the same conclusions.
33
Rofstad and B rust ad ( 1987 ) found that the
radioresponsiveness of human melanoma xenografts grown in 
nude mice was positively correlated with the initial 
slopes of the in-vitro cell survival curves. There was no 
relationship between the radioresponsiveness and any known 
growth or microenvironmental parameter. These authors 
strongly supported the suggestions of Fertil and Malaise 
and Deacon et al that the clinical radioresponsiveness may 
be positively correlated to the initial slope of the 
in-vitro cell survival curve. Studies on the radiation 
response of human tumour spheroids have likewise indicated 
suggestive correlations between clinical
radioresponsiveness and the response to fractionated 
irradiation of spheroids derived from the different tumour 
types ( Wheldon et al, 1985(a); Evans et al, 1986 ). In
addition to these investigations of "intrinsic" cellular 
radiosensitivity, Weichselbaum and co-workers have 
reported a series of studies . indicating important
differences in the capacity of human tumour cells in vitro
to undertake repair of potentially lethal damage. Here
too, the observations correlated with clinical 
radioresponsiveness ( Weichselbaum et al, 1982; 
Weichselbaum and Little 1982 (a) & (b); Guichard et al, 
1984 ).
Taken collectively, these observations suggest that at 
least some of the mechanisms responsible for variability 
of tumour response in the clinic are operative at the 
cellular level and hence may be amenable to experimental 
investigation in vitro. Conversely, in vitro studies may
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be capable of providing cellular radiosensitivity data 
which are applicable to clinical treatment. The work
described in a later chapter on the subject of optimal
scheduling proceeds on the assumption that this is the
case. It follows that in vitro radiation survival curves
of human tumour cells are the basic data required. In 
order to approach this subject in a scientific way it is' 
essential to have a method or methods of quantitating the' 
effects of radiation on living cells.
The ability of cells to proliferate indefinitely can only 
presently be assessed by observing whether or not they do 
so when placed in a permissive environment. Experimental 
data generally consists of paired information, given dose 
and the associated proportion of "surviving" cells. Here 
survival has the restricted meaning of retention of the 
capacity to give rise to a colony of cells ( e.g. Alper, 
1979 ). The most convenient way of displaying cell
survival data is in the form of a graph of the logarithm 
of the surviving fraction as a function of radiation dose. 
The logarithmic scale is neccessary to encompass the range 
of surviving fractions commonly produced in experimental 
studies. It also reflects the fact that the surviving 
fraction has a relationship with dose which is essentially 
exponential.
When radiation interacts with matter energy is deposited 
in discrete ionization events along the path of the 
ionising particle. With biological material some of these 
ionization events will occur outside cells or in a 
non-critical region within cells. These will not give rise
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to cell sterilisation. However other events will produce 
damage in critical cellular targets, possibly leading to 
death ( Elkind, 1980 ). The concept of intracellular
targets has been dominant in radiobiology for many years 
and all models for radiation effects on cells are based on 
this.
2.1 CELL SURVIVAL EQUATIONS
2.1.1 EXPONENTIAL
Pure exponential survival curves are unusual but not 
absent in the study of mammalian cells ( Alper, 1979 ).
Inactivation curves for prokaryotic cells, viruses and 
proteins are almost invariably exponential in form. 
Historically the explanation for this type of curve has 
been provided by assuming that critical targets required 
only a single "hit". Simple Poisson statistics then 
determine the survival curve. If a dose D- is defined asO
the mean inactivation dose i.e. it gives an average number
-i
of one critical hit per cell then a proportion € cells 
will have experienced no hits and will therefore survive. 
The surviving fraction after a dose, d will be given by
S(J) = e ' * ' *  (z-0
This is the simplest form of survival curve equation. 
Almost all survival curves for mammalian cells exhibit a 
"shoulder" region at low doses. This indicates that the 
effectiveness of cell killing by low doses is less than 
that for high doses. Survival curve equations must be able 
to describe this shape. The first attempts to describe 
shouldered survival curves mathematically were also based 
on the Poisson statistics of ionization but with the
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assumption of either a multiplicity of critical targets 
which all had to be hit or a target which had to be hit 
more than once to sterilise the cell.
2.1.2 MULTITARGET
It is postulated that a cell contains n sensitive targets, 
all of which must be inactivated or "hit" in order to 
achieve sterilisation ( Alper, 1979 ). It follows that the 
probability of hitting one target is given by
( , - £ - d/» 0  t*-*)
That of hitting n independent targets is therefore
h  = 6  - -s'a/P° ?  ( * ' V
and the probability of a cell surviving 
5(d). I -  ( I  - e - ' M  (?.<;
The slope of the survival curve is given by
i . - « - * * < • , &-0
dJ D0
It can be seen that at low doses
a .  n  w  -  0 l ,  ‘)
This means that the initial slope of the survival curve is 
zero.
At high doses i ,
L:~  U -  S(J)\ = " A -  e
U J  A
S(d) = ne~d/D' (z-f)
Therefore at high doses the survival curve approximates to 
a pure exponential. On a log-linear plot it will appear as 
a straight line of gradient -1/De . If the terminal part
of the curve is extrapolated back to the log(S) axis it 
will intersect at a value log(n). n is known as the 
"extrapolation number" ( Alper et al, 1960 ).
Alternatively it can be assumed that there are ^  separate 
regions in a cell and deactivation of any one of these is 
lethal. Each region behaves as if it were composed of r 
individual targets. The survival curve equation for this 
case is given by ^
s « .  [ > -
This equation again specifies a survival curve with an 
initial slope of zero. At high doses the curve 
approximates to an exponential with an extrapolation 
number of t'** .
It is possible to use an alternative parameter to describe 
this form of survival curve rather than the extrapolation 
number. This is the "quasi-threshold dose" denoted Dq ( 
Alper et al, 1962 ). It corresponds to the ' intercept on 
the dose axis of the extrapolation of the terminal 
straight line portion of the survival curve. It is 
therefore not independent of n. They are interchangeable 
and are related by
- i>. & ( « )  (Z.io)
By virtue of their mathematical form the multitarget 
equations have an initial slope of zero. This means that 
the first increment of dose will not kill any cells. 
Experimentally this is not usually found to be the case ( 
see Alper, 1975 ). Most survival curves have non-zero 
initial slopes. The biological implication of this from 
the perspective of the theoretical background to the 
multitarget formulae is that there is some component of 
"single-hit" damage i.e. deactivation of a critical target 
by only one "hit" is sufficient for cell sterilisation.
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This observation can be built into the mathematical 
formulae simply
50| . &■»>
At low doses
S^i) = e  d/,p' (2 . >2)
At high doses
%  • * *"+ - ( H x e - v
The observed final slope is related to the separate slope 
components by
Po :
P. + Pi L
2.1.3 LINEAR QUADRATIC
In recent years the linear-quadratic model has come to 
pre-eminence due to its use as a normal tissue isoeffect 
relationship*, however the use of a quadratic function of 
dose to describe radiation effects has a longer history. 
Several theoretical models of the mechanism of radiation 
damage to living cells predict that the surviving fraction 
of cells following a single dose, d, will be given by the 
relationship 2
„ (dJ t pJ ) £
S(J): e L r
where S(d) is the fraction of cells surviving after a 
dose,d and d and j? are constants. The linear-quadratic 
cell survival model has been proposed on the basis of the 
theory of "dual radiation action" by Kellerer and Rossi ( 
1972 ) and also on the molecular model of Chadwick and
Leenhouts ( 1973 ) which assumed that cell death was due
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to double strand breaks in DNA and that low LET radiation 
could cause these lesions due to the interaction of two 
single strand breaks in complementary strands in close 
proximity.
: 2.2 DISCUSSION
As empirical formulae for the construction of survival 
curves equations 2.4, 2.11 & 2.15 have been used
successfully to fit experimental data. Opinions vary on 
whether a better fit is provided by the multitarget or 
quadratic function. Certainly in some cases it appears 
that the quadratic fit is superior, especially at low 
doses, but there are also cases where the terminal part of 
the curve does not appear to possess continuous curvature. 
There is a body of evidence from split dose studies which 
suggests that survival curves have finite final slopes. 
Using CHO cells Elkind & Sutton ( 1959 & 1960 )
demonstrated that when cells were exposed to a radiation 
dose and then given a sufficient interval for full 
recovery, the survival curves following a second dose had 
final slopes that were parallel to single dose curves. 
Also the difference between the two doses ( one given as a 
single exposure and the other being the sum of the 
split-dose components) required for the same effect was 
independent of the size of the conditioning dose once it 
was higher than a minimum value. This is contrary to what 
would be expected for continuously bending survival 
curves. Although determining whether quadratic or 
multitarget functions best describe cell survival may seem 
important in the understanding of underlying mechanism, it
40
is not possible to decide on the basis of experimental 
data with it's associated uncertainties. Alper ( 1980 )
has pointed out that any curve passing through the origin 
can be fitted.by the polynomial
y = A* + + £*T ( j-u )
provided there is a non-zero initial slope and also that
the slope does not become obviously straight over the
observed dose range. The first 2 terms will suffice if the
degree of curvature is not too great. Caution is therefore
nec essary in attempting to deduce underlying mechanisms
from survival data. Both the multitarget and
linear-quadratic models interpret the shoulder region of
survival curves as being due to the accumulation of
radiation damage. In the multitarget format damage is
accumulated as independent targets are hit. This damage is
"sub-lethal” in that only by hitting the last remaining
target is it translated into lethality. In the
2.
linear-quadratic model the £ d term is due to the 
interaction of two "sub-lethal" lesions either of which in 
isolation will not result in sterilisation. The use of the 
LQ model as a normal tissue isoeffect relationship will be 
reviewed in the next section, where it will be seen that a 
mathematical representation of repair, operating on 
sub-lethal lesions, can be incorporated. Nevertheless the 
LQ model is still essentially an accumulation model. 
Multitarget and LQ equations have been very successful in 
empirically fitting survival data, for which purpose they 
are still used to the virtual exclusion of all other 
formulae. However conceptually, from the point of view of
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underlying mechanism, opinion is moving away from them and 
is turning to a class of models known as repair models.
2.3 REPAIR MODELS
The vast amount of DNA in the genome of mammalian cells is 
replicated every cell cycle. There is thus an enormous 
potential for errors in replication, even before 
considering the damage which environmental factors could 
possibly cause. It is therefore not surprising that cells 
have highly developed systems for the detection and repair 
of damaged DNA. Any model of radiation sterilisation of 
cells would therefore, appear inadequate if it did not 
include repair as an important factor. Radiation can cause 
a variety of lesions in DNA including double strand breaks 
(DSB), single strand breaks, base damage, DNA-DNA and 
DNA-protein cross links ( Cole et al, 1980 ). The most
widely held view at present is that it is DSB which are 
the critical, lesion from the point of view of viability ( 
Painter, 1980; Ward, 1986 ). However there is considerable 
evidence that most of the induced DSB can be enzymatically 
repaired ( Elkind, 1985; Collins, 1987; Teoule, 1987 ) an 
effect not taken account of in, for example, derivations 
of the linear-quadratic model of Chadwick and Leenhouts. 
There are fundamental differences between accumulation 
models and repair models. The resultant survival curve is 
assumed in the case of accumulation models to be due to a 
base line of irrepa rable damage from where processes of 
damage accumulation further reduce survival to the 
observed survival curve. In the case of repair models a 
base line of potentially lethal damage is subject to
42
repair processes which increase the survival probability 
to the level of the resultant survival curve. Single hit 
inactivation is the basic mechanism of cell sterilisation 
in repair models.
One type of repair model explains survival curve shapes by 
a postulated' repair process which operates most 
efficiently at low doses but becomes increasingly 
ineffectual as the dose increases. This is a 
repair-saturation model ( Laurie et al, 1972, Goodhead, 
1980 ). Haynes (1966) description of survival for the 
repair proficient bacterial strain E.coli B/r after 
irradiation by u.v. light is consistent with a repair 
saturation model ,
S(d) r & x f >  [ - * < *  +  * ( * '  * '  > J  (Z-'t
In this equation the -kd term represents the linear 
induction of radiation damage which is partially offset by 
the repair term cC( 1 - e ' ). This initially increases
with dose but asymptotically approaches a cut-off value of 
oi representing the saturation of repair capacity. Models 
of this type can effectively explain the shapes of
survival curves. Another repair model is the
repair-misrepair or RMR model of Tobias et al ( 1980 ).
Repair enzymes can begin to operate only after the initial 
physical and chemical processes are over. These processes 
leave a quantity of "uncommited" lesions, U, which are
subject to repair processes. Repair can either be linear
or quadratic so that
-  (4) = - m  - *  (?. i t )
db
Each of the linear and quadratic processes can then either
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yield "eurepaired states" ( i.e. perfect repair ) or 
"misrepaired states". In a simple case of the RMR model it 
can be assumed that linear repair is always "eurepair",
interpreted as e.g. correctly rejoining broken DNA. 
Quadratic repair is always misrepair, which can be 
interpeted as the joining of pieces of broken DNA which 
don't belong together. Misrepair leads to lethality or 
mutation. Survival is determined by the competition 
between eurepair and misrepair. This procedure leads to an 
equation for surviving fraction
S(sl) - ( \ + — ) J (?* ^
assuming enough time for full repair and where
6 = repair ratio = 3 / >
ei D is the postulated linear relationship between dose and 
DNA strand breaks. This equation appears to fit 
experimental data on lethal effects of low LET radiation 
well. More complex equations can be derived from the RMR 
model depending on the nature of the assumptions regarding 
repair and on the post-irradiation time available for 
repair. Another repair model is the lethal and potentially 
lethal (LPL) model of Curtis (i986). This model 
incorporates a number of mechanisms such as the creation 
of irrepairable lesions, lesion repair by first order
kinetics, binary misrepair and the existence of two 
different types of repairable lesion.
There is no explicit necessity for repair saturation in 
the RMR or LPL models although such a mechanism could be 
accomodated in the equations. These equations can describe 
a wide range of experimental results very well. As has
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been pointed out several times, it is not possible to 
decide between models on the basis of curve fitting. The 
models based on repair processes do, however, seem to be 
more biologically realistic and one would anticipate that 
the future development of cell survival models will owe 
more conceptually to these than to the "physical" models 
of the multitarget or linear quadratic type.
It will be useful to define here a quantity which will be 
used in subsequent chapters to describe the effects of 
radiation on tumour cells. This is the "log cell kill" 
function.
i.e. the negative logarithm of the surviving fraction. 
This is a monotonically increasing function of tumour cell 
sterilisation. When base 10 logarithms are used, T 
represents the number of decades of reduction of tumour 
cells. However use will also be made of base e logarithms 
when mathematical convenience dictates.
The number of surviving tumour cells following 
fractionated course of radiation treatment depends not 
only on dose-associated parameters but also on 
time-associated ones. This is due mainly to the 
repopulation of tumour cells.
Studies on experimental animals have revealed a 
characteristic growth pattern for transplanted tumours
2.4 THE LOG CELL KILL FUNCTION
2.5 TUMOUR KINETICS
2.5.1 REPOPULATION
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( reviewed by Steel, 1977 ). At small volumes ( depending 
on species), growth is rapid and exponential. This 
corresponds to the "silent interval" ( Brues et al, 1939 ) 
where the existence of a tumour may be inferred but no 
detectable mass is observable. Tumours at this stage are 
avascular and essential nutrients are available only 
through diffusion from outside. As the tumour mass 
increases it as been observed that tumours can produce a 
substance - tumour angiogenesis factor ( Folkman, 1976; 
Walker et al, 1984; Buki and Seppa, 1985 ) which
stimulates the neovascularization of the tumour i.e. blood 
vessels form to supply the tumour with nutrients. As
tumours become larger the growth slows down tending
towards some asymptotic limit which is usually not 
reached because of either a) death of host or b) size 
reduction after treatment or cure. Mathematically the 
macroscopic growth curve follows a "decelerating" pattern 
which appears to be well described by the Gompertz 
equation (. Winsor, 1932 ). This suggests a composite
Gompertz-exponential or "Gomp-ex" growth curve ( Steel, 
1977 ) with tumours in the microscopic size range
following rapid exponential growth kinetics. Little is 
known about the regeneration of bulk tumours following 
radiation treatment. There is no obvious reason why 
repopulating tumour cells should follow the same growth 
curve as the original untreated tumour cells. It is 
possible that a pre-existing blood capillary network may 
support growth up to the immediately pre-treament size. 
However, radiation damage to the vasculature may restrict
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the regeneration. Also repopulating tumour cells will 
experience a different microenvironment composed of killed 
and degenerating cells.
The potential doubling time or Tpot is the time required 
for a cell population to double if there are no cells 
lost. Cells may be lost from the proliferating tumour 
population by maturation or differentiation, by death or 
by emigration from the tumour mass. The potential doubling 
time and the actual population doubling time, Td together 
give the cell loss factor,
Trott and Kummermehr ( 1985 ) reported their studies of 
three mouse tumours. In two out of three cases the average 
repopulation rates following radiation treatment were
to three sets of clinical data :
1/ The data of Maciejewski et al (1983 ) suggests that the 
time dependence of the 50% tumour control dose for 
carcinoma of the larynx is consistent with a repopulation 
doubling time of 4 days, equal to the potential doubling 
time calculated for squamous cell carcinoma of the head 
and neck.
2/ The data of Friedman et al ( 1967 ) is consistent with 
a dose equivalent of 0.3 Gy per days repopulation. This is 
compatible with the calculated Tpot.
3/ There is a correlation between measured Tpots for 
Burkitt's lymphoma and the clinical data of Norin and 
Onyango ( 1977 ) relating the complete response rate to 
the interfraction interval.
X  --
equal to the potential doubling rates. They also referred
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Trott and Kummermehr conclude that "the cell production 
rate of the tumour before treatment may be an indicator of 
the repopulation potential and might therefore serve as a 
guide to selecting tumours for accelerated fractionation 
schedules.
The in-vitro data of Wheldon et al (1985(a)) on human 
neuroblastoma multicellular tumour spheroids ( MTS ) 
indicates that spheroid regrowth following radiation is 
exponential and equal to the original growth rate. As MTS 
may be a suitable in-vitro model of avascular 
micrometastases in-vivo this is especially relevant in 
the context of microscopic systemic disease, the prime 
candidate for systemic radiation therapy. Other data 
germane in this context include :
1/ For paediatric solid tumours ( an important patient 
group for systemic radiation therapy) the likelihood of 
fast growth kinetics is supported by the the occurence of 
palpable tumours in very young children below the age of 
one year ( Voute et al, 1986; Tournade et al, 1986; 
Barrett, 1986 ). For example, neuroblastoma belongs to a
group of paediatric tumours for which the volume doubling 
time, estimated in the clinical size range, is of the 
order of 20 days, considerably less than the estimated 
volume doubling time of various adult tumours of 
comparable size. Measurements on the volume doubling time 
of Ewing's sarcoma classify them as the fastest growing 
sarcomas and are also of the order of 20 days. Since such 
estimates apply to tumours in the Gompertzian growth 
range, it is likely that the rate of growth of microscopic
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populations is considerably more than this.
2/ Some detailed studies of cell population kinetics have 
been made on neoplasms for which systemic radiotherapy is 
used or being considered. Estimates of the intermitotic 
interval for acute leukaemias indicate a rapidly dividing 
population. The median of 6 independent series of 
measurements of intermitotic time was approximately 2.5 
days ( Steel, 1977 ). The Tpots for paediatric tumours 
classify them as one of the fastest growing groups. The 
median of 5 measurements of Tpot for neuroblastoma has 
been reported as 5.2 days ( Aherne and Buck, 1971 ). These 
values may provide realistic estimates of the population 
doubling time of clonogenic cells in metastases and of the 
primary tumour when it is small or regrowing after 
therapy.
Steel ( 1977 ) concluded from data on labelled mitoses
curves for a variety of human tumours that "In human 
tumours, even more than in tumours of laboratory animals, 
there is no clearly defined "cell cycle", but a broad band 
of intermitotic times whose median value (in cases where 
it has been reliably determined) has been in the region of 
2-3 days."
For radical systemic treatment with, hopefully, patients 
in clinical remission only low levels of diffuse or 
metastatic disease are present. In these circumstances it 
is reasonable to assume that the proliferation of tumour 
cells will be fast and exponential.
Measurements of tumour cell kinetics have suffered from 
their extremely laborious and time-consuming nature. A new
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technique with potential to dramatically reduce the time 
required and increase the quantitative resolution of cell 
kinetic measurements has been described ( Danova et al, 
1987; Wilson et al ( 1988 ). This approach is based on the 
incorporation of the thymidine analogue bromodeoxyuridine 
( BrdU ) into DNA. A monoclonal antibody raised against 
BrdU integrated in DNA and flow cytometric techniques of 
measuring it enable rapid ( within 24 hours ) estimation 
of the cycling fraction, cell cycle time and the durations 
of the individual phases of the cell cycle. The next few 
years are likely to see the application of this method to 
the clinic where it may be useful as a predictive assay of 
tumour response.
2.5.2 REDISTRIBUTION
Cell cycle redistribution was briefly mentioned in chapter 
1 with reference to the hypothesis of Zeman and Bedford ( 
1984 ) on its likely effects in normal tissues. Cellular
radiosensitivity is dependent on cell cycle phase. Cycling 
cells surviving a dose of radiation tend to be 
synchronised in resistant phases of the cycle. This effect 
may be enhanced by radiation-induced blocks in cell cycle 
progression at the Gl/S and G2/M interfaces ( Denekamp, 
1986 ). However the synchronisation does not last long due 
to variations in the speeds with which individual cells 
progress round the cycle. This breakdown in 
synchronisation is called redistribution. Redistribution 
may be an important factor determining the responses of 
cells which are actively progressing through the cycle. It 
will have the effect of proportionately re-sensitising
50
cells which have fast cycling times. This will work in an 
opposite sense to repopulation processes in terms of its 
effects on the cellular population size following a 
fractionated course of radiation treatment. One would 
expect that cells in a non-cycling "GO" state will not be 
affected by redistribution. However following radiation 
insult these cells may be recruited into the cycling 
population and, hence, be subject to the effects of 
redistribution.
2.5.3 REOXYGENATION
At the beginning of this chapter the "problem of hypoxic 
cells" was alluded to. The oxygen effect was noted as 
early as 1921. Briefly it has been found that the dose 
required for a certain level of survival is about three 
times greater- under hypoxic conditions than it is under 
fully oxygenated conditions ( Hall, 1978 ). The ratio of 
hypoxic to oxic doses needed to achieve the same 
biological effect is the same at all survival levels and 
is called the oxygen enhancement ratio ( OER ). Thomlinson 
and Gray in-1955 reported the histology of some bronchial 
carcinoma specimens where they found a characteristic 
pattern of viability and necrosis. Regions of viable 
tumour cells were seen around blood vessels, but further 
away from the supply of nutrients were large areas of 
necrotic tissue. They deduced the existence of a hypoxic 
region between the anoxic necrotic areas and the fully 
oxygenated tumour cells and suggested that the presence of 
a relatively small proportion of hypoxic cells could limit 
the success of radiotherapy in some clinical
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circumstances. There is a body of evidence for the 
existence of hypoxic cells in human tumours ( Glassburn, 
1977; Thomlinson et al, 1976; Fowler, 1983 ) but it is a 
moot point whether they affect radiocurability when 
standard fractionated treatment schedules are used which 
^llow reoxygenation. Following irradiation there are 
several possible mechanisms of reoxygenation, none of 
which excludes the others ( Denekamp, 1986 ). It is
possible that radiation-damaged cells respire more slowly 
and thus use less oxygen. This may allow- oxygen to diffuse 
further. When the lethally irradiated cells die and are 
removed by lysis, previously hypoxic cells may move back 
to the oxygen-rich region. Also recirculation of blood 
through vessels which were previously closed may 
facilitate ' reoxygenation. Given all the radiobiological 
effort in investigating hypoxia, there is no doubt that 
clinical approaches based on countering "the problem of 
hypoxic cells" have been disappointing. The treatment of 
systemic microscopic disease is probably the least likely 
clinical situation where hypoxia may be * a contributory 
factor to treatment failure.
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3.0 THE LINEAR-QUADRATIC ISO-EFFECT MODEL
FOR NORMAL TISSUES
Various theoretical models of the effects of radiation on 
cells predict linear-quadratic survival curves as 
described in Chapter 2. Empirically there appears to be a 
satisfactory agreement between a quadratic equation and 
experimental data for single dose survival curves for, at 
least, some of the dose range including what, up till now, 
has been the dose range of clinical interest ( e.g. Steel 
et al, 1987 ). Although it is a matter of some controversy 
as to whether the prime factor determining survival of 
parenchymal cells is radiation damage to the vasculature 
or clonogenic sterilisation of the parenchymal cells 
themselves it seems reasonable to assume that there is a 
one-to-one correspondence between the level of depletion 
of parenchymal or stromal cell number and the impairment 
of physiological function of an organ or tissue ( Thames 
et al, 1982; Withers et al, 1983 ). This assumption is
central to the use of the linear-quadratic equation, and 
in fact any cell survival equation, as the basis of a 
normal tissue isoeffect model.
Douglas and Fowler ( 1976 ) used a quadratic function of 
dose,
to analyse the effects of fractionated radiation on mouse 
skin reactions. These authors originated the so-called 
Fe plot ", a plot of reciprocal total dose against dose
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3.1 FRACTIONATED RADIATION SCHEDULES
Effect F
per fraction for a set of fractionation patterns judged to 
be isoeffective. If the quadratic equation was a realistic 
description of what was happening this plot will produce a 
straight line. The ratio of intercept on the reciprocal 
dose axis to slope is the ratio °Vp . Alternatively, as 
pointed out by Michael ( 1985 ) the intercept on the dose 
per fraction axis is also •‘/p . In 1982 Thames et al used 
a quadratic equation as the basis for an isoeffect model 
which distinguished between acute and late normal tissue 
reactions. Late reactions had a consistently lower 
ratio of around 3 Gy in comparison to acute reactions, 
which had a characteristic *!p ratio of around 10 Gy 
This suggested that the underlying cell survival curve for 
the target cells was more " curvy " than for those 
responsible for acute effects. In their theoretical 
development of the model these authors assumed:
1/ The same level of cell killing results from each 
successive dose i.e. equal effects per fraction.
2/ The effects of proliferation were negligible, therefore 
the surviving fraction after N successive doses was simply 
(S(d))" .
3/ The biological effect is determined exclusively by the 
survival level of the target cells.
The level of biological effect, E was written as
£  -  A  [ slJ ) T  ( i t )
as the survival equation used was
5 0 .  ( H )
This enabled the relationship
to be obtained which is equivalent to the equation used by 
Douglas and Fowler ( the basis of' the Fe plot ). 
Simultaneously, Barendsen ( 1982 ) proposed a
linear-quadratic model for isoeffective dose prediction. 
Barendsen"s approach, although computationally identical 
to Thames et al, differed conceptually in that he invoked 
a specific " micro-theory " to explain the quadratic 
dependence. A number of assumptions were made, 
specifically:
1/ Radiation causes cell sterilisation by the induction of 
lesions. Some of these lesions are produced linearly with 
dose ( single hit damage ) while others are produced by 
the interaction of two " sub-effective " lesions. Lethal 
lesions produced by sub-effective lesion interaction 
increase as the square of the dose.
2/ Sub-effective lesions must be produced close enough 
together in space and time in the same cell. In the case 
of low LET radiation these will be produced independently 
by different ionising particles.
3/ Sub-effective lesions remain available for interaction 
for only a limited time after their induction. Although 
Barendsen proposed an exponential decay in the capacity 
for sub-effective lesion interaction with a half-time of 
between 0.5 and 2 hours this theme was not fully developed 
until Dale's modification to the linear-quadratic model in 
1985.
4/ In a similar fashion to Thames et al, ( 1982 ) 
Barendsen assumed that equal dose fractions are equally
effective, independent of the preceding or following 
fractions.
5/' The response of an organized tissue is dependent on the 
average number of lesions in the constituent cells. This 
number depends on what level of response is considered 
but, if the relationship between tissue response and 
surviving fraction is unknown, a response level of Fr, 
say, can be used without reference to a survival curve.
6/ proliferation effects must be allowed for each type of 
tissue on an individual basis.
Barendsen introduced a useful quantity which he called the 
relative effectiveness per unit dose" or RE. This 
follows simply from
fr = ( W  t p J l )  ( } • * )
for a single dose of size d,( in Barendsen's notation. 
oL =al; =a2 ).
For n fractions giving rise to the response level of 
interest
Fr - n (ci d +• )
__ r\ A (oi +■ ^ ) (?* 4)
RE is defined as ^
* ■  t i  ■ 0 * 4 0  ^
It should be noted that nd is simply the total dose D .
Barendsen defined the " extrapolated tolerance dose" ETD
£rp * (yt)
The term "tolerance” may perhaps convey the wrong
impression as these relationships would also hold for
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sub-tolerance levels of radiation damage. He also used the 
term " extrapolated response dose" ERD and this is the 
term used in this work.
E R p  * s?e » p  (i.*)
The ERD can be thought of as the dose required for a
particular biological effect if the radiation is given as 
an infinite number of infinite simaly small fractions
Zjm
rt->e6 : A -*>0
Equation ( 3.9 ) can be used to examine the conditions for 
equivalences between schedules. Two schedules are 
isoeffective for a particular biological effect 
characterised by if their ERDs are equal
ERD, = E R \  U.io)
i.e.
-T), * Rt( = \  * 0>|)
For fractionated radiotherapye - t  * 4 1
Therefore
n'd' ('* 4 )  ’ "xJx ' ■ " & 1
So, for example, if it is desired to give a radiotherapy 
schedule with fraction size d^ to produce an equivalent 
effect ( j/p ratio ) to a schedule of n, fractions of 
size dx , the appropriate number of fractions n4 is found 
from
K
Alternatively if it is decided to choose a certain number
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of fractions, n^, is found by rearranging equation (
3.12 )
2.
It now follows from the formula for the roots of a
quadratic equation that
A  ‘ [ j W  - 4 - r t j'2
The negative root is obviously not meaningful in this 
context and is ignored.
Withers et al ( 1983 ) have pointed out that no single
isoeffect curve can describe the dose-fractionation 
response of all tissues. It follows that, in order to use 
these equations to derive isoeffective fractionation 
schedules for a particular biological effect it is 
neccessary to know the characteristic * /r ratio for that 
effect. Published values of ratios cover quite a
large range ( e.g. Barendsen, 1982; Fowler, 1984 )
depending on the organ system studied. However the 
consensus view at present appears to be that there is a 
broad category of "late responders" with //$ ratios in
the range of about 1 Gy to 5 Gy and a broad category of
"early responders" with ratios in the range of about
6 Gy to 14 Gy ( e.g. Fowler, 1984 ). Taking a value of 3 
Gy as representative of late effects and a value of 10 Gy 
as representative of acute effects is a reasonably 
justifiable position. In the treatment of systemic 
malignancy, the theme of this thesis, radiation induced
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pneumonitis is a particularly important toxicity. For this 
biological endpoint, which is described in the next 
chapter, several studies in mice have indicated that an
Parkins et al, 1985; Parkins and Fowler, 1985; Vegnesa et 
al, 1985; Travis and Tucker, 1986 ).
Dale ( 1985 ) used the same microdosimetric assumptions as 
Barendsen ( 1982 ) and a similar theoretical development 
to the "accumulation" model of Roesch ( 1978 ) in his 
extension of the linear quadratic model to continuous 
.radiation exposures at constant or exponentially decaying 
dose-rates. He assumed that sub-lethal damage repairs 
exponentially with a time constant, /A , or, more 
accurately, that the probability of a sub-effective lesion 
existing decays exponentially with a decay constant, /a 
Dale produced an equation for the RE of a continuous 
radiation exposure at a constant dose-rate, r, over a 
time, T
This finding of Dale is computationally identical to that 
of Thames’ ( 1985 ) incomplete repair ( IR ) model when 
applied to a linear-quadratic survival equation for 
continuous low dose-rate exposures. Thames’ model, in 
turn, is a generalisation of Oliver’s ( 1964 )
dose-equivalent of incomplete repair" model to 
multifractionated and continuous radiation exposures. This 
approach does not invoke a "microtheory" but instead makes
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pj//J of 3 Gy is a good predictor of isoeffective schedules (
3.2 CONTINUOUS RADIATION SCHEDULES
RE I * ■ --------------------- I
a more empirical assumption. Following sufficient time for 
complete repair after a single radiation dose the survival 
curve for a second dose will retrace that of the first. 
If, however, repair is not complete the second survival 
curve will retrace the first starting from a non-zero dose 
value. This value is 9 d where 0 - exp( -/& where 
T is the time between doses and is the repair constant. 
Both this analysis and that of Dale yield conclusions 
which can be expressed as equation ( 3.15 ). Dale has
shown that when fractionated high dose-rate and continuous 
low dose-rate exposures are considered^ in order for the 
same dose to be of equal biological effect the following 
condition must be satisfied
This is also the general equation for equating acute and 
protracted treatment schedules derived by Liversage ( 1969 
). Dale examined the correspondence between the 
predictions when equation ( 3.13* ) was used and doses
which were -found clinically to be equivalent in the 
treatment of carcinoma of the cervix given as both 
fractionated high dose-rate and continuous low dose-rate 
exposures. He found that an ° /^p ratio of 2.5 Gy and 
value of 0.46 hr-1 ( corresponding to a repair half-time 
of 1.5 hours ) gave a good fit to the clinical data. Using 
the NSD, CRE and TDF models in their fractionated and 
continuous forms ( and including experimentally derived 
normalisation factors where neccessary ) to predict the 
isoeffective doses led to a gross overestimate of the
n
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equivalent fractionated dose. Thames et al ( 1984 ) found 
that for three acutely responding tissues in the mouse ( 
jejunum, colon and bone marrow ) repair half-times ranged 
from 0.3 to 0.9 hours. For mouse lung, using the LD50 for 
pneumonitis endpoint and also for rat spinal cord, they 
estimated a repair half-time of 1.5 hours. Thames ( 1985 ) 
has shown that the IR model, which is computationaly 
identical to the Dale model, is also equivalent to the LPL 
model of Curtis ( 1986 ) for fraction sizes of the order 
of 4 Gy or less and for dose-rates of the order of 0.2 Gy 
per minute or less. There is thus intermodel 
correspondence in the clinical dose and dose-rate range.
In his 1985 paper Dale also addressed the situation of 
exponentially decaying dose-rates. For irradiation of
Where r0 is the initial dose-rate.
If the irradiation time is long enough that the dose-rate 
decays effectively to zero the equation for RE simplifies
3.3 EXPONENTIALLY DECAYING DOSE-RATES
time, T with a decaying dose-rate of decay constant,^
the full expression for the RE is
to
Re i +
3.4 REPAIR KINETICS
Currently the most-used models for the interpretation of
experimental fractionation ( when repair is not complete ) 
and low dose-rate studies are the Thames ( IR ) model, the 
Dale ( LQ ) model and the Curtis ( LPL ) model. These 
formulations are based on monoexponential repair kinetics. 
Recently this tenet has come under attack from several 
experimental studies. Stephens et al ( 1987 ) found that 
for 3 mouse tumour cell lines and for 1 human tumour 
xenograft ( HX34 melanoma ) irradiated in-vitro the data 
were well fitted by both the IR and LPL models. However 
for 2 of the 4 lines the estimated repair half-time based 
on low dose-rate exposures was a factor of 10 less than 
that derived from split dose experiments ( 0.1 hour versus 
>1.0 hour ). These authors suggested that this could be 
due to temperature factors in the experimental procedure. 
Alternatively they pointed out that it could be due to the 
existence of 2 components of repair rather than a single 
exponential. Steel et al ( 1987 ) stated that there was a 
systematic tendency for split dose half-times to be longer 
than those derived from analysis of the dose-rate effect. 
It has been suggested ( Ang et al, 1985 ) that for mouse 
mucosa the' half-time of repair could depend on the 
fraction size. Dale et al ( 1988 ) in a re-examination of 
the data of Huczkowski and Trott ( 1984 & 1987 ) relating 
to jejunal crypt survival in C3H mice following 
fractionated total body irradiation^ found that the repair 
rate appeared to slow down as the dose-rate increased. In 
contrast Scalliet et al ( 1987 ) found, using Dales' LQ 
model, that the half-time of repair in the mouse mucosa 
system remained constant over the range of dose-rates
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investigated ( 642 Gy hr-1 to 1.5 Gy hr-1 ). Braby et al ( 
1980 ) found the repair rates for the eukaryotic algae
Chlamydomonas reinhardi to be dependent on temperature but 
no significant differences were found between split-dose 
and dose-rate based techniques of measurement. It is shown 
in the appendix to this chapter that the isoeffect data of 
Paterson and Green as embodied in the continuous CRE 
formula is consistent with a ( = 3 Gy : = 1.5 hour )
quadratic model tissue with monoexponential repair. The 
situation is therefore in a state of flux, new 
experimental data may show deficiencies in the current 
models which will suggest ways in which they should be 
revised. In the meantime the LQ model is one of the best 
available and will be used in the following chapters as 
the basis of analysis of radiation damage to normal 
tissues.
3.5 APPENDIX
COMPARISON OF THE PREDICTIONS OF THE LQ MODEL AND THE CRE 
- MODEL FOR CONTINUOUS IRRADIATION
3.5.1 CONSTANT DOSE-RATES
Returning to equation ( 3.10 ) the condition for
equivalence between two radiotherapy schedules 1 and 2 is 
that their ERDs are equal.
This relationship can be used, together with equation 
(3.15 ) to compare the predictions of the linear quadratic 
model with those of the continuous CRE formula. The ERD 
for a continuous radiation exposure at a constant
dose-rate, r, for a time, T, is given by
E/?£> = r T  i +
/
J ]  (J-'V
For example schedule 1 is chosen to be 60 Gy in 7 days, a 
fairly standard doseage for low dose-rate treatments ( 
Paterson, 1948 ). A different irradiation time for
schedule 2 can be chosen and the dose-rate, and hence the 
total dose which is required for the two schedules to be 
isoeffective, calculated using the above equation. By 
varying the irradiation times for schedule 2 a curve of 
isoeffective dose as a function of irradiation time can be 
produced. Estimates of - 3 Gy: T - In2/y4c = 1.5
hours and = 10 Gy: = ln2/^_ = 1 . 0  hours are
taken for late and acute responding tissues respectively. 
One may expect that the resulting curves will be valid for 
these tissues if the model is an adequate description. The 
derived curves are shown in Fig ( 3.1 ) together with the 
CRE isoeffect curve based on the combined clinical 
experience of Paterson and Green ( Kirk et al, 1972 ). It 
can be seen that the "late effects" and CRE curves 
correspond closely while the "acute effects" and CRE 
curves do not. Bearing in mind that the continuous LQ 
formula is a theoretically derived construct while the CRE 
is simply a mathematical description of a clinical 
isoeffect, the inter-model correspondence is encouraging. 
No cellular repopulation factor is incorporated in the 
continuous LQ model. For this reason the behaviour of 
"real" acute responses at long irradiation times is likely 
to deviate from the plotted curve. Repopulation will have
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Fig 3.1
Calculated doses isoeffective to 60 Gy given at a 
constant dose-rate in a total time of 7 days using the LQ 
model for acute and late effects and the CRE model.
i
the consequence of increasing the isoeffective dose as the 
irradiation time increases, thus bringing the acute 
effects curve closer to those for the CRE formula and late 
effects. Although not shown in Figure 3.1, the 
late-isoeffective dose curve does not increase 
indefinitely as the irradiation time increases. Instead it 
approaches a plateau dose of appromimately 90.5 Gy 
asymptotically. This means that the CRE and the late 
effects LQ formulae become incompatible at very long 
irradiation times where, unfortunately, there is no 
relevant isoeffect data.
3.5.2 EXPONENTIALLY DECAYING DOSE-RATES
For the case of dose-rates which deacy exponentially to 
zero, again the predictions of the linear-quadratic model 
can be compared with those of the CRE formula. From Kirk, 
et al, 1973, the total dose D* given as an exponentially 
decaying dose-rate with decay constant which is
equivalent to a dose D, , given at an exponentially 
decaying dose-rate with time constant is
* ' ( I f *  ^
For the LQ model, using equations ( 3.10 ), ( 3.11 ) and (
3.18 ) together with the formula for total dose for an 
exponentially decaying dose-rate
D %  &0
It is staightforward to show that for equivalence
v 2Z)
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A ‘ schedule of 60 Gy total dose given by a dose-rate which
decays exponentially to zero with an effective half-time
of 5 days has been taken arbitrarily as a reference.
Figure 3.2 shows the predicted isoeffective dose curves,
based on equation ( 3.20 ) for the CRE formula and
equation ( 3.22 ) for the LQ model, as a function of the
effective radionuclide half-time. This is a somewhat
unusual index of comparison given that for any implant or
insertion using radioactive sources the decay half-time
remains constant. However, as will be described in a later
chapter, for biologically targeted radiotherapy ( BTR )
using radionuclides linked to molecules such as monoclonal
antibodies or meta-iodobenzylguanidine ( mIBG ) this
comparison is highly relevant. Parameter values used were
- 3 Gy : T,^  = 1.5 hours for late effects and
10 Gy : T,. = 1.0 hours for acute effects. It can be seen 
4
that all three curves are quite different although the CRE 
curve is closer to the late effects quadratic than it is 
to the acute effects quadratic. Good curve matches can be 
obtained by using = 3 Gy : Tj^  = 4 hours or
alternatively = 1 Gy : T^ = 1. 5 hours. This analysis
indicates that the CRE formula describes a tissue response 
which has a greater dose-rate effect than is expected for 
an = ' 3  Gy : T^ = 1. 5 hour LQ model tissue. The
discrepancy is somewhat surprising given the 
correspondence for the constant dose-rate case. There is 
no available clinical or experimental data which can be 
used to resolve this inconsistency. Both CRE and LQ 
formulations reduce to their constant dose-rate forms if
66
80.0-1 DOSE FOR ISOEFFECT/Gy
60.0-
50.0-
40.0-
1 2 3 4 5 6 7 8 9 1
EFFECTIVE HflLF-TIME/DRT
Fig 3.2
Calculated doses isoeffective to 60 Gy given by 
exponentially decaying dose-rate with 5 day half-time. 
A = LQ model-acute effects 
B = LQ model-late effects 
C = CRE model
0
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the decay half-time tends to infinity. The LQ version 
however, has the advantage that the equations reduce to 
their fractionated form for very short half-times. The CRE 
equations do not. Another observation on the CRE formula 
is that, similarly to the constant dose-rate case, as the 
half-time increases there is no region of dose-rate 
independence. Any doubling of the effective half-time will 
always increase the predicted equivalent dose by 22%. This 
is not the case for the LQ model. As the half-time becomes 
very large, doubling it has no significant effect on the 
predicted equivalent dose. Again attention is drawn to the 
lack of any repopulation factor in the LQ model. This 
will be of importance for acute effects and it is 
undoubtedly a deficiency of the LQ model that it does not 
take account of this factor. Neither the LQ nor the CRE 
formulae are based on clinical data. Both are 
extrapolations. The LQ formula, as derived by Dale ( 1985
), is based on the same "microtheoretical" assumptions as 
the constant dose-rate version. The CRE formula of Kirk et 
al ( 1973 ) is a more empirical derivation from the 
constant dose-rate equation. It should be pointed out that 
the discrepancy between the models is produced in the 
mathematical manipulations and not in any underlying 
biological database.
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4.0 TOTAL BODY IRRADIATION
After many years of the clinical application of TBI there 
is still some controversy as to the rationale for its use. 
In this section an attempt is made to state the rationale
for TBI and marrow transplantation in the context of the
treatment of systemic malignant disease.
TBI is a form of systemic treatment. As such, it has 
similarities and differences to chemotherapy. Both are 
cytotoxic in a general sense and produce damage to
"target" cells and "non-target" cells. This means that for 
both modalities the limitation on dose is provided by the 
tolerance of normal organs and tissues. Different
chemotherapeutic agents give rise to different patterns of 
toxicity e.g. methotrexate dose is limited by effects such 
as myelosuppression, mucositis and renal and liver 
dysfunction, adriamycin dose can be limited by 
myelosuppression, cardiomyopathy, encephalopathy and 
tissue necrosis ( Olive and Peeters, 1986 ). If these
problems could be overcome, particularly myelosuppression, 
doses could be escalated until other organ toxicities 
became prominent. As a systemic cytotoxic therapy this 
principle applies equally to TBI which has^ its own pattern 
of toxic side-effects. Dose escalation is desirable if 
this produces a greater effect on the target cells i.e. if 
there is a dose-response curve. Conceivably, 
chemotherapeutic drugs may not always have a simple 
dose-response curve and dose escalation may not always be 
useful. This could happen with, for example, cycle 
specific drugs which may kill all cycling cells. Further
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increasing the dose will not cause a greater amount of 
cell kill. With radiation, although there are variations 
in radiosensitivity between cells in different phases of 
the cycle and with cells in the GO state, increasing the
dose invariably increases the biological effect. In the 
absence of haematological reconstitution the limit on TBI 
dose is set by the blood forming cells of the bone marrow. 
Beyond doses of about 2 Gy to the whole body the incidence 
of marrow failure increases rapidly ( UNSCEAR, 1982 ). If 
the bone marrow can be replaced after TBI it is no longer 
dose limiting since the functioning marrow after TBI is 
not the irradiated marrow which was present during TBI. 
This procedure enables the dose to be increased to what is 
recognised from accident data to be well over the lethal 
limit ( Nenot, 1987 ). This is the primary rationale for
the combination of TBI with bone marrow transplantation. 
There is also ■ the problem of "sanctuary sites". The
central nervous system ( Inati et al, 1983; Schweinle and 
Alperin, 1980 ) and the testes ( Mahoney et al, 1981; 
Stoffel et. al, 1975 ) are protected to some extent from 
the effects of chemotherapeutic drugs, but can be reached 
by the use of externally applied radiation beams. Another 
widely known phenomenon is the emergence of drug resistant 
tumour cell populations following treatment with a single 
chemotherapeutic agent ( Curt et al, 1984; Goldie and 
Coldman, 1984 ). This provides one of the rationales for
multi-agent chemotherapy which has proved so successful in 
the treatment of diseases like Hodgkin’s lymphoma. In the 
laboratory the development of radiation resistant clones
is much rarer and for this reason TBI has a potential 
advantage over chemotherapy. The disadvantages of TBI are 
due to its Late cftzcks,, which tends to be more severe than 
that of chemotherapy. This aspect will be discussed later. 
The above considerations lead to the conclusion that TBI 
is another systemic cytotoxic agent with some potential 
advantages and disadvantages in comparison to 
chemotherapy. The purpose of TBI is to sterilize target 
cells and dose escalation, beyond that afforded by marrow 
rescue, is limited by the characteristic pattern of toxic 
side-effects. In the case of neoplastic disease the 
fundamental goal of radical therapy is the elimination of 
every tumour cell. The "target" cells for TBI are 
therefore tumour cells and the use of marrow rescue means 
that more tumour cells can be sterilised. It follows that 
any malignant disease which is widespread may be a 
candidate for TBI. In other words there is no a priori 
reason why TBI should not be considered when deciding how 
a particular malignant condition should be treated. Of 
course there may be good reasons for deciding not to use 
it.
Ablation of existing bone marrow has been quoted as a 
primary objective of TBI ( e.g. Quast, 1987 ). This
assertion bears some examination. For non-malignant
haemopoietic disorders, marrow ablation and replacement by 
healthy cells is the basis of the therapeutic procedure. 
Is there any reason to disbelieve this for malignant
conditions ? In order to answer this question it is
instructive to answer two further ones. If TBI produced
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marrow ablation but did not sterilize tumour cells, would 
it be used? Additionally, if TBI sterilized tumour cells 
but did not ablate normal marrow, would it be used? It is 
suggested that the answers to these questions are no and 
yes, respectively. Historically leukaemia, a malignant 
haemopoietic condition, was the first neoplastic disease 
to be treated with TBI and marrow transplantation ( Thomas 
et al, 1975 ). It was perhaps natural in this context to 
think that the purpose of TBI was to ablate the leukaemic 
marrow. It is only a small step for this to be 
conceptually identified as ablation of normal marrow. The 
distinction may not be very important in the case of 
leukaemia where the radiation sensitivities of leukaemic 
and normal haemopoietic cells appear to be broadly 
similar. However for other neoplastic diseases where TBI 
and marrow rescue may have a role the differences can be 
greater. Thinking of marrow ablation as an objective of 
TBI may therefore lead to the mis-identification of the 
appropriate target cell population and a consequent 
reduction in the potential therapeutic ratio. For this 
reason it appears to be an error to consider marrow 
ablation an objective of TBI. It should rather be thought 
of as a side-effect.
Another aspect of the use of TBI is the severe immune 
suppression which it produces. This is due to the 
sterilization of normal radiosensitive lymphocyte 
populations. It is useful to examine critically to what 
extent immune suppression should be regarded as a goal of 
TBI.
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There are three categories of marrow transplant. In
syngeneic transplants the donor marrow is provided by a
genetically identical twin of the recipient. Statistically 
this accounts for only a small proportion of cases. There 
is no incompatibility between graft and host and a host 
versus graft response is lacking as is any 
graft-versus-host reaction. The immune supression caused 
by TBI in this context can only be regarded as an
unwelcome side-effect as it reduces the patients ability 
to respond to infection.
In autologous transplants the incoming graft has been 
removed from the patient prior to intensive 
chemoradiotherapy and returned following it. This 
procedure has the potential disadvantage that any tumour 
cells removed with the marrow will be re-introduced at the 
time of infusion. For some categories of disease it is 
possible to purge the marrow graft of tumour cells 
ex-vivo. In principle this seems a logical and sensible 
thing to do, although as yet opinion is divided as to 
whether it- has any clinical relevance ( Philip et al, 
1986; Glorieux et al, 1986; Prindull, 1986 ). Obviously
for autologous transplants there are no histocompatibility 
problems. Again, in this context TBI-induced immune 
suppression is apparently unavoidable but not desirable.
In allogeneic transplants the incoming marrow graft is 
provided by a genetically non-identical donor. Ideally the 
donor should be a sibling who has inherited the same 
histocompatibility antigens as the recipient. However, 
even with perfect HLA matching host-graft reactions can
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occur ( Yunis et al, 1983 ). Immune suppression of the 
recipient is neccessary to enable the graft to "take", 
otherwise it will be rejected. The withdrawal of the 
timmune defence system of the recipient leaves him open to 
opportunistic infections e.g. pneumocytis carinii, etc in 
a similar way as patients with AIDS. There is however an 
additional problem posed by the immune competence of the 
incoming graft which can attempt to "reject" the 
recipient. This is graft-versus-host disease ( GvHD), an 
often fatal complication of allotransplantation ( Sullivan 
and Parkman, 1983 ). The reaction may be mediated by donor 
T-lymphocytes which are cytotoxic to host cells ( Tsoi et 
al, 1983 ). Many attempts have been made to reduce the
incidence of GvHD ( e.g. Ramsay et al, 1982; Thierfelder 
et al, 1981; Trigg et al, 1985 ) but, with the exception 
of one series ( Prentice et al, -1982 ) using marrow
depleted of T-cells by the monoclonal antibody 0KT3, these 
have not been encouraging. It was hoped it may have been 
possible to.rescue with histoincompatible marrow after 
T-cell depletion as is possible in mice ( Vallera et al, 
1981 ). This prospect now seems less promising and it was 
recently recommended that T-cell depletion should not be 
pursued in standard-risk patients ( Maraninchi et al, 1987 
) .
The major problem of this approach stems from the apparent 
antileukaemic effect produced by the allograft ( Weiden et 
al, 1979 & 1981 ). Current techniques of T-cell depletion 
for reduction of GvHD concomitantly reduce the level of 
antileukaemic effect ( Apperley et al, 1986; Helenglass et
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al, 1987 ). Ideally it seems that one would like a 
controllable GvH reaction. At present it is unknown 
whether the sub-population of cells which mediate the 
antileukaemic effect is the same as that responsible for 
GvHD. If it is then the antileukaemic effect may be due to 
the general increase in the cytotoxicity of the treatment. 
Alternatively, if the sub-populations are distinct it may 
be possible to increase the therapeutic ratio by selective 
elimination of the cells responsible for GvHD. The 
antileukaemic effect of allogeneic transplantation may 
provide a rationale for the ablation of pre-existing 
functional marrow, but as previously observed, it seems 
counter-productive to concentrate on the effectiveness of 
TBI for marrow sterilisation, rather than in its. role as a 
antitumour agent.
TBI is a non-specific cytotoxic agent. For all organs 
except bone marrow, transplantation is not a practical 
option. Consequently the escalation of dose will increase 
the radiation damage in all the organs and tissues of the 
body eventually limiting the possible TBI dose. Clinically 
observable toxicities include damage to the liver ( 
veno-occlusive disease) ( Shulman et al, 1980; Woods et 
al, 1980; McDonald et al, 1985 ), kidneys ( Tarbell et al, 
1987(a) ) also in the heart, GI tract and the CNS ( Bortin 
et al, 1983 ). Latent effects in children can be expressed 
as growth abnormalities ( Barret et al, 1987 ) and
intellectual impairment (Meadows et al, 1981 ). However it 
is generally accepted that the most important dose 
limiting organ for TBI with marrow rescue is the lung
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where radiation damage is manifest as interstitial 
pneumonitis.
4.1 RADIATION DAMAGE TO LUNG
Interstitial pneumonitis (IP) indicates a tissue reaction 
with infiltration and thickening in the walls of the 
alveoli (Cardozo and Hagenbeek, 1985). Clinical symptoms 
include dyspneoa, tachypneoa, pyrexia, non-productive 
cough and cyanosis. Chest X-rays often show bilateral 
diffuse shadowing. Lung function studies indicate a 
reduction in lung volume and a low diffusing capacity ( 
Depledge et al, 1983). IP has been reported in up to 50% 
of all marrow transplants, approximately 50% of these 
cases are lethal. IP occurs most often between 30 and 100 
days after transplant (Cardoso and Hagenbeek, 1985).
There are a number of factors associated with IP including 
infectious agents (e.g. viruses such as CMV), grade of 
GvHD, type of chemotherapy (e.g. busulphan) and radiation 
parameters (e.g. dose-rate and fractionation). Radiation 
damage to lung certainly appears to be a predisposing 
factor, at least, in the aetiology of IP. This section 
will deal with the relationship between radiation 
parameters and IP, although it should be realised that it 
is somewhat unrealistic to focus on one variable in 
isolation.
In 1978 Fryer et al published a study describing the toxic 
effects of large single doses of radiation given to the 
entire lung during upper half body irradiation for 
metastatic disease. In 1981 van Dyk et al re-evaluated 
this data using a more accurate method of calculating lung
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dose. Dose-rates ranged from 0.5 to 4 Gy per minute. These 
authors found that the incidence of IP was a steeply 
rising sigmoid function of dose with the onset of IP 
occurring at a dose level of about 7.5 Gy. Keane et al in 
1981 compared the incidences of IP from a number of 
centres using allogeneic bone marrow transplant and all 
giving a nominal TBI dose of 10 Gy with those from centres 
using a lower TBI dose. The higher TBI doses were 
associated with a greater incidence of idiopathic IP. For 
the low dose group, based on published data on the 
specific irradiation procedures used, these authors 
estimated the actual dose to lung for each of the centres. 
They used a probit regression analysis to relate the crude 
incidence of IP to absolute dose in lung. A clear 
dose-response relationship was found which suggested that 
the development of IP in patients receiving allogeneic 
transplants was directly related to lung dose. Several 
studies since have shown that, over a more protracted 
timsocale there is a dimunition of lung function ( Depledge 
et al, 1983). Some of these changes were associated with 
previous IP and some were not ( Springmeyer et al, 1983). 
Based on an accumulation of radiobiological knowledge and 
also specifically designed animal experiments it is 
apparent that total dose by itself is not an independent 
parameter but has to be considered in association with the 
dose-rate ( Depledge and Barrett, 1982 ) and fractionation 
details. Peters et al in 1979 argued that 
multifractionated TBI should provide a higher therapeutic 
ratio than single fraction TBI. This is because
haemopoietic cells have a lesser repair capacity than 
dose-limiting organs such as lung. There is a body of data 
from animal experiments which illustrates the dependence 
of lung damage on radiation dose-rate and the sizes of the 
individual fractions ( e.g. Cardoso et al,1985; Travis et 
al, 1986 ). Analyses of such data can yield parameters 
such as 0 j^p ratios and repair half-times for the LQ 
model ( Parkins and Fowler, 1985; Vegnesa et al, 1985 ).
Typical parameter values are S/p - 3 Gy and repair
half-time = 1.5 hours.
4.2 DISEASE CATEGORIES
In this section some features of neoplastic diseases which 
are currently treated, or could be treated in the future, 
with systemic radiotherapy are reviewed. These include a 
high proportion of childhood cancers.. This reflects both 
the relative ease of marrow transplantation in children in 
comparijDn with adult patients and also the relative 
radiosensitivity of some paediatric neoplasms.
4.2.1 LEUKAEMIA/LYMPHOMA
By far the largest number of patients treated with TBI and 
bone marrow transplantation for a malignant condition are 
suffering from leukaemia of some form. Leukaemia literally 
means "white blood" and the leukaemias are a group of 
conditions where there is a progressive uncontrolled 
proliferation of white blood cells. Two main varieties of 
leukaemia are recognised; one involving the lymphocytic 
series ( lymphocytic leukaemias) and the other involving 
myeloid cells which normally proliferate and mature in the
bone marrow ( myeloid or granulocytic leukaemias). Both 
these versions can occur in acute or chronic form. 
Contrary to popular belief leukaemia is a disease of old 
age with the incidences of all forms rising to a peak at 
about 80 years of age. There is a smaller peak in 
childhood and adolescence for the acute leukaemias and 
patients considered for TBI and marrow transplant are 
usually from this group. Acute lymphocytic leukaemia ( ALL 
) is the most frequent malignancy in childhood comprising 
30% of all neoplasms. In 1965 fewer than 1% of children 
with ALL were reported to be long term survivors ( 
Burchenal and Murphy, 1965 ). Nowadays approximately 50% - 
75% of patients will have an unmaintained remission of 
longer than 5 years and a large majority of these will 
actually be cured ( Moe, 1964 ). TBI with marrow
transplantation has a role for patients with ALL in 2nd or 
subsequent remission and, more controversially, for high 
risk patients in first remission. For patients 
transplanted in 2nd or subsequent remission 20% - 40% 5 
year survivals have been reported with leukaemic relapse 
being the main problem ( Thomas et al, 1983(a) ). There is 
a risk of children with ALL developing meningeal 
leukaemia. This may be from 66% to 5% depending on whether 
CNS prophylaxis, including cranial irradiation, is used ( 
Littman et al, 1987 ). However, cranial irradiation is a 
major factor in the development of intellectual impairment 
and neuropsychological dysfunction ( Meadows et al, 1981; 
Pfefferbaum-Levine et al, 1984 ). For this reason the use 
of intrathecally administered antibody-conjugated
radionuclides is under consideration. It may be possible 
with this approach to preferentially irradiate the 
cerebro-spinal fluid without irradiating the underlying 
brain and spinal cord. This would be expected to 
significantly reduce the side-effects. The same approach 
may be suitable for leptomeningeal malignancy derived from 
other tumours,, such as rnedulloblastoma, glioblastoma and 
neuroblastoma ( Lashford et al, 1988 ). Acute
nonlymphocytic leukaemia ( ANL ) is less frequent than 
ALL. It constitutes about 20% of childhood acute leukaemia 
( Choi and Simone, 1976 ). TBI and marrow transplantation 
appears to have a more definitive role than for ALL ( 
Willoughby, 1986 ). 70% - 80% of children can be brought
into complete remission (CR) with current • induction 
chemotherapy. Clinical studies with TBI and marrow 
transplantation have produced encouraging results ( 
Sanders et al, 1981; Kersey et al, 1982; Forman et al, 
1983; Dinsmore et al, 1984 ) with low relapse rates and 
50% - 60% disease free survivals at 1 - 2 years. However
there is evidence that as many as 25% of patients may 
relapse up to as much as 6 years after transplant ( Thomas 
et al, 1983(b) ). Recurrence rates are higher for patients
transplanted in relapse or 2nd or subsequent remission ( 
Applebaum et al, 1983 ). Chronic leukaemia accounts for 
only approximately 2% - 5% of childhood leukaemias. This 
is of the granulocytic or myelocytic variety and it has 
been suggested that childhood chronic lymphocytic 
leukaemia does not occur ( Schaison and Castro-Malaspina, 
1986 ). Philadelphia chromosome positive ( Ph’+) CML
occurs predominately in adults, usually presenting in 
middle age. Systemic chemoradiotherapy and marrow 
transplantation offers a possible improvement in the 
treatment of these patients, at least in the chronic phase 
of the disease ( Feter et al, 1982; Goldman, 1987 ). A 
very rare juvenile form of CML occurs in children under 
the age of 4. It is Ph'- and has different clinical 
features from Ph' + CML. Marrow transplantation may have 
some potential in this disease category ( Sanders et al, 
1979 ).
Lymphoma is the third most common malignant diagnosis in 
children following acute leukaemia and brain tumours. 
About 45% of patients have Hodgkin’s lymphoma, the 
remainder have a diverse group of diagnoses collectively 
referred to as non-Hodgkins lymphoma ( NHL ) ( Young and 
Miller, 1975 ). The peak incidence of Hodgkin's lymphoma
is in the third decade of life ( Thompson, 1977 ).
Improvements in the treatment of Hodgkin's lymphoma in the 
last 20 years have been dramatic. Today five-year survival 
figures of over 80% are common ( Fowler, 1983 ). Children 
with Hodgkin's have a better than 90% likelihood of cure 
if they are treated in a specialist centre ( Donaldson, 
1986). TBI and marrow transplantation may have a role in
relapsed or non-responding Hodgkin's. Dicke and Spitzer in
their 1986 review recommend a group of categories of 
Hodgkin's and non-Hodgkin's lymphomas where high dose 
cytoreductive therapy and marrow support should be
considered. The cytoreduction could conceivably include 
TBI. Goldstone ( 1986 ) reported a study of 44 patients
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undergoing autologous marrow transplantation for NHL in 
first complete or partial remission. The long-term 
disease-free survival was 65%. Verdonck et al in 1987 
reported 20 patients with high grade NHL treated with high 
dose cyclophosphamide and TBI followed by autologous 
transplant. Two of five patients treated in partial 
remission became long term disease-free survivors. Seven 
of ten treated in complete remission were in unmaintained 
remission, four with long follow up.
4.2.2 NEUROBLASTOMA
Neuroblastoma (NBL) is the most common extracranial solid 
tumour of childhood accounting for about 10 % of
paediatric cancers. Although NBL is a clinically 
radiosensitive tumour ( D ’Angio and Evans, 1983 ) it is
characterised by early dissemination and at least 50 % of 
children with NBL are first diagnosed with advanced 
disease. CR rates of Evans stages III and IV NBL have been 
quoted as 30-40% (Dicke and Spitser, 1986). They are 
higher in Europe ( 65 - 80 % ) but overall survival is 
around 20 % ( Barrett, written communication, 1987 ). The 
use of high dose TBI with marrow rescue following 
intensive induction chemotherapy is made more attractive 
by the availability of ex-vivo methods of separating 
neuroblastoma cells from haemopoietic cells ( Kemshead et 
al, 1985(a) ; Treleaven et al, 1984 ) thereby allowing the 
use of autologous marrow. Philip et al ( 1985 ) reported
preliminary results of a study of high dose cytotoxic 
therapy and autologous bone marrow transplantation ( ABMT 
) using purged marrow on 16 children, 13 of whom received
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TBI. The mean follow up for the entire group was short ( 5 
months ) but a sub-group consisting of 10 stage IV 
patients had a mean follow up of 18 months with 8/10 
survivors. The authors compared this with their previous 
experience with non-ABMT treatment where survival at 18 
months was 24%. Other groups have embarked on supralethal 
therapy with marrow reconstitution for advanced NBL. 
Although the results are encouraging, the toxicity of 
treatment is great ( D'Angio et al, 1985 ). NBL is a
particulary interesting neoplasm from the points of view 
of molecular biology and its potential for biological 
targeting by cytotoxic modalities. Amplification of the 
N-myc oncogene has been reported to be directly related to 
disease stage and prognosis ( Brodeur et al, 1984; Seeger 
et al, 1985; Tsuda et al, 1987). Due to the sythesis of 
epinephrine and nor-epinephrine by tumour cells some NBLs 
can be targeted with the catecholamine precursor molecule 
meta-iodobensylguanidine ( mIBG ) ( Treuner et al, 1984; 
Gerrard et al 1987 ). Biologically targeted radiotherapy ( 
BTR ) may have the potential to increase the tumouricidal 
effect while reducing the treatment toxicity. mIBG is to 
be the subject of a forthcoming clinical trial organised 
by the United Kingdom Childrens Cancer Study Group ( 
UKCCSG ) Also a number of monoclonal antibodies ( moabs ) 
have some specificity for NBL. In particular the moab 
UJ13A has been used for both scintigraphic imaging ( Horne 
et al, 1985) and radioimmunotherapy ( Kemshead et al, 
1985(b) ). NBL is therefore one of the prime candidate 
neoplasms for BTR.
4.2.3 EWING’S SARCOMA
Ewing’s sarcoma is a malignant disease of bone. It 
accounts for 10% - 15% of all primary malignant bone
tumours ( Huvos, 1979 ). Ewing’s sarcoma rarely occurs
under the age of 5 years or over the age of 30 years, the
peak incidence is between 10 and 15 years ( Glass and
Fraumeni, 1970 ). Approximately 20% of patients present 
with clinically detectable metastases, of these 50% have 
lung metastases and about 40% have multiple bone 
involvement and/or diffuse bone marrow involvement ( 
Jurgens et al, 1986 ). Before adjuvant chemotherapy the 
5-year survival rates were in the dismal range of 5% - 10% 
due to rapid systemic spread.of the disease ( Falk and 
Alpert, 1967; Phillips and Higinbotharn, 1967 ). Ewing’s
sarcoma is clinically radiosensitive ( Razek et al, 1980; 
Perez et al, 1981; Thomas et al, 1984 ) although there is 
a definite risk of local failure following radiation ( 
Donaldson and Hendrickson, 1983 ). The combination of
local control with radiotherapy and/or surgery in
association with systemic multidrug chemotherapy has 
improved disease free survival to within the range 50% - 
60%. The use of TBI followed by autotransplant is the 
subject of current clinical trials ( Kinsella et al, 1984 
).
4.2.4 OTHER TUMOURS
Several other neoplastic diseases are candidates for high 
dose cytotoxic therapy and marrow rescue. Whether or not 
TBI is incorporated depends on the efficacy of available
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chemotherapeutic agents and the radiosensitivity of the 
tumour. Examples of neoplasms where there is a potential 
role for TBI and marrow rescue are :
1/ Small cell bronchogenic carcinoma or oat cell carcinoma 
of lung. CR rates of 60% are achievable but few are 
maintained, relapses continuing to occur after 2 years of 
disease free survival. Contamination of bone marrow and 
peripheral blood with tumour cells is a frequent 
occurrence ( Dicke and Spitser, 1986 ). High dose
chemotherapy, chest irradiation and autotransplant have 
shown some encouraging results ( Spitser et al, 1985 ).
2/ Breast cancer is highly prone to metastatic spread. 
Intensification therapy of multiple chemotherapeutic 
drugs, each course in conjunction with marrow rescue has 
been proposed ( Dicke and Spitser, 1986 ). Breast cancer 
is a heterogeneous disease but radiation is a current 
mainstay of local treatment, both as external beam therapy 
and also delivered via interstitial implantation.
3/ Malignant melanoma is prone to dissemination and 
although widely believed to be uniformly radioresistant 
actually appears to have a wide spectrum of 
radiosensitivity, both clinically ( Habeshaw and Wheldon, 
1984 ) and experimentally in vitro ( Rofstad, 1986 ).
Local radiotherapy certainly has a role in disease 
management ( Overgaard, 1986 ). At least some widespread 
melanomas may therefore be candidates for TBI and marrow 
transplant. The availability of anti-melanoma antibodies 
means that there is also a potential for the use of 
biologically targeted radiotherapy ( Larson, et al, 1983 )
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4/ For ovarian cancer the cure rate can be high for 
minimal disease. However for extensive disease only low 
levels of cure are acheived. Intensification of 
chemotherapy has been proposed ( Dicke et al, 1984 ). 
Ovarian cancer is also high on the list of candidates for 
biologically targeted radiotherapy and some encouraging 
results have been obtained with intraperitoneal infusions 
of monoclonal antibody conjugated radionuclides ( 
Epenetos, 1987 ).
These examples suffice to show the possible applications 
of systemic chemo-radiotherapy and marrow rescue to the 
treatment of widespread malignant disease.
4.3 PHYSICAL ASPECTS OF TBI
TBI is a systemic therapy and contrasts with the usual 
techniques of radiotherapy where the object is to deliver 
a high dose of radiation to a specified, generally small, 
volume while at the same time reducing the dose to regions 
outwith the treatment volume to a minimum. Conventionally 
for TBI the treatment volume encompasses the whole body. 
This gives rise to a number of physics and dosimetry 
problems. Very large radiation field sizes are required 
typically between 1.5 and 2 metres in length. There is a 
wide spectrum of TBI techniques in use ( Quast, 1987 ). A 
few centres have dedicated TBI facilities available ( e.g. 
Leung et al, 1981 ) but, with the proliferation of centres 
now performing TBI, in most cases a conventional cobalt 
machine or linac is used ( Miller et al, 1976; Aget et al, 
1977; Goolden et al, 1983 ). In order to achieve the large 
field sizes it is nec essary to use a very long treatment
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distance ( 4 metres or therabouts). Due to the inverse
square dependence of radiation dose-rate on distance 
comparatively low dose-rates are common. This has
consequences from a radiobiological point of view. Whole
body dosimetry is a notoriously complex subject; many
factors contribute to this ( van Dyk, 1987 ). The
transition from standard radiotherapy beam measurements to 
the TBI situation requires investigation of dose build-up 
distances, the validity of the inverse square relationship 
and the modifying effects of attenuating filters. There 
are wide variations in body contours, for example from the 
neck to the pelvis. Density fluctuations also occur, the 
most obvious being in the region of the lungs. These 
fluctuations are age-dependent- and also depend on the 
treatment position ( Lagrange et al, 1987 ). Patient
orientation With respect to the treatment fields ( Shank, 
1983 ) and the number of fields used ( Doughty et al, 1987 
) affect the resultant dose distribution as does the 
proximity of structures such as floors and walls in the 
treatment room. With all these factors in operation it is 
no surprise that a great deal of the efforts of physicists 
have been devoted towards achieving an accurate, 
controllable and uniform dose distribution. This has been 
with the aid of CT scanners, complex dose calculation 
algorithms and measurements of actual dose delivered 
either using TLDs or in real-time with diode detectors. 
Dose uniformity can be improved by the liberal use of 
tissue-equivalent bolus material and individualised beam
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compensators. A question which is seldom asked is - How 
important is dose uniformity ? If it is imagined that a 
biologically targeted radiotherapy ( BTR ) technique 
produced a uniform dose throughout the body, then it would 
be considered a failure. In the BTR situation it is easy 
to see that what is required is higher radiation doses 
where there are concentrations of tumour cells. If this 
logic is applied to external beam TBI, in the absence of 
information about the concentrations of tumour cells, it 
is less clear what the conclusions should be. Increasing 
the dose to all regions which can tolerate it may be a 
way, but ,,tolerance, is only a term for a certain level, 
conventionally 5%, of serious side-effects. Many centres 
currently shield lung from the full TBI dose. It seems 
reasonable to ask; if lung is shielded what constitutes 
the next limitation on how high the dose can go ? and, is 
it worth increasing the dose to the rest of the body ? It 
is likely that organs such as liver or kidney may be the 
next most vulnerable to TBI. Can these be shielded and the 
dose increased still further ? This philosophy could be 
described as differential shielding and would result in a 
situation where there were a variety of dose 
prescriptions, one for each individual region of the body. 
Techniques such as localised radiotherapy boosts to the 
CNS and testes are frequently employed to reduce the risk 
of relapse at these sites. They are also explicit 
deviations from uniformity. These illustrations indicate 
that perhaps dose uniformity should f\c>t the goal of TBI 
treatment planning and rather that an engineered
non-uniformity may be better. Biologically targeted 
radiotherapy may be the only practical way in which a 
useful engineered non-uniformity may be achieved. This 
will be the subject of the concluding three chapters of 
this thesis.
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5.0 THE IN-VITRO RADIOSENSITIVITIES OF HUMAN 
JuEUKAEM I A/LYMPHOMA, NEUROBLASTOMA 
AND EWING' S SARCOMA CELLS
Data on the radiosensitivities of human tumour cell lines 
are often published in the scientific and clinical 
literature. A computerised literature search of papers 
published up till the end of 1987 was used to gather the 
survival curve information reported in this thesis. These 
data have been used to derive representative survival 
curves for some forms of human cancer which are currently 
being treated or are proposed to be treated by high dose 
TBI and bone marrow transplantation. The justification for 
following this approach is provided by the work of Fertil 
and Malaise ( 1981 & 1985 ), Deacon et al ( 1984 ) and
Rofstad and Brustad ( 1987 ) who have all reported a
correlation between the in v.ivo qualities of 
radiocurability and controlabi1ity and the in vitro 
radiation responses of relevant tumour cell lines. Where a 
number of data on tumour lines of the same type are 
available the median values of the radiosensitivity 
parameters can be derived. In order to do this reasonably, 
some selection rules are neccessary.
5.1 SELECTION RULES FOR MEDIAN SURVIVAL CURVE PARAMETERS
The most justifiable position to take, appears to be the 
following one. The independent variable is the patient 
from whom a cell line or lines was derived. In effect this 
means that multiple measurements on a cell line or lines 
from the same patient should be pooled before a set of
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pooled measurements are combined to yield median values. 
This approach has the disadvantage that the principle that 
multiple measurements on one line increase the precision 
of the estimate is not allowed for i.e. there is no 
weighting of individual data on the basis of repeat 
measurements. Although this is not ideal it is preferable 
to the alternative position. If individual measurements 
rather than individual patients are taken as the 
independent variable then a disproportionate amount of 
experimental data for one or two cell lines will produce a 
biased estimate of the median. The procedure adopted here 
is thus:
1/ Pool the radiosensitivity data from the cell line or 
lines derived from each individual patient.
2/ Use the pooled data to derive median parameter values.
5.2 IN-VITRO DATA 
5.2.1 LEUKAEMIA/LYMPHOMA
The complete database for human leukae. mi a/lymphoma is 
presented -in Tables C I, II and III ) segregated into the 
three categories of lymphocytic and nonlymphocytic 
leukaemia and lymphoma. Weichselbaum et al ( 1981 )
reported the radiosensitivities of 4 human leukaemic cell 
lines, HL-60 ( promyelocytic leukaemia ), K562 (
erythroleukaemia ), 45 ( acute lymphocytic leukaemia ) and
176 ( acute monomyelogenous leukaemia ). Survival was 
assayed by a colony counting technique. The data of 
Johansson et al ( 1981 ) on 4 B-cell lymphomas was arrived 
at by means of a " growth extrapolation" procedure. This 
involved measuring the concentrations of tumour cells in
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LYMPHOCYTIC LEUKAEMIA
DESIGNATION TYPE DO n REFERENCE
45 ALL 1. 47 1. 1 Weichselbaum, 198
K45 T-cell 0. 61 0. 80 Fitzgerald, 1986
Reh non-B,non-T 0. 53 13. 9 Lehnart, 1986
MOLT-4 T-cell 0. 49 0. 92 Szekely, 1985
MOLT-4 T-cell 1. 30 1.5 Seshadri, 1985
JM ( Jurkat ) T-cell 2. 30 1.6 Seshadri, 1985
CCRF-CEM T-cell 1. 16 1. 1 Seshadri, 1985
APHID-D2 T-cell 1. 13 1.4 ’ Seshadri, 1985
RCH-ACV pre-B-cell 0. 92 1.0 Seshadri, 1985
LYMPHOMA
DESIGNATION TYPE DO n REFERENCE
P3HR-1 B-lymphocytio 1.3 1.2 Johansson, 1982
U715 B-lyphocytic 1.6 1.0 Johansson, 1982
U 698 B-lymphocytic 1.8 1.2 Johansson, 1982
SU-DHL-4 DHL (B-origin) 1. 4 1.2* Johansson, 1982
JY B-lymphocytic 0. 61 2. 13 Fitzgerald, 1986
Daudi B-lymphocytic 0. 57 1. 25 Fitzgerald, 1986
U937 h i st i o/monocyt i c 0. 88 4. 60 Fitzgerald, 1986
HRIK B-lymphocytic 1. 50 1.1 • Seshadri, 1985
FMC-HU-1B B-lymphocytic 0. 90 1. 4 . Seshadri, 1985
DHL = diffuse histiocytic lymphoma
TABLE II
NONLYMPHOCYTIC LEUKAEMIA
3IGNATION TYPE DO n REFERENCE
HL60 promye1ocytic 1. 17 1.3 Weichselbaum, 1981
HL60 APL 0. 83 2.5 Rhee, 1985
HI. 60 monomyeloid 1. 25 2.2 Fitzgerald, 1986
HL60 APL 1. 37 1. 1 Lehnart, 1986
K562 erythro1eukaemi a 1. 65 1.4 Weichselbaum, 1981
K562 erythroleukaemia 1. 41 1. 1 Fitzgerald, 1986
K562 CML 1. 39 4. 5 Lehnart, 1986
KG1 monomyeloid 1. 25 2.2 Fitzgerald, 1986
KG+ e ryth roleukaemia 0. 64 3. 45 Lehnart, 1986
176 AML 0. 76 4. 0 Weichselbaum, 1981
1 AMML (BM) 2. 10 1. 3 Ozawa, 1983
2 APL (BM) 1. 80 1.2 Ozawa, 1983
2 APL (PB) 1. 95 1.0 Ozawa, 1983
3 AMML (PB) 1. 90 1.7 Ozawa, 1983
3 AMML (PB) 1. 85 1. 1 Ozawa, 1983
4 AMML (BM) 1. 40 1.4 Ozawa, 1983
4 AMML (PB) 1. 30 1.3 Ozawa, 1983
4 AMML (PB) 1. 00 1. 1 Ozawa, 1983
5 AML (PB) 1. 35 1.3 Ozawa, 1983
6 AML (PB) 1. 20 1.3 Ozawa, 1983
7 AML (BM) 0. 90 1.2 Ozawa, 1983
8 AMML (PB) 0. 70 1.2 Ozawa, 1983
TABLE III
9 AMML (PB) 0. 70 1. 1 Ozawa, 1983
10 AMML (PB) 0. 55 1.0 Ozawa, 1983
11 AML (PB) 0. 50 1.0 Ozawa, 1983
12 AML (PB) 0. 30 1.0 Ozawa, 1983
CS ANL 0. 63 0. 86 Kimler, 1985
CS ANL 0. 52 0. 97 Kimler, 1985
GH ANL 0. 41 0. 93 Kimler, 1985
GH ANL 0. 61 0. 98 Kimler, 1985
JR ANL 0. 68 0. 91 Kimler, 1985
TC ANL 0. 68 1. 01 Kimler, 1985
GS ANL 0. 72 0. 84 Kimler, 1985
HF ANL 0. 56 1. 11 Kimler, 1985
JL ANL 0. 48 1. 07 Kimler, 1985
LJ ANL 0. 95 1. 29 •Kimler, 1985
APL = acute promyelocytic leukaemia 
CML = chronic rnyeloid leukaemia 
AMML - acute myelomonocytic leukaemia 
AML = acute myeloblastic leukaemia 
ANL = acute nonlymphocytic leukaemia 
BM = bone marrow sample 
PB = peripheral blood sample
TABLE III ( CONTD )
suspension culture 3 to 4 times per week. Repeated 
dilutions were made to keep the concentrations between 
10E5 and 10E6 cells per ml. The increase in cell number 
following varying degrees of dose-dependent inhibition 
stabilised to an exponential function of time. These 
exponential growth curves when extrapolated back to zero 
time yield estimates of the apparent number of initial 
clonogens following radiation insult. Split-dose 
experiments confirmed that these cell lines had little 
repair capacity as suggested by the low values of 
extrapolation number found. Ozawa et al ( 1983 ) reported 
the radiation sensitivities of leukaemic progenitor cells 
in 12 cases of acute nonlymphocytic leukaemia utilising a 
colony counting assay. They found DO values ranging from 
0.3 Gy to 2.1 Gy with a maximum observed extrapolation 
number of 1.7. Kimler et al ( 1985 ) published the results 
of their analysis of the radiosensitivities of human 
nonlymphocytic leukaemia cells. Bone marrow samples were 
obtained from patients prior to treatment. Survival was 
assayed by colony counting. These authors found that the 
leukaemic colony forming cells had survival curves with 
steep slopes and no shoulders. They also found normal bone 
marrow cell radiosensitivity to be high, although not as 
high as for the leukaemic samples. Seshadri et al ( 1985 ) 
reported the radiation sensitivities of two human 
B-lymphocytic lymphoma lines HRIK and FMC—HU-1B, four 
T-cell acute lymphocytic leukaemias; MOLT-4, JM ( Jurkat 
), CCRF-CEM and APHID-D2 and one pre-B-acute lymphocytic 
leukaemia RCH-ACV. These authors used a clonogenic end
point and found DO values in the range 0.90 Gy to 2.3 Gy 
with extrapolation numbers ranging from 1.6 to 1.0. They 
singled out the T-cell ALL line JM ( Jurkat ) as being 
radioresistant ( DO = 2.3 Gy : n = 1.6 ) while all the
others were said to be similar to previously studied 
nprmal T-lymphocytes. Rhee et al ( 1985 ) studied the 
response of the acute promyelocytic cell line HL-60 to 
fractionated irradiation and single irradiations at 
different dose-rates. They found a substantial split-dose 
repair capacity and a dependence of the observed DO on 
dose-rate ranging from 0.76 Gy at 1.1 Gy/rnin to 1.20 Gy at 
0.03 Gy/min. The survival curve parameters of DO =0.83 :
n = 2.5 which were reported for a dose-rate of 0.78 Gy/rnin 
are taken for the purposes of the derivation of the 
median. Szekely and Lobreau ( 1985 ) reported a high
radiosensitivity for the T-cell acute lymphocytic 
leukaemia cell line MOLT-4 ( DO = 0.49 Gy : n = 0.92 ). No 
split dose recovery was seen as predicted by the 
exponential - nature of the survival curve. The data of 
Fitzgerald et al ( 1986 ) for the human B-cell lymphoma 
lines JY and Daudi, the histiocytic/monocytic lymphoma 
line U937 and the leukaemic lines K45 ( T cell ), K562 (
erythroleukaemia ), HL60 and KG1 ( monomyeloid ) were 
derived using a colony counting procedure. These authors 
used 3 different dose-rates of 0.05 Gy/'min, 0.20 Gy/min 
and 2.00 Gy/min on each of the cell lines. They found that 
for 6/7 of the human cell lines examined there was no 
significant dose-rate effect. However for 1 line ( U937 ) 
a clear dose-rate effect was seen. For the purposes of the
derivation of the median parameters, the result from the
2.00 Gy/min experiments on this line are used. Lehnart et 
al ( 1986 ) reported the radiosensitivities of 5 human
leukaemic cell lines, Reh ( non-T, non-B ALL ), NALM-6 ( 
B-cell ALL ), HL60 ( acute prornyelocytic leukaemia ), KG+ 
( erythroleukaemia ) and K-562 ( chronic myelocytic
leukaemia ) based on a colony counting assay. These 
authors used both linear quadratic and multitarget
functions to describe the resultant survival curves. The 
linear quadratic gave a better fit to the data. 
Multitarget functions appeared to be innappropriate, as 
the survival data was of the continuously bending variety. 
However, in order to define median radiosensitivity 
parameters the multitarget descriptions must be used. This 
is because the data from all the other groups were 
analysed using multitarget functions and it is not 
possible to define medians when two different 
representations are used. The quantity of mean 
inactivation dose, as defined by Kellerer and Hug ( 1972 ) 
and subsequently used by Fertil et al ( 1984 ) is a
possible way to compare survival curves described by
different mathematical functions, but this suffers from 
the disadvantage that the "fine structure" of the curve 
shape is lost. The high extraploation numbers and very low 
DO values found for two of these lines ( Reh, KG+ ) may be 
partially explained by the innappropriateness of the curve 
fit.
Several cell lines were the subject of studies by more 
than one group. Line HL60 was used by Weichselbaum et al,
Rhee et al, Fitzgerald et al and Lehnart et al and with 
the exception of Rhee et al so was line K562. Line K45 of 
Fitgerald et al is the same as 45 of Weichselbaum et al. 
Line KG1 of Fitgerald et al is equivalent to line KG+ of 
Lehnart et al. Finally, some of the data of Ozawa et al 
and Kimler et al involve repeat measurements on the same 
sample or on samples from different sites ( e.g. 
peripheral blood versus bone marrow ). The intercomparison 
of derived radiosensitivity parameters for these lines is 
shown in Table ( IV ).
There is a degree of variation between measurements on 
equivalent tumour lines. The lines where the DOs measured
by different groups differ by a factor of 2 or more are
45/K45, MOLT-4 and KG1/KG+. The differences in the last 
line may be partly due to the innappropriateness of a 
multitarget fit to the data of Lehnart, et al as described 
above. This line is also classified differently by the two 
experimental groups. Lehnart’s value of 4.5 for the
extrapolation number -of line K562 contrasts with the
measurements of the other two groups as does the 
histological classification. It appears that there are 
greater differences between established cell lines than 
between fresh patient material, but this may be deceptive. 
Intercomparisons between established cell lines are 
between different laboratories, while the multiple 
measurements on fresh patient samples were carried out in 
the same labs using the same techniques and subject to the 
same sources of error. It is not possible to say to what 
extent these differences are due to true variations in the
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»INTERCOMPARISON OF LEUKAEMIC CELL LINES OF COMMON ORIGIN
>IGNATION TYPE DO n REFERENCE
45 ALL 1. 47 1.1 Weichselbaum, 1981
K45 T-cell ALL 0. 61 0. 80 Fitzgerald, 1986
HL60 promyelocytic . 1. 17 1.3 Weichselbaum, 1981
HL60 APL 0. 83 2.5 Rhee, 1985
HL60 monomyeloid 1. 25 2.2 Fitzgerald, 1986
HL60 APL 1. 37 1. 1 Lehnart, 1986
K562 erythroleukaemia 1. 65 1.4 Weichselbaum, 1981
K562 erythro1eukaemi a 1. 41 1. 1 Fitzgerald, 1986
K562 CML 1. 39 4.5 Lehnart, 1986
MOLT-4 T-cell ALL 1. 30 1.5 • Seshadri, 1985
MOLT-4 T-cell ALL 0. 49 0. 92 Szekely, 1985
KG1 monomyeloid 1. 25 2.2 Fitzgerald, 1986
KG+ erythroleukaemia 0. 64 3. 45 Lehnart, 1986
2 APL (BM) 1. 80 1.2 Ozawa, 1983
2 APL (PB) 1. 95 1.0 Ozawa, 1983
3 AMML (PB) 1. 90 1.7 Ozawa, 1983
3 AMML (PB) 1. 85 1. 1 Ozawa, 1983
4 AMML (BM) 1. 40 1. 1 Ozawa, 1983
4 AMML (PB) 1. 30 1.3 Ozawa, 1983
4 AMML (PB) 1. 00 1.0 Ozawa, 1983
CS ANL 0. 63 0. 86 Kimler, 1985
CS ANL 0. 52 0. 97 Kimler, 1985
GH ANL 0. 41 0. 93 Kimler, 1985
GH ANL 0. 61 0. 98 Kimler, 1985
TABLE IV
cell lines as they have evolved. Some offshoots may have
become radiation sensitive, others more resistant. 
Alternatively different experimental techniques may be the 
cause of the variations, or a combination of the two. Had 
there been some intergroup comparisons of fresh patient
material, the sources of variation may have been more
clearly seen.
The intrinsic radiosensitivity of lymphocytes in chronic 
lymphocytic leukaemia was the subject of a study reported 
by Thomson et al in 1985. These authors examined the 
radiation responses of lymphocytes from 18 patients. 
Apparent survival was assayed by determining the number of 
intact cells exhibiting nuclear pyknosis, which was a 
function of both dose and the time elapsed since
irradiation. They found that the survival levels of 14/18 
could be described by a function
5 (J,t) = e*K'ir)+ ~
Where d is the dose, t is the time elapsed since
irradiation, DO is the exponential survival curve
parameter describing radiosensitivity and is the first 
order constant governing cell death. The computed values 
of DO for these 14 cases ranged from 0.31 Gy to 1.28 Gy 
with a mean value of 0.88 Gy and standard deviation of
0.27 Gy. For the remaining 4 samples atypical responses 
were observed. Two behaved as if there were 2
sub-populations of differing radiosensitivity. One behaved 
as if there were a single responding sub-population ( DO
2.2 Gy) co-existing with extremely radioresistant cells
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which v/ere not affected by the highest radiation dose used 
( 5 Gy). The last sample's behaviour could be explained by 
either a single population of radiosensitive cells with a 
very slow death rate or alternatively by a mixed 
population of radiosensitive and radioresistant cells in 
indeterminate proportions. It should be noted that the 
assay used could not assess clonogenic potential. These 
data are therefore not directly comparable with the 
conventional survival curves reported above and are not 
used in the estimation of median radiosensitivity 
parameters. CLL is a condition not presently considered 
for TBI and marrow rescue, but it is interesting to note
that, for the most part, the responses are suggestive of
high radiosensitivity and no shoulder on the part of CLL 
lymphocytes.
The database consists of 54 sets of radiation survival 
measurements made on cell lines derived from 40 individual 
patients. Multiple measurements on the same cell line have 
been pooled-as described previously and the pooled data is 
shown in Table V and plotted as a scatter diagram in fig (
5.1 ). This diagram shows some degree of heterogeneity
but, in general, the values of the extrapolation number, n 
are clustered around 1 indicating a characteristic lack of
shoulder. The median value of n is 1.2. The values of DO
are typically below 1 Gy, the median is 0.9 Gy. This 
indicates that the radiosensitivities are relatively high 
in comparison with other tumour types. Taking both 
parameters together, for the most part, the leukaemias 
exhibit high radiosensitivity and little or no capacity to
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POOLED DATA FOR LEUKAEMIC CELL LINES
DESIGNATION DO
HL60 1.21
. K562 1.41
45/K45 1.04
KG1/KG+ 0.95
176 0.76
Reh 0.53
P3HR-1 1.3
U715 1.6
U698 1.8
SU-DHL-4 1.4
JY 0.61
Daudi 0.57
U937 0.88
MOLT-4 0.9
JM(Jurkat) 2.3
CCRF-CEM 1.16
APHID-D2 1.13
RCH-ACV 0.92
HRIK 1-50
FMC-HU-1B 0.90
1 2.1
2 1-88
3 1-88
4 1.30
n REFERENCE
1.75 W,F,L,R
1.4 W,F,L
0.95 W,F
2.83 F,L
4. 0 W
13.9 L
1.2 J
1.0 J
1.2 . ' - J
1.2 J
2. 13 F
1.25 F
4.60 F
1.21 SI, S2
.1.6 SI
1. 1 SI
1.4 SI
1.0 SI
1. 1 SI
1.4 SI
1.3 0
1.1 0
1.4 0
1.3 0
TABLE V
5 1. 35 1.3 0
6 1. 20 1.3 0
7 0. 90 1.2 0
8 0. 70 1.2 0
9 0. 70 1.1 0
10 0. 55 1.0 0
11 0. 50 1.0 0
12 0. 30 1.0 0
CS 0. 58 0.92 K
GH 0. 51 0. 96 K
JR 0. 68 0.91 K
TC 0, 68 1. 01 K
GS 0. 72 0.84 K
HF 0. 56 1. 11 K
JL 0. 48 1.0? K
LJ 0. 95 1. 29 K
KEY TO REFERENCES
W - Weichselbaum et al, 1981 
F - Fitzgerald et al, 1986 
L - Lehnart et al, 1986 
R - Rhee et al, 1985 
J - Johansson et al, 1982 
SI - Seshadri et al, 1985 
S2 - Szekely et al, 1985 
0 - Ozawa et al, 1983 
K - Kimler et al, 1985
TABLE V ( CONTD )
LEUKREMIR/LYMPHOMR RRDIOSENSITI VITY
D0/Gy
0
Median n5
0
5
0
X X
5
. 0
Median D0
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n
Fig 5.1 Scatter diagram of the values of the survival 
curve parameters DO and n found for human 
leukaemia/lymphoma. The values of DO are typically low ( 
median 0.9 Gy ), those of n are clustered around 1.0 (
median 1.2 )
repair radiation damage. They consequently would not be 
expected to display a significant fraction size or 
dose-rate effect. Where this prediction was tested ( 
Johansson et al, Fitzgerald et al, Szekely and Lobreau ) 
it was usually found to be true, although the studies of 
Rhee et al on HL-60 and Fitzgerald et al on U937 should be 
borne in mind.
As the best estimate of a representative survival function 
the median radiosensitivity parameters DO and n are used 
in an unmodified multitarget equation viz.
5(d) = i -  (> - ®*lp(7 (f-7)
This function is used in the calculations of the effects 
of different fractionation schedules on
1eukaemi a/lymphoma.
5.2.2 NEUROBLASTOMA
The in-vitro radiosensitivity database for neuroblastoma 
presently consists of measurements from cell lines derived 
from 8 different patients. The line NB-100 reported by 
Evans et al, 1986 is the same as CHP-100 ( Bellamy et al, 
1984; Schlesinger et al, 1976). Cells were irradiated as 
exponentially growing monolayer cultures ( NB1, Ohnuma et 
al, 1977; CHP-100, Lan-1, Bellamy et al, 1984; Lan-1, 
Weichselbaum et al, 1980, SK-N-SH, Marchese et al, 1987 ) 
as single cell suspensions ( HX138, Deacon et al, 1985a; 
HX142, Deacon et al, 1985b) and as multicellular tumour 
spheroids ( HX138, Deacon et al, 1985a; NB1-G, NB2—G, 
Wheldon et al, 1985a; NB-100, Lan-1, Evans et al, 1986). 
Ohnuma et al ( 1977 ) found an unshouldered survival curve
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for NB-1 with a DO of 1.13 Gy and suggested that this 
indicated the absence of sub-lethal damage repair, 
although this was not tested experimentally. Weichselbaum 
et al ( 1980 ) reported the radiation sensitivity of the 
human neuroblastoma line Lan-1 passaged over 100 times. 
They found DO to be 1.49 Gy, not significantly different 
from the DOs of the 8 other tumour types examined but the 
extrapolation number of 1.2 was one of the two smallest. 
The lines Lan-1 and CHP-100 were included in the study of 
Bellamy et al ( 1984 ) on the sensitivities of human and 
murine tumour cell lines to radiation and drugs. These 
authors found Lan-1 to be very sensitive to radiation ( DO 
= 0.66 Gy ) in contrast to the data of Weichselbaum ( DO = 
1.49 Gy ). Examination revealed differences in morphology 
and surface markers between the two strains and Bellamy et 
al suggested -that their Lan-1 was identical to the 
original reference ( Seeger et al, 1977 ) whereas that
used by Weichselbaum had altered characteristics. They 
also found the line CHP-100 to be radiosensitive ( DO = 
0.79 Gy ) as was another neuroblastoma line TR-14A, data 
for which was not reported. Deacon et al ( 1985a ) studied 
the radiation response of the human neuroblastoma line 
HX138 in-vitro with single cell suspension and 
multicellular tumour spheroids ( MTS ) and also in-vivo as 
xenografts in immune suppressed mice. Radiation response 
was assessed by growth delay for spheroids and xenografts 
and by clonogenic assay for all experimental systems. A 
high degree of radioresponsiveness was observed in the 
growth delay experiments. Clonogenic assay produced
shoulderless survival curves. The cell suspension system 
yielded a DO of 0.9 Gy under oxic conditions. The mean DO 
from the MTS experiments was 1.26 Gy while for cells from 
xenografts irradiated in oxic conditions the DO value was 
1.51 Gy. Sub-lethal damage repair capacity assessed in the 
suspension experiments was modest. PLDR following a 24 
hour delay in plating with the MTS experiments had the 
effect of increasing the DO value by a factor of 
approximately 1.4. No PLDR was seen in the xenograft 
experiments. The authors concluded that this tumour line 
was intrinsically highly radiosensitive with a limited 
repair capacity. In another paper Deacon et al ( 1985b ) 
reported on the line HX142. Irradiated in suspension 
culture this yielded a survival curve with n = 2.3 and DO =
0.74 Gy. Xenograft experiments produced estimates of 1.4 
for n and 1.43 Gy for DO. Again they concluded that 
neuroblastoma cells were intrinsically highly
radiosensitive. Wheldon et al ( 1985a ) reported the »
radiosensitivities of . two neuroblastoma lines designated 
NB1-G and NB2-G grown as MTS. Clonogenic surviving 
fraction was estimated for each dose level by 
extrapolation of the regrowth curve to zero time. The 
consequent survival curves indicated radiosensitivity with 
little capacity for the accumulation and repair of 
sub-lethal damage ( DO = 1.04 Gy : n = 1.18 for NB1-G, DO 
= 0.81 Gy : n = 1.36 for NB2-G ). In a subsequent paper (
Wheldon et al, 1986 ) split dose experiments were carried 
out on the line NB1-G showing no significant difference in 
the effectiveness of single compared to split dose
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irradiation. Another paper ( Wheldon et al, 1987 )
examined the effect on NB1-G spheroids of fractionated 
regimes calculated to be isoeffective for late responding 
normal tissues. As this constituted a test of some of the 
predictions to be described later in this thesis 
discussion of this experiment will be deferred until then. 
Evans et al ( 1986 ) examined three human neuroblastoma 
lines Lan-1, NB-100 and NB-134 grown as MTS. Data were 
presented only for Lan-1 and NB-100 in the form of 
regrowth curves of spheroid diameter versus time for a 
variety of single doses. The neuroblastomas were found to 
be significantly more radiosensitive than other tumour 
lines examined ( Yuhas, written communication, 1984 ). In 
order to derive survival curve parameters, diameters have 
been converted to log( volume) assuming spherical geometry 
and apparent surviving fractions calculated by 
back-extrapolation of the exponential portion of the 
regrowth curve as described by Wheldon et al, 1985. The 
transformed growth curves of Evans et al are reproduced in 
figures 5.2 & 5.3 along with the construction lines used 
to derive apparent clonogenic surviving fraction. It can 
be seen from the figures that this approach seems more 
valid for the Lan-1 data than for the NB-100 data. However 
both sets and the survival curve parameters derived from 
them are included in the review. Marchese et al ( 1987 ) 
presented survival curves for a human neuroblastoma line 
SK-N-SH growing in both exponential and density-inhibited 
plateau phase culture for both immediate and 6 hour 
delayed plating. For consistency with the other data the
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Fig 5.2 Regrowth curves for human neuroblastoma MTS line 
LAN-1 after Evans et al, 1986. The numbers refer to the 
given doses for the corresponding regrowth curve. 
Diameter values have been converted to log ( volume ). 
The straight lines are constructions used to estimate 
clonogenic surviving fraction based on the method of 
Wheldon et al, 1985.
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Fig 5.3 Regrowth curves for human neuroblastoma MTS line 
NB-100 after Evans et al, 1986. The numbers refer to the 
given doses for the corresponding regrowth curve. 
Diameter values have been converted to log ( volume ). 
The straight lines are constructions used to estimate 
clonogenic surviving fraction based on the method of 
Wheldon et al, 1985.
exponential phase results have been used here ( this is 
the closest to the clinical situation with disseminated 
microscopic disease, plateau phase may be more 
representative of bulk disease ). The data for immediate 
plating was selected, although it is apparent that there 
is little difference between the survival curves for 
immediate and 6-hour delayed plating for exponential phase 
culture. The survival curve was redrawn to yield the 
radiosensitivity parameters. This study indicated that the 
line SK-N-SH had a high capacity for PLDR in plateau 
phase.
Survival curve data are shown in Table VI and plotted as 
a scatter diagram in figure ( 5.4 ). The median values of 
the multitarget parameters n and DO derived in accordance 
with the rules described earlier were: median n = 1.75; 
median DO = 1.06 Gy. These data describe small shouldered 
radiosensitive cells, although not so radiosensitive as 
the leukaemias. Rather than take these at face value and 
use a standard multitarget equation to describe radiation 
sterilisation an attempt has been made to derive a "best 
estimate" of the median survival curve with a non-zero 
initial slope for this group of neuroblastoma cell lines. 
The "best estimate" was arrived at by the following 
procedure. For all the survival curves surveyed the upper 
limit on the initial slope was the gradient of the
straight line joining the origin and the first data point. 
For pure exponential curves ( NB1, HX138 ) the initial
slope is simply equal to the final slope. For the line 
HX142 an actual survival curve was not available, only the
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NEUROBLASTOMA RADIOSENSITIVITY
DESIGNATION DO n REFERENCE
NB1 1. 13 1.0 Ohnuma, 1977
LAN-1 1. 49 1. 20 Weichselbaum, 1980
LAN-1 0. 66 2. 13 Bellamy, 1984
LAN-1 1. 78 5.4 Evans, 1986
CHP-100 0. 79 3. 12 Bellamy, 1984
NB-100 1. 19 15. 8 Evans, 1986
HX138(sus) 0. 9 1.0 Deacon, 1985(a)
HX138(sph) 1. 26 1.0 Deacon, 1985a
HX142 0.74 2.3 Deacon, 1985b
NB1-G 1. 04 1. 18 Wheldon, 1985a
NB2-G 0. 81 1. 36 Wheldon, 1985a
SK-N-SH 1.29 3.0 Marchese, 1987
N E U R O B L A S T O M A  RAD I O S E N S I T I  VITT
D0/Gy
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Fig 5.4 Scatter diagram of the values of the survival 
curve parameters DO and n found for human neuroblastoma. 
.The values of DO are typically low ( median 1.06 Gy ), 
although not as low as found for leukaemia/lymphoma. The 
values of n are also low ( median 1. 75 )
parameters n and DO, the initial slope was taken as 0 i.e. 
in the equation
The values of these initial slopes are shown in table VII. 
The median was D1 = 2.04 Gy. The second component of slope 
D2 was calculated from the relationship
where DO is the median value of the final slopes. 
Therefore D2 = 2.21 Gy.
T W O  e n n f t + ' . i  n n « 3  w p r p  ‘hhf=»n o n n  c f r i  1 r>+- p H
As a best estimate of the true survival* curve for all 
doses the mean on a log-linear scale of these two 
equations was taken
i.e. the geometric mean in terms of surviving fractions. 
This modified survival curve equation was used in the 
calculations of the effects of different fractionation 
schedules on neuroblastoma.
The database on the in-vitro radiosensitivity of Ewing's 
Sarcoma is rather limited. Only two cell lines, designated 
5838 and 4 5 7 3 have been the subject of studies aimed at 
producing survival curves ( Kinsella et al, 1984 ). The
survival data were analysed using a multitarget function 
to yield n = 6.0 : DO = 1.26 Gy for the line 5838 and n =
5.2.3 EWING'S SARCOMA
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NEUROBLASTOMA INITIAL SLOPES
DESIGNATION D1 REFERENCE
NB1 1. 13 Ohnuma, 1977
LAN-1 2. 05 Weichselbaum, 1980
LAN-1 1 . 30 Bellamy, 1984
LAN-1 5. 5 Evans, 1986
CHP-100 25. 6 Bellamy, 1984
NB-100 4. 2 Evans, 1986
HX138(sus) 0. 9 Deacon, 1985a
HX138(sph) 1 . 26 Deacon, 1985a
HX142 00 Deacon, 1985b
NB1-G 1. 47 Wheldon, 1985a
NB2-G 2. 64 Wheldon, 1985a
SK-N-SH 2.03 Marchese, 1987
TABLE VII
3.2 : DO = 2.04 Gy for line 4573. On the basis of these 
data the authors rec ommended a schedule of 2 fractions of 
4 Gy for TBI. It is apparent from examination of the 
survival data that a continuously bending function with a 
non-zero initial slope would give a better fit. The 
parameters which fit a linear-quadratic to the survival 
data are d. =0.16 Gy-1 : p =0.051 Gy-2 for line 5838 and 
si =0.25 Gy-1 : p =0.01 Gy-2 for line 4573 ( Wheldon et 
al, 1985b ). It is interesting to note that the
Ujf ratios for the two lines ( 3 Gy for 5838 and 25 Gy for 
4573 ) are very dissimilar suggesting that their
dose-rate dependence are also dissimilar. This is another 
example of the heterogeneity of tumour radiosensitivity 
within the same clinical entity. Due to the scarcity of 
data it is not possible to come to any conclusions 
regarding the radiation characteristics of a "typical" 
Ewing's Sarcoma cell line. In the subsequent analysis both 
sets of oL and p  are used individually. The different LQ 
parameters - will lead, to different predictions of optimal 
fractionation schedules for the two lines as will be seen 
later.
The survival equations which will be used to describe 
Ewing's Sarcoma are therefore;
fractionation dependence and; by implication, their
Line 5838
Line 4573
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6 .0 FRACTIONATED VERSUS LOW DOSE-RATE TOTAL BODY 
IRRADIATION : RADIOBIOLOGICAL CONSIDERATIONS IN THE 
SELECTION OF TREATMENT SCHEDULES
As has been described in previous chapters the major
dose-limiting constraint for TBI with marrow rescue is
lung where radiation damage is manifest as interstitial
pneumonitis. It is widely recognised that fractionating
the dose or reducing the dose-rate enables a substantial
increase in total dose for the same level of toxicity. In
1979 Peters et al suggested that this phenomenon when
considered alongside the shapes of murine haemopoietic
cell radiation survival curves provided a rationale for
using fractionated TBI schedules for bone marrow
transplantation rather than a single fraction given at a
high dose-rate. Similar arguments can be advanced for low
dose-rate TBI. Song et al ( 1981 ) challenged these
suggestions stating that in their judgement the
therapeutic gain due to fractionation was overestimated by
other investigators. 'This prompted a correspondence (
Peters and Withers, 1982; Song et al, 1982 ) where the two
sides of the disagreement were set out. The crux of the
problem relates to the repair capacities of the target
cells for TBI. In the previous chapter the in-vitro
radiosensitivities for human leukaemias and neuroblastomas
were reviewed. The conclusion was that these
have,typically, little repair capacity as evidenced by the
lack of a shoulder on the survival curves, although there
were exceptions with significant repair capacity. However,
on the whole, this work supports the argument of Peters et
al over that of Song et al. For these tumour types cell
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survival after fractionated TBI would be little influenced 
by fraction size and consequently the increase in total 
dose brought about by fractionation or dose-rate reduction 
will provide a corresponding proportional increase in log 
cell kill ( i.e. the number of decades of reduction of 
clonogenic tumour cells ). Compared to a single high 
dose-rate fraction the irradiation time required for a low 
dose-rate exposure is longer. For fractionated schedules 
it is longer still. The proliferation effects therefore 
favour single, high dose-rate fractions but, as will be 
shown in the next chapter, the magnitude of these effects 
\ Si not large enough to change the above conclusions. The 
work reported in this chapter therefore starts from the 
premise that fractionated or low dose-rate TBI is more 
appropriate for the treatment of radiosensitive tumours 
like leukaemia and neuroblastoma which have low capacities 
for repair of sub-lethal damage.
6.1 EQUIVALENCE CONDITIONS FOR FRACTIONATED 
AND LOW DOSE-RATE TBI
In this section Dale's extension of the LQ model to low 
dose-rates will be used in order to calculate the 
dose-rates required to make continuous irradiation 
treatment therapeutically equivalent to fractionated 
treatment. This will enable some conclusions to be drawn 
with respect to which of these 2 modalities is preferable. 
The response of lung to fractionated radiation is 
characterised by a large dependence on fraction size and 
almost independence of the overall treatment time ( Travis 
et al, 1983; Wara et al, 1973 ). In terms of the LQ model
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the characteristic value of is low, most estimates
being around 3 Gy. Based on the radiobiological 
characteristics of human leukaemias and neuroblastomas, to 
a first approximation and in the absence of proliferation 
effects, the sterilisation of tumour cells will depend 
only on total dose ( i.e. independent of fractionation and 
dose-rate ). In his 1985 paper Dale derived an equation 
describing the parameters of fractionated and continuous 
low dose-rate schedules of equal total dose which should 
also be of equal biological effectiveness. This was 
arrived at by equating separately the linear and quadratic 
components of damage. The relationship is independent of 
U p  ratios and can be written as
Where N is the number of fractions in the fractionated 
schedule and T is the irradiation time.of the continuous 
schedule. The parameter yu is the first order time 
constant for the decay of the capacity of sub-effective 
lesions to interact. This is usually interpreted as repair 
of sub-lethal damage. The equation is identical to the 
general formula of Liversage ( 1969 ). Solutions to this 
equation will satisfy the dual criteria that:
1/ They will be biologically equivalent for a tissue with 
repair constant
2/ They will be biologically equivalent for tumour cells 
having low capacities for SLD repair ( same total dose ). 
The schedules with the required parameters will thus be 
Interchangeable and the choice of which type to use for
K-v^ J
CcO
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TBI can be determined by convenience. This equation can be 
solved for T for different values of N and ^  , 
corresponding to different numbers of fractions in the 
fractionated schedule and different repair constants. The 
alternative quantity of repair half-time T,y is given 
simply by
T*
Due to the appearance of the term exp( -^ w-T) equation 
(6.1) must be solved by a numerical approach. A 
computer-based method of false position has been used. 
Figure 6.1 shows how T varies as a function of N for 
different values of the repair half-time, Ty^.
For lung the repair half-time has been estimated as 1.5 
hours ( Thames et al, 1984 ). The use of the analysis is 
illustrated in the following example.
6.1.1 APPLICATION TO FRACTIONATED AND PROTRACTED TBI
A TBI schedule of 6 fractions of 2 Gy ( i.e. a total dose 
of 12 Gy ) is currently used in a number of centres for 
the treatment of leukaemia ( Clift et al, 1982; Goolden et 
al, 1983 ). By examination of figure 6.1 it can be seen
that the irradiation time required for a continuous low 
dose-rate exposure to achieve the same total dose ( and
hence anti-leukaemic effect ) and also the same level of 
lung damage is 23.6 hours ( corresponding to a dose-rate 
of 0.51 Gy hr-1 ). In the next chapter it is suggested 
that 10 fractions of 1 .4 Gy ( i.e. a total dose of 14 Gy ) 
can be an optimal fractionation schedule in some
circumstances. For this schedule fig'ure 6 . 1 and thus
equation ( 6 . 1 ) predicts an isoeffective irradiation time
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Fig 6.1 T is the irradiation time for a single low 
dose-rate exposure to produce the same biological effect 
as a fractionated schedule of the same total dose given 
in N fractions. The relationship is shown for different 
assumed values of T y , the half-time for repair of 
rad i at i on darnage.
of 41.0 hours ( corresponding to a dose-rate of 0.34 Gy 
hr-1 ). It is apparent that these times are unlikely to be 
acceptable for practical reasons.
When the term exp( -yUT) can be neglected (i.e. << 1 )
approximately when ^  T > 5 or in this example T > 10
hours equation (6 .1 ) can be reduced to
* .
/  -  0
Inverting and separating the terms gives
therefore ___________
x I - ]/ \I —  z / a/
/UT " Z
rejecting the alternative root which violates the 
condition > 5. Finally
^ __________________
T  = ■ s *  0  - ~ * /A) )
T may then be found directly from the above equation. From 
figure 6 . 1 it can be seen that this may be used for values 
of N of 3 or more.
It should be noted that equivalence can only be achieved 
for one value of the repair kinetic parameter yU . This 
value determines the irradiation time and hence dose-rate 
which must be used. Taking the previous example and using 
a repair half-time of 1 hour the required irradiation 
times are 15.7 hours ( equivalent to 6 fractions of 2 Gy) 
and 27.3 hours ( equivalent to 10 fractions of 1.4 Gy ). 
For a repair half-time of 2 hours the times are 31.4 hours 
( equivalent to 6 fractions of 2 Gy ) and 54.7 hours
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( equivalent, to 10 fractions of 1.4 Gy ). This information 
is presented in Table VIII.
SCHEDULE
10 X 1.4 Gy
27.3 hr
41.0 hr
54.7 hr
Irradiation times required for single fractions.
TABLE VIII
In terms of the LQ model equation (6.1) must be satisfied 
in order that the non-linear components of radiation 
damage from fractionated and continuous schedules be 
equal. There is some evidence that the timescale of repair 
may vary from tissue to tissue with acute responders 
having shorter times- ( Thames et al, 1984 ). This means 
that equation (6 .1 ) will not be satisfied for all tissues. 
If a value appropriate for lung is taken the fractionated 
schedule will produce a greater amount of quadratic damage 
in acute responders than the continuous schedule. This 
would not be expected to be a large effect because for 
high values of ( "10 Gy ) the quadratic damage will
be relatively less important. The irradiation time 
required for the continuous schedule is dependent on the 
number of fractions in the fractionated schedule. It 
follows that hyperfractionated schedules require a longer 
irradiation time for an equivalent continuous exposure and
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EQUIVALENT 
REPAIR HALF-TIME/HRS 6 X 2 Gy
1.0 15.7 hr
1.5 23.6 hr
2.0 31.4 hr
will be consequently more difficult to mimic 
radiobiologically. This point was illustrated in the 
numerical example.
6.2 PROLIFERATION EFFECTS
Up till now the assumption has been made that 
proliferation effects are negligible. This enabled the 
Liversage formula ( equation (6.1) ) which applies for
equal total doses to be used. In reality tumour cell 
proliferation is an important process and may in some 
sorts of treatment be one of the major factors determining 
cure ( e.g Trott and Kummerrnehr, 1985 ). For TBI,
proliferation effects may be expected to be important for 
fractionated schedules but probably negligible for 
continuous low dose-rate irradiations ( even those lasting 
an entire day ). This means that, from the point of view 
of tumour cells, fractionated schedules must have a 
greater total dose than single irradiations to produce the 
same level of sterilization. The difference in dose is 
that required to counteract the growth in the tumour cell 
population over the duration of the fractionated schedule. 
For example if a TBI schedule of 5 days duration is being 
used to treat a tumour cell population with a doubling 
time of 2 days, 2. 5 doublings will occur over this time ( 
i.e. 0.75 logs ). The total dose of the fractionated 
schedule will have to be higher by the equivalent of 0.75 
logs of tumour cell reduction. The possible dose reduction 
for a single exposure compared to a fractionated schedule 
depends on the radiosensitivity of the target tumour 
cells. Based on the information contained in chapter 5 for
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human leukaemias and neuroblastomas a reasonable 
approximation of a "typical" survival curve would be 
shoulderless and would have a DO of about 1 Gy. In order 
to arrive at a mathematical equivalence condition to 
describe this situation it is necessary to use some of the 
LQ model quantities described in chapter 3.
For a continuous low dose-rate schedule to be equivalent 
to a fractionated schedule we require
Rff * e s p  = « T>t  (i.u)
REf is simply ( l+d/( <kjjS )) where d is the dose per 
fraction of the fractionated schedule.
.. . fi - r ,  U - » K > ~ r»\ Ll »
*• / “-(P/p) t ^  '
Where R is the dose-rate, T is the irradiation time and 
is the time constant for repair of radiation damage. As Dc 
= RT, equation (6.4 ) may be written as
which can be expressed as __
ZVc I I -  \  0 - ~ ^  + ^  )g 0
I ^  U
It is reasonably simple to solve this equation for T 
numerically by computer using the method of false 
position. This approach is used in the following examples.
6.2.1 APPLICATIONS
For lung the e</j? ratio has been estimated at around 3Gy. 
Taking the same two schedules as in the previous example 
we will look at the predicted irradiation times
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for equivalent effects on lung tissue and tumour cells. A 
schedule of 6 fractions of 2 Gy, two fractions per day 
takes approximately 2.5 days to complete. For a tumour 
cell population doubling time of 2 days this corresponds 
to 1.25 doublings or 0.38 logs. The dose needed to reduce 
the surviving fraction by this amount is 0.87 Gy therefore 
the total dose of the single irradiation can be reduced by 
this amount i.e. to 12-0.87 = 11.13 Gy. Substituting this 
value into equation ( 6.7 ) and solving gives a T of 17.68 
hours
This value along with the corresponding values for tumour 
doubling times of 4 days and 20 days are shown in Table 
IX. For a schedule of 10 fractions of 1.4 Gy, twice daily 
the duration of treatment is approximately 4.5 days. This 
corresponds to 2.25 doublings of a tumour cell population 
with a doubling time of 2 days ( i.e. 0.68 logs ). The 
required dose for this level of sterilisation is 1.56 Gy. 
Consequently the single fraction need only have a total 
dose of 14-1.56 = 12.44 Gy. Solving equation ( 6.7 ) for 
this leads to a predicted irradiation time of 25.22 hours. 
The corresponding times for 4 and 20 day doubling times 
are also shown in Table IX. It should be noted that this 
argument neglects any effects of tumour cell cycle 
redistribution, which would be expected to favour the 
longer ( fractionated ) schedule. The irradiation times of 
Table IX should therefore be considered as lower limits.
EQUIVALENT SCHEDULE 
DOUBLING TIME/DAYS 6 X 2 Gy 10 X 1.4 Gy
2 Dose = 11. 13 Gy Dose = 12. 44 Gy
Irr.time = 17. 68 hr Irr.time = 25. 22 hr
4 Dose = 11.57 Gy Dose = 13. 22 Gy
Irr.time = 20.49 hr Irr.time = 32. 16 hr
2 0 Dose = 11.91 Gy Dose = 13. 84 Gy
Irr.time = 22.91 hr Irr.time = 38. 99 hr
Equivalent total doses and nec essary irradiation times 
for single fractions to be equivalent to the indicated 
fractionated schedules for both tumour cells with doubling 
times shown and a LQ model tissue with 3Gy and Ty^  =
1 .5 hours.
TABLE IX
It should be noted that where the term exp(-yfcT) can be 
neglected an analytical solution for T is possible. In 
this case equation ( 6 . 6 ) reduces to
rearranging this
/ i .  ^  J. 4- — ---- £-----    - O
ts+r)-/>-r
from the roots of a quadratic equation_____
' * - A 4- /A)
rejecting the other root as in applicable, finally
— 7----- z  . — , , - ((.?)
l^ i - Ji - z hfcC T>j - pQ - ?/* j  j
In this equation it should be noted that if D f D c  the
expression reduces to equation ( 6.3 ). The main potential
radiobiological advantage low dose-rate irradiation has 
over fractionated radiation treatment is the shorter
overall time. Two characteristics of the tumour cell
population will determine the importance of the difference 
in treatment time. The first is the proliferation kinetics 
of the tumour cells. Table IX illustrates that more slowly 
growing tumour cell populations imply that higher total 
doses given at a low dose-rate are necessary in order to 
match the sterilization produced by the fractionated 
treatment. This, in turn, implies longer irradiation times 
in order to limit lung damage. Conversely, for fast 
growing populations more doublings are spared and the 
number of tumour cells which must be sterilized is less. 
Consequently, in this case, less dose is necessary for an 
equivalent tumour effect. The other factor of importance 
is the radiosensitivity of the tumour cells. This 
determines the dose-equivalent of a population doubling. 
For example, if we have two cell populations; PI and P2, 
possessing shoulderless survival curves with associated DO 
values; D1 and D2, where D2 = 2 X Dl, then the amount of 
dose required to reduce the number of cells in P2 by a 
particular amount is twice that required for P 
apparent how this factor will affect the importance of the
number of doubling times saved.
114
It is possible to set limits on the parameters a tumour 
cell population must have in order to make low dose-rate 
irradiation better than fractionated treatments. Less dose 
is given by the single exposure. Because of this fewer 
cells are sterilized by radiation. For cells with 
shoulderless survival curves the proportional difference
F, - (- & / % )
where ^  is the difference in dose between the two 
techniques. Also, because the low dose-rate exposure is 
completed in a shorter time there is less proliferation 
throughout the duration of treatment. The proportional 
difference here is
Fp = ( y & z / ' r p )
where ZT is the difference in total time between the two 
techniques and TD is the tumour population doubling time. 
The approximation can be made that X. is equal to the 
duration of the fractionated treatment schedule. For both 
techniques to have equal effects on the tumour cell 
population we require
. FP = '
i.e.
I'D ' ^  %  ^ n Z  U.H)
t
It can be seen that the required tumour doubling time for 
equal effect is dependent on the values of DO, and ^ .
If, on grounds of practicality, we take the upper limit on 
how long a single exposure could last as 10 hours and 
require that it must be isoeffective for lung with a 
fractionated schedule of 6 fractions of 2 Gy in 2.5 days
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it can be shown by solving equation ( 6 . 7 ) that the total 
dose is 9.6 Gy ( i.e. at 0.96 Gy/'hr). It is necessary for 
equivalence that the population increase over 2 . 5 days be 
equal to the sterilization produced by ( 12 - 9 .6 ) = 2 . 4  
Gy. For cells with shoulderless survival curves and a DO 
of 1 Gy this dose is equivalent to 1.04 logs or 3.5 
doublings and requires that the tumour cells have a 
doubling time of less than 18 hours. Required doubling 
times for other values of DO and other fractionated 
schedules may be found from equation ( 6.9 ) and some of 
these are shown in Table X.
DO/Gy
FRACTIONATED SCHEDULE 
3 X 3.32 Gy 6 X 2 Gy 10 X 1.4 Gy
0.5
1.0
1.5
2.0
8 .7 days
17.3 days
26.0 days
34.7 days
8 . 7 hrs
17.3 hrs 
26. 0 hrs.
34.7 hrs
8 .5 hrs
17.0 hrs
25.5 hrs
34.0 hrs
Required doubling times for tumour cell populations in 
order that the effects of both the indicated fractionated 
schedule and also a continuous low dose-rate exposure of
9.6 Gy in 10 hours are equal
TABLE X
The examples in the Table show that there is little 
possibility of a low dose-rate exposure of 10 hours or 
less being better than a fractionated schedule consisting 
of 6 or more fractions. Only for very fast growing tumour
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*bell populations is the low dose-rate treatment better. It 
is also apparent from Tables VIII and IX that the 
irradiation times calculated for equivalent biological 
effects on lung tissue and tumour cells are usually very 
long. For any foreseeable clinical scenario they are 
almost certainly too long to be practicable.
Given that fractionated schedules are likely to be better 
than single low dose-rate exposures and also that these 
are better than single high dose-rate exposures, it may 
seem plausible that combining the two modalities i.e. 
using a fractionated low dose-rate schedule would give the 
best of both worlds and may be an optimal method of 
treatment. In fact, this is not the case, as the following 
analysis will show.
Equation ( 6.7 ) gives the condition for a single low 
dose-rate exposure of dose Dc to be equivalent for an LQ 
model tissue to a fractionated schedule of total dose Df 
in N fractions. This equation can be modified to answer 
the current question if we put
Df = df, the fraction size of a single high dose-rate
schedule
and N = 1
Equation ( 6.7 ) can be rewritten
6.3 FRACTIONATED LOW DOSE-RATE SCHEDULES
Say we want to take advantage of the "dose-rate" effect in
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order to increase the given dose by x% 
i.e. Do = df( 1 + x/100 )
By substituting the appropriate values into equation ( 
6 . 1 0  ) and solving by numerical iteration the required 
irradiation times may be found.
6.3.1 APPLICATIONS
1/ We start with a relatively high dose, given at a high
dose-rate, 6 . 6 Gy say, and ask the question. What
irradiation time and dose-rate is required in order that 
this dose can be increased by 5%, which is probably at the 
limit of clinical detectability, and still have the same 
biological effect on (a) - late responding and (b) - acute 
responding tissues.
In equation ( 6.10 ) df = 6.5 Gy’ : Be = 6.826 Gy
(a) - Late effects
Taking tt/p = 3 Gy and Ty = In2/^* = 1. 5  hours 
The necessary irradiation time is. .0. 81 hours i.e. at a 
dose-rate of 8.4 Gy/hr ( 14 cGy/min ). This is still
quite a high dose-rate, well within the clinical TBI 
range.
(b) - Acute effects
Taking oijp = 10 Gy and T^  = 1.0 hours
The irradiation time is again 0.81 hours i.e. a dose-rate
of 8.4 Gy/hr.
So a 5% increase in dose for the same toxicity, compared 
to a high dose-rate fraction, is certainly possible 
without any significant logistic problems for a baseline 
fraction of 6.5 Gy.
118
2/ Fraction size = 2 Gy
Again calculating the required irradiation time for a 
possible 5% dose increase.
In equation ( 6 .10 ) df = 2 Gy : Dc = 2. 1 Gy
(a) - Late effects
ft//? - 3 Gy : Ty^ = 1.5 hours 
The required irradiation time is 1.2 hours at a dose-rate 
of 1.8 Gy/hr. This dose-rate is at the lower end of the 
clinical TBI range.
(b) - Acute effects
djp - 10 Gy : Ty^ = 1.0 hours 
The required irradiation time here is 1.85 hours at a
dose-rate of 1.1 Gy/hr. This dose-rate is beyond the lower
limit of TBI schedules used clinically so far.
These values indicate that the reqared dose-rates may be a
good deal lower for smaller fractions than for larger ones. 
This is made clearer by Table XI where these values 
together with the corresponding ones for a fraction size 
of 1.4 Gy and different levels of dose enhancement are 
shown.
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DOSE INCREASE
BASELINE FRACTION 5% 1 0% 15% 20%
6.5 Gy L :8 .43 
A:8.48
L :4.3 5 L :2.98 L:2.29
A:4.19 A:2.73 A:1.97
2.0 Gy L:1.76 
A:1.13
L:0.87 L :0.57 
A :0.44 A:0.17
L :0.41 
A: NP
1.4 Gy L:1.02 
A:0.54
L :0.49 L :0.30
A :0. 15 A: NP
L : 0. 21 
A: NP
Dose-rates in Gy/hr required to enable an increase in 
total dose by the specified amount for 3 different 
baseline fraction sizes. NP denotes not possible.
It should be noted from table XI that :
1/ In order to affect the dose increases very low 
dose-rates are -required for standard fraction sizes 
2/ Acute effect equivalence requires lower doses than late 
effects
3/ Some levels of enhancement are impossible for acute 
effects. This is because the ERD values of the high 
dose-rate baseline fractions are lower than the doses 
required for the low dose-rate fractions. This is also 
true of late effects at higher levels of enhancement. The 
maximum enhancements for late effects are 67% for 2 Gy 
fractions and 47% for 1.4 Gy fractions. This corresponds 
to dose-rates tending towards zero and consequently having 
irradiation times tending towards infinity.
The work of Tarbell et al ( 1987b ) is relevant to the
TABLE XI
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above considerations. These authors found that, for mice, 
using" fractionated or low dose-rate irradiation did not 
reduce the effectiveness of haemopoietic stem cell 
sterilisation in comparison to high dose-rate single 
fractions, indeed there was a lower apparent DO value 
associated with fractionated radiation, which could be due 
to the effects of tumour cell cycle redistribution as 
mentioned previously. Toxic side-effects for thoracic 
irradiation however, were dependent on the method of 
delivery. Two toxicity endpoints were used. The first was 
the LD 50/30 endpoint i.e mortality at 30 days 
post-irradiation. The second endpoint was the LD 50/30-180 
i.e. mortality between 30 and 180 days post-irradiation. 
The actual mechanisms of death were not specified but, 
loosely, we can think of the LD 50/30 as acute toxicity 
and the LD 50/30-180 as late toxicity. Several different 
irradiation protocols were used; Single doses at both high 
( 48 Gy/hr) and low ( 3 Gy/hr ) dose-rates and
multifractionated schedules of 2 or 1.2 Gy fractions at 
both dose-rates. The authors found that for the LD 50/30 
endpoint there was a highly significant dose-rate effect 
when single fractions were used; 14.88 Gy for high 
dose-rate ( HDR ), 24.87 Gy for low dose-rate ( LDR ). 
Fractionation produced a higher LD 50/30 than the single 
LDR exposure ( approximately 30 Gy ) but there was no 
discernible dose-rate effect within the fractionated 
schedules. In the context of the previous analysis these 
observations are not surprising, especially for an acute
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endpoint. It. was seen that dose enhancement by dose-rate 
reduction is more difficult for acute effects than for 
late effects, but becomes easier the higher the baseline 
dose used. Tarbell et al used a HDR baseline dose of 14.88 
Gy. For the fractionated schedules the baseline doses were 
2 Gy and 1.2 Gy where, it would be anticipated, much lower 
dose-rates are required to show a dose enhancement. For 
the LD 50/30-180 endpoint again a highly significant 
dose-rate effect was seen with single fractions; 12.99 Gy 
for HDR against 22.47 for LDR.
Fractionation brought about an even greater increase; to 
32.66 Gy for once-daily HDR fractions of 2 Gy; to 24.1 Gy 
for twice-daily HDR fractions of 2 Gy with 6 hours between 
fractions; to 28.42 Gy for twice-daily LDR fractions of 2 
Gy with 6 hours between fractions; and to. approximately
28.4 Gy for three times daily doses of 1.2 Gy with four 
hours between fractions independent of dose-rate. The 
differences in the isoeffective doses between HDR and LDR 
fractions of 2 Gy is surprisingly great, given the 
previous analysis. Although it would be predicted to be 
easier to achieve an enhancement for late effects compared 
to acute effects, the sise of the difference ( 18% ) is 
greater than expected. In these experiments fractionation 
appeared to be better than low dose-rate. This may be 
because the "low dose-rate used ( 3 Gy/hr ) is not low 
enough. The difference between the LD 50/30-180 for once 
and twice daily fractions of 2 Gy is interesting. It is 
not possible to say if this is due to incomplete repair
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for the tv/ice daily treatment or to proliferation effects 
in some important target cell population. Had the 1.2 Gy 
fractionation experiments been performed for different 
interfraction intervals this may have been clarified 
somewhat. It does appear, judging by the scale of the 
effect, that proliferation effects are responsible.
6.4 DISCUSSION
It must be emphasised that these conclusions apply to the 
treatment of radiosensitive neoplasms which have low SLD 
repair capacities like leukaemia and neuroblastoma by 
high-dose TBI followed by bone marrow rescue. Here 
dose-limiting boxicities are highly dependent on fraction 
size or dose-rate / irradiation time and these factors can 
be manipulated to increase the therapeutic ratio. For low 
dose TBI without marrow transplantation failure of the 
haemopoietic system would be dose-limiting and, in this 
context, a substantial increase in total dose via 
fractionat ion or dose-rate reduction would not be 
predicted. Some neoplasms where high dose TBI has been 
used can have radiation survival curves which are not 
shoulderless and radiosensitive ( Kinsella et al, 1984 ). 
In these cases the choice of fractionation or low 
dose-rate may be less clear cut and, as will be seen in 
the next chapter, in some circumstances neither may be 
appropriate.
To summarize this chapter; for the treatment of 
radiosensitive neoplasms by TBI followed by bone marrow 
rescue all the benefits of fractionation can be achieved
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by using low dose-rate irradiation. However, in practice, 
the irradiation times required for low dose-rate schedules 
are likely to render them impracticable. Fractionated 
radiation appears, therefore, to be a better way of 
exploiting the potential advantages inherent in the 
different radiobiological properties of neoplastic cells 
and lung.
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7.0 OPTIMAL SCHEDULING OF FRACTIONATED TBI 
WITH BONE MARROW RESCUE
In this chapter some aspects of the theoretical 
optimisation of TBI treatment will be described. Use will 
be made of the LQ model as described in chapter 3 to 
describe the radiation response of normal tissues. The 
human tumour radiosensitivity data of chapter 5 will be 
used to describe tumour effects. Mathematical expressions 
for the effects of radiation on normal tissues and those 
for the effects of radiation on tumour cell survival can 
be combined to yield optimal dose sizes and schedules. The 
first part of this chapter will deal with what could be 
described as analytical optimization. Although this 
approach is not directly applicable to the clinical 
situation it is a useful exercise and, in some 
circumstances, does provide an insight into the reasons 
why optimal schedules take the forms they do.
7.1 ANALYTICAL OPTIMIZATION
Analytically it is possible, in some circumstances, to 
derive the optimal size of dose to maximise the 
therapeutic ratio. For this approach the effects of 
cellular proliferation must be ignored.
If we can write an expression which represents the effects 
of a dose of radiation, d, on tumour cells and also an 
expression which represents normal tissue damage then it 
is possible to derive therapeutically optimal doses. This 
follows simply from the following analysis :
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Tumour effect of dose, d = T(d) = T
Normal tissue effect = N(d) = N
A measure of the therapeutic ratio, R is given by
R(d) = T(d)/N(d) or for convenience R = T/N
The value of R will depend on the dose. Some doses will
give a high value of R, others a low value. However, one
value of d will produce a maximum value of R and this will
be the optimal dose size in the absence of the effects of
cellular proliferation.
For the optimal dose size
= e>
and
il
£ * 0
where R' denotes the derivative of R with respect to d and
R" denotes the second derivative of R with respect to d.
As R = T/N
/ r ' M  - N T
K
Therefore the requirement for R'" = 0 is
T’N - N'T = 0 .
The requirement for this stationary point of R(d) to be a 
maximum is R" < 0
*>"_ a? (t "*  -  «>“t) - (t -'h -
f^ “ — - —— - ~
As T'N - N ’T = 0 at a stationary point this expression 
reduces to
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And the condition R" < 0 is given by
r" n < n "t (j-t)
Substitution of expressions for tumour and normal tissue 
effects into equations ( 7.1 ) and ( 7.2 ) enable optimal 
dose sizes to be calculated. This will be done for two 
cases :
1/ Tumour effects are given by a log cell kill value from 
a multitarget equation with zero initial slope. Normal 
tissue effects are given by a LQ equation
Substituting these expressions into equations ( 7.1 ) and 
( 7.2 ) enables gt to be cancelled out. The optimal dose
It then follows that
/VJ' - oi (i +  /)[)
N" -- 2  *  /A
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size then depends only on the n and DO of the tumour cells
)■
Example Human Leukaemia/Lymphoma
From chapter 5 the median values of the parameters n and 
DO for human leukaemia/lymphoma were found to be
These values are used to evaluate the optimal dose size. A 
numerical solution to equation ( 7.1 ) is required and a 
computer program was written to perform this task using a 
"false-position" approach.
The optimal dose size for the above values of n, DO and 
-da is 0. 46 Gy. For the same values of n and DO but an
f  ratio of 10 Gy ( more descriptive of an acute responding 
normal tissue ) the optimal dose size is 1.09 Gy.
These dose values illustrate that,. in this case, 
hyperfractionation is an approach more likely to increase 
the therapeutic ratio 'with respect to late responding 
tissues rather than acute responders.
2/ Tumour effects are given by a log cell kill value 
derived from a multitarget equation with a non-zero 
initial slope, the so-called two-component or TC equation. 
Normal tissue effects are again given by a LQ equation. In
and the of the normal tissue ( denoted by $
n = 1. 2 ; DO = 0.9 Gy
ratio is 3 Gy.
this case
It then follows that
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Again ^  can be cancelled on substitution of these 
expressions into equations ( 7 . 1 ) and ( 7.2 ). Now the
optimal dose size depends only on the parameters n, D1 and
n =  «nd the Ala ratio of the normal D2 of the tumour cells and rn //
tissue.
Example Human Neuroblastoma
. . • _ c.p+- nf values of n» D1 and
From chapter 5 a representative set
D2 for human neuroblastoma were found to
n = 1.75 ; D1 = 2.04 Gy ; D2 = 2.21 Gy
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Numerical solutions to the equations are again required 
and the computer program referred to previously was used 
to calculate these. For a normal tissue ratio of 3
Gy the optimal dose size is 0.39 Gy. The optimal dose size 
consistent with an Jjp ratio of 10 Gy is 1.69 Gy. This 
example again illustates the increased effectiveness of 
hyperfractionation as a therapeutic strategy with respect 
to late responding rather than acute responding tissues. 
The best estimate of a "typical" neuroblastoma survial 
curve was a composite of the above TC equation and a zero 
initial slope equation. The analytical optimal dose size 
found here refers to the TC equation component only and, 
therefore, is not applicable to the composite equation.
The approach described above, although illustrative of the 
principle of optimal scheduling is not particularly useful 
in practice. There are three main reasons for this :
1/ Using a quadratic equation as the mathematical 
representation of tumour effects allows only two possible 
optimal dose values zero and infinity.
2/ Proliferation is ignored which means that it is not 
suitable for schedules of more than one fraction.
3/ There is no intuitive feeling for how much better the 
optimal dose size is as opposed to some other dose.
For these reasons this approach will not yield true 
optimal schedules. In the next section a model will be 
presented which overcomes the objections listed above and 
enables optimal fractionation schedules to be derived.
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7.2 A MODEL FOR THE OPTIMAL SCHEDULING 
OF FRACTIONATED TBI WITH BONE MARROW RESCUE
The approach adopted here is as follows :
A clinically acceptable treatment schedule is taken. A set 
of schedules can then be calculated using the LQ model 
which should all be isoeffective for some dose-limiting 
side-effect. The effects on a tumour cell population of 
these schedules can then be calculated. In general these 
will not be the same and the schedule which produces the 
smallest surviving fraction of tumour cells is the optimal 
schedule. In the case of TBI with marrow rescue, as 
described previously, the primary dose-limiting toxicity 
is due to lung damage in the form of radiation-induced 
pneumonitis. A variety of treatment schedules have been 
clinically used, however one which has been employed in a 
number of centres is a fractionated course of treatment 
consisting of 6 fractions of 2 Gy, total dose 12 Gy. This 
schedule has been given either as 1 fraction per day or as 
2 fractions per day-. From the point of view of lung 
toxicity there should be no significant difference between 
these as long as sufficient time is allowed between 
successive fractions for effectively full repair of 
repairable radiation damage. Additionally, in the case of 
lung, one would expect proliferation-associated factors to 
be irrelevant for the timescale of these treatments ( 1 
week or therabouts ). Figure 7.1 shows the set of 
isoeffective schedules for fraction numbers from 1 to 100 
which are equivalent to 6 fractions of 2 Gy on the basis
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Fig 7.1 Total dose as a function of fraction sise 
calculated to have the same effect on lung as 6 fractions 
of 2 Gy. ( Based on the LQ model with = 3 Gy )
of the LQ model with aCjj^  = 3 Gy. As was pointed out in 
chapter 3 there is some doubt as to the LQ models* 
validity at small fraction sizes. However for the purposes 
of this analysis the isoeffective schedules are taken at 
face value. The next step in the optimization process is 
to rank these schedules in terms of their effects on 
tumour cells. In this regard there are three variables of 
importance :
1/ The intrinsic radiosensitivity of the tumour cells in 
question expressed as the single dose survival curve 
equation for S(d)
2/ The proliferation rate of the tumour cells described by 
a population doubling time and assuming exponential growth 
kinetics.
3/ The temporal distribution of the dose fractions i.e.
the number of fractions given per day. As described in
chapter 3 a minimum interfraction interval of 6 hours is
believed to be necessary for essentially full repair of
repairable radiation damage and this interval is assumed
for all schedules considered. This means that the
theoretical maximum number of fractions per day is 4.
Taking these three factors into consideration an equation
can be written for the effect on tumour cells after a
fractionated course of radiotherapy 
r '>N "XT
S = |5id)J e
where T is the duration of the schedule and
' X  =  -&Z /rP
where TD is the tumour cell population doubling time.
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It- is convenient here to use the "log cell kill" function 
representing the number of decades of reduction of tumour
cells k , - U  (5)
* - A) ^ |C [Stf)] + o ^ o i tAp
The allov/able combinations of N and d are set by the 
normal tissue isoeffect model and the reference schedule 
chosen. These are shown in Fig 7.1. Fractions are taken to 
be delivered at a sufficiently high dose-rate that its 
exact value has little influence on cell killing. In this 
way the dose-rate factor is removed from the analysis. 
Finally the object is to maximize K(N,d,S(d),T,TD). The 
schedule which does this is the optimal schedule. The 
relationship between the calculated optimal schedules and 
the parameters S(d), T and TD is the subject of the next 
section.
7.3 HUMAN LEUKAEMIA/LYMPHOMA 
From chapter 5 the equation used to describe the surviving 
fraction of human leukaemia/lymphoma cells following a 
dose d is
S(d) =
In the computer calculation the tumour doubling times are 
allowed to have the values of 2, 4 and 20 days. 2 days 
represents a fast growing tumour cell population and 20 
days represents a rather slowly growing one. Schedules can 
be given at 1, 2, 3 or 4 fractions per day. This enables 
the advantages of accelerated fractionation to be
. - 0 -  «• )
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assessed. Schedules are also considered in which treatment 
is given only on conventional working days ( i.e. Monday 
to Friday ) and during conventional working hours ( i.e. 9 
a.m. to 5 p.iry ). The latter factor means that only once or
i ■
twice daily fractionation schedules are considered, due to
■' i
the minimum'requirement of 6 hours between fractions. This 
enables the effects of "social" constraints to be 
assessed. Figures 7.2-7.7 plot the tumour log cell kill 
against fraction size for all these situations.
7.3.1 RESULTS OF COMPUTER SIMULATION
It is immediately apparent from examination of figures 
7.2-7.7 that they are all of a similar shape. When moving 
from schedule^ with large fraction sizes to schedules with 
small ones there is first an increase in the tumour effect 
( and thus the therapeutic ratio ) until a maximum is 
reached. This.is because the schedules are becoming more 
efficient at exploiting the different radiobiological 
parameters of the tumour cells and lung. Thereafter the 
therapeutic - effect decreases owing to the effects of 
cellular proliferation. The fraction sizes of the optimal 
schedules are the dose values corresponding to the turning 
points of the curves. Examining any of figures 7.2-7.7 
shows that the tumour cell population doubling time is a 
factor of importance in determining the optimal schedule. 
Fast doubling times lead to predictions of optimal 
schedules which have a relatively fewer number of 
Fslatively larger fractions than those predicted for slow 
doubling times. This is not difficult to understand,
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Fig’ 7.2 Leukaemia log1 cell kill as a function of dose per 
fraction for TBI schedules of one fraction per day, 
isoeffective to 6 fractions of 2 Gy on the basis of the 
LQ model with ~ ^ Oy. The leulcaemic
radiosensitivity parameters are the median values for -10 
cell lines as described in the text.
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Fig 7.3 Leukaemic log cell kill as a function of dose p^r 
fraction for TBI schedules of two fractions per day, 
isoeffective to 6 fractions of 2 Gy on the basis of the 
LQ model with */p - 3 Gy. The leukaemic
radiosensitivity parameters are the median values for 40 
cell lines as described in the text.
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Fig 7.4 Leukaemic log cell kill as a function of done per 
fraction for TB1 schedules of three fractions per day, 
isoeffective to 6 fractions of 2 Gy on the basis of the 
LQ model with - 3 Gy. 'the leukaemic
radiosensitivity parameters are the median values for -1 n 
cell lines as described in the text.
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Fig 7.5 Leukaemic log cell kill as a function of dose p» 
fraction for TBI schedules of four fractions per day, 
isoeffective to 6 fractions of 2 Gy.on the basis of the 
LQ model with ofj3 = 3 Gy. The leukaemic 
radiosens itivity parameters are the median values for i1 
cell lines as described in the text.
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Fig 7.6 Leukaemic log' cell kill as a function of dose pei: 
fraction for "socially constrained" TBI schedules of one 
fraction per day, isoeffective to 6 fractions of 2 Gy on 
the basis of the LQ model with djp - 3 Gy. The 
leukaemic radiosensitivity parameters are the median 
values for 40 cell lines as described in the text.
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Fig 7.7 Leukaemic log cell kill as a function of dose per 
fraction for "socially constrained" TBI schedules of two 
fractions per day, isoeffective to 6 fractions of 2 Gy on 
the basis of the LQ model with = 3 Gy. The
leukaemic radiosensitivity parameters are the median 
values for 40 cell lines as described in the text.
temporal factors become increasingly important as the 
doubling time decreases and there is an advantage in 
having schedules with shorter durations. In no case does 
the optimal schedule consist of a large single fraction. 
This provides the justification for the assertion in 
chapter 6 that multifractionated ( or single low dose-rate 
fractions ) are most appropriate for the treatment of 
radiosensitive neoplasms with TBI followed by marrow 
rescue. For the leukaemic cell radiosensitivity parameters 
used here the optimal dose size in the absence of 
proliferation was found to be 0.46 Gy when the normal 
tissue constraint was provided by a LQ model tissue with
on the optimal fraction size. One would expect that the 
optimal fraction sizes would all be larger than this to
proliferation effects are ( i.e. for low fractionation 
frequencies and fast doubling times ) the greater would be 
the expected deviation from the no-proliferation value. 
Figure 7.8 shows the relationship between the optimal 
fraction sizes, the doubling time of the leukaemic cell 
population and the number of daily fractions in cases 
where treatment is given every day. On examination of this 
graph three observations can be made:
1/ The faster the tumour cell proliferation the larger the 
optimal fraction size.
2/ The lower the fractionation frequency the larger the 
optimal fraction size.
an ratio of 3 Gy. This value provides a lower limit
greater or lesser extents. The more important
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Fig 7.8 The optimal dose per fraction as a function of 
the number of daily fractions for three different values 
of leukaemic doubling time.
3/ Ihe faster the tumour cell proliferation the more 
variation there is between the fraction sizes of optimal 
schedules with different fractionation frequencies.
These effects are caused solely by proliferation and 
reflect the fact that the longer a schedule takes to 
complete, in terms of tumour doublings, the more the 
differential radiosensitivities of tumour cells and lung 
are overcome by kinetic factors.
The tumour log cell kills produced by the optimal 
schedules as a function of the fractionation frequency are 
shown in figure 7.9. These schedules produce a degree of 
tumour cell kill of the order of 5-7 logs. This is higher 
than the corresponding values for neuroblastoma, as will 
be seen later, and reflects the relative radiosensitivity 
of human leukaemia/lymphoma cell lines. Two important 
effects are immediately obvious from figure 7.9 :
1/ The faster the tumour cell proliferation the more 
advantageous is increasing the fractionation frequency.
2/ There is a greater advantage in going from one fraction 
per day to two a day than there is in going from two to 
three a day, which in turn is more advantageous than going 
from three to four a day i.e. there is a steadily 
diminishing return as the fractionation frequency is 
increased.
Now going on to consider those schedules which are subject 
to "social" constraints ( i.e. treatment during the period 
9 a.m. to 5 p.m. on weekdays only ), figures 7.6 and 7.7 
show the tumour log cell kills against fraction size for
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Fig' 7.9 The leukaemic log' cell kill produced by the 
optimal schedules as a function of the number of daily 
fractions for three different leukaemic doubling times.
the lung-isoeffective schedules in this category. The 
discontinuities in the graphs correspond to weekend breaks 
in treatment. The number of fractions in the optimal 
schedules tends to be an integral number multiplied by 5n 
where n is the number of daily fractions. This is not 
surprising as schedules on either side of these divides 
are separated by 2 days of tumour proliferation but no 
radiation-induced sterilization. It is always true that 
for schedules with the same numbers of equal dose 
fractions, those with twice daily fractionation are better 
than those with one fraction per day. Figure 7.7 shows 
that the twice daily schedule with a fraction size of 1.37 
Gy is close to the optimal for tumour doubling times of 
both 2 and 4 days. This schedule is, in fact, 10- fractions 
of 1.37 Gy. As doubling times of 2-4 days are thought to 
more relevant to human leukaemia/lymphoma, it appears that 
a fractionated TBI schedule of 10 fractions of 1.37 Gy 
would be appropriate for the treatment of this disease. In 
order to test this prediction further the effects of two 
schedules, 6 fractions of 2 Gy in 2.5 days and 10 
fractions of 1.37 Gy in 4.5 days, have been calculated for 
all 40 independent sets of radiosensitivity parameters. 
This information is shown in Table XII. This lends further 
support to the clinical use of the latter schedule. The 
precise numerical value of 1.37 Gy is dependent on the 
value chosen for the reference schedule ( 6 X 2  Gy ) and 
on the fractionation response of lung. Errors in radiation 
dosimetry and variations in the behaviour of lung from
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SCHEDULE COMPARISON FOR LEUKAEMIA/LYMPHOMA
DESIGNATION TD=2 TD=4 TD=£
HL60 A A A
K562 A B B
45/K45 B B B
KG1/KG+ A A A
176 A A A
Reh A A A
P3HR-1 B B ' B
U715 B B B
U698 A B B
SU-DHL-4 B B B
JY A A B
Daudi B B B
U937 A A A
MOLT-4 B B B
JM(Jufkat) A A A
CCRF-CEM B B B
APHID-D2 A B B
RCH-ACV B B B
HRIK B B B
FMC-HU-1B B B B
1 A A B
2 B B B
TABLE XII
3 A A B
4 A B B
5 A B B
6 B B B
7 B B B
8 B B B
. 9 B B B
10 B B B
11 B B B
12 A B B
CS B B B
GH B B B
JR B B B
TC B B . ' B
GS B B B
HF B B B
JL B B B
LJ B B B
This table shows which of the two, twice daily, schedules 
A or B produce the greatest sterilizing effect on the 
cells of the specified line, for different values of the 
tumour cell population doubling time. Schedule A is 6 
fractions of 2 Gy in 2.5 days; schedule B is 10 fractions 
of 1.37 Gy in 4.5 days. The number of times schedule A is 
better for doubling times of 2 or 4 days is 24. The 
corresponding number for schedule B is 56.
TABLE XII ( CONTD )
patient to patient as well as deviations from a strict LQ 
response may be expected to introduce some uncertainty to 
estimates of the optimal schedule. Bearing this in mind 
the conclusions of the optimal scheduling study for 
leukaemia/lymphoma may be summarized as follows :
1/ It is clear that accelerated hyperfractionation is the 
optimal strategy for the treatment of leukaemia/lymphoma 
by TBI with marrow rescue.
2/ Single high dose-rate treatments are substantially less 
effective than multifractionated schedules.
3/ A TBI schedule of 10 fractions of between 1.3 and 1.5 
Gy, two fractions per day, is practicable, worth 
considering for the treatment of leukaemia/lymphoma and 
should be tested clinically.
7.4 NEUROBLASTOMA
The equation arrived at in chapter 5 as a best estimate of
the single dose survival curve for human neuroblastoma is 
\ , - s'** s f - *k-cif . -
SG0* [ G - C ' - e  ) O - O - *  > J >)
Exactly the same computer analysis as was carried out for 
leukaemia/lymphoma is reported here for neuroblastoma.
7.4.1 RESULTS OF COMPUTER SIMULATION FOR NEUROBLASTOMA
Figures 7.10-7.15 show the effects on neuroblastoma cells 
of the set of lung-isoeffective schedules given at 1-4 
fractions per day and once and twice daily subject to 
conventional "social* constraints. Figures 7.10—7.15 are 
j Q-f similar shape, both to each other and also to those 
^©ukaemia/lymphoma. Optimal schedules are dependent on
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Fig 7.10 Log cell kill for neuroblastoma as a function of 
dose per fraction for TBI schedules of one fraction per 
day, isoeffective to 6 fractions of 2 Gy on the basis of 
the LQ model with djp = 3  Gy. The neuroblastoma 
radiosensitivity parameters are the median values for 8 
cell lines as described in the text.
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Fig 7.1.1 Log cell kill for neuroblastoma as a function of 
dose per fraction for TBI schedules of two fractions per 
day, isoeffective to 6 fractions of 2 Gy on the basis of 
the LQ model with - 3 Gy. The neuroblastoma
radiosensitivity parameters are the median values for 0 
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-LO
TUMOUR TYPE: N E U R O B L A S T O M A
3 F R A C T I O N S  PER DAT
KET
1 : T U MOUR D O U B L I N G  TIME 2 OATS
2 .* TUMOUR D O U B L I N G  TIME * DATS
3 : TUMOUR D O U B L I N G  TIME » 20 DATS
0.5 -
FRACTION SIZE/Gy
Fig 7.12 Log cell kill for neuroblastoma as a function of 
dose per fraction for TBI schedules of three fractions 
per day, isoeffective to 6 fractions of 2 Gy on the basis 
of the LQ model with <*Jf> - 3 Gy. The neuroblastoma
radiosensitivity parameters are the median values for 8 
cell lines as described in the text.
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Fig 7.13 Log' cell kill for neuroblastoma as a function of 
dose per fraction for TBI schedules of four fractions per 
day, isoeffective to 6 fractions of 2 Gy on the basis of 
the LQ model with = 3 Gy, The neuroblastoma
radiosensitivity parameters are the median values for 8 
cell lines as described in the text.
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Fig 7.14 Log cell kill for- neuroblastoma as a function of 
dose per fraction for "socially constrained" TBI 
schedules of one fraction per day, isoeffective to 6 
fractions of 2 Gy on the basis of the LQ model with 
- 3 Gy. The neuroblastoma radiosensitivity parameters are 
the median values for 8 cell lines as described in the 
text.
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Fig 7.15 Log cell kill for neuroblastoma as a function of 
dose per fraction for "socially constrained" TBI 
schedules of two fractions per day, isoeffective to 6 
fractions of 2 Gy on the basis of the LQ model with 
- 3 Gy. The neuroblastoma radiosensitivity parameters are 
the median values for 8 cell lines as described in the 
text.
the fractionation frequency and the population doubling 
time. In no case is a single fraction optimal. This 
further supports the underlying assumption of chapter 6, 
namely that multifractionated ( or single low dose-rate ) 
treatments are most appropriate for the treatment of 
radiosensitive neoplasms, with small shouldered survival 
curves, by TBI and marrow rescue. The optimal fraction 
sizes are shown in figure 7.16 as a function of tumour 
cell doubling time and fractionation frequency. In figure 
7. 17 the log cell kills produced by the optimal schedules 
are shown. It is apparent that the absolute level of 
tumour sterilisation is less than that for 
leukaemia/lymphoma ( by about 2 logs ). Apart from this 
all the observations made • on the corresponding 
leukaemia/lymphoma graphs are equally applicable to 
neuroblastoma.' Treatment schedules subject to "social" 
constraints are shown in figures 7.14 and 7.15. As can be 
seen in figure 7.15 twice daily schedules of between 6 
fractions of 2 Gy and 10 fractions of 1.37 Gy are in the 
optimal region for doubling times of 2 and 4 days. The 
evidence presented in chapter 2 suggests that doubling 
times of this order are characteristic of neuroblastoma. 
The effects of two schedules, 6 X 2 Gy in 2.5 days and 10 
X 1.37 Gy in 4.5 days, were again calculated for the 8 
independent sets of neuroblastoma radiosensitivity 
parameters. These results are shown in Table XIII and 
support the relative superiority of the 10 fraction 
schedule. The conclusions of the optimal scheduling study
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Fig 7.17 The log cell kill produced by the optimal 
schedules, as a function of the number of daily fractions 
for three different values of tumour doubling time for 
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SCHEDULE COMPARISON FOR NEUROBLASTOMA
DESIGNATION TD=2 TD=4 TD=20
NB1 B B B
HX138 B B B
LAN-1 B B B
CHP-100/NB-100 A A A
HX142 A A A
NB1-G B B B
NB2-G B B B
SK-N-SH A B B
This table shows which of the two, twice daily, schedules 
A or B produce the greatest sterilizing effect on the 
cells of the specified line, for different values of the 
tumour cell population doubling time. Schedule A is 6 
fractions of 2 Gy in 2.5 days; schedule B is 10 fractions 
of 1.37 Gy in 4.5 days. The number of times schedule A is 
better for doubling times of 2 or 4 days is 5. The 
corresponding number for schedule B is 11.
TABLE XIII
for human neuroblastoma are:
1/ Accelerated fractionation is the optimal strategy for 
the treatment of neuroblastoma by TBI with marrow rescue. 
The value of hyperfractionation ( i.e. < 2  Gy per fraction 
) seems less clear cut than for leukaemia/lymphoma, 
although table XIII does show some advantages of 10 X 1.37 
Gy in comparison with 6 X 2  Gy.
2/ Single high dose-rate treatments are substantially less 
effective than multifractionated schedules.
3/ TBI schedules of between 6 fractions of 2 Gy and 10 
fractions of between 1.3 and 1.5 Gy, two fractions per 
day, are recommended for the treatment of neuroblastoma.
7.5 EWING'S SARCOMA
As the only two sets of survival curve measurements on 
this tumour type are dissimilar, each set of 
radiosensitivity parameters are taken separately. It is 
interesting to see how the differences in radiosensitivity 
parameters are expressed in terms of the implied optimal 
schedules. In this case only radiotherapy schedules of 
twice daily fractions are considered. Tumour cell 
population doubling times of 2, 4 and 20 days are allowed.
7.5.1 RESULTS OF THE COMPUTER SIMULATION FOR 
EWING'S SARCOMA
Figures 7.18 and 7.19 show the effects on the two Ewing's 
sarcoma lines of the lung-isoeffective schedules. In 
contrast to the leukaemia/lymphoma and neuroblastoma lines 
both Ewing's sarcoma lines are relatively radioresistant.
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Fig 7,18 Log cell kill for Ewing's; sarcoma line 5838 as a 
function of dose per fraction for TBI schedules of two 
fractions per day, isoeffective to 6 fractions of 2 Gy on 
the basis of the LQ model with /^(3 ~ 3 Gy.
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Fig 7.19 Log cell kill for Ewing's sarcoma line 4573 as a 
function of dose per fraction for TBI schedules of two 
fractions per day, isoeffective to 6 fractions of 2 Gy on 
the basis of the LQ model with - 3 Gy.
On the basis of the survival curve parameters no more than 
2 log's of tumour cell reduction are possible in stark 
comparison to the 5-7 logs for leukaemia/lymphoma and 3-4 
logs for neuroblastoma. One line ( 5838 ) displays a high 
degree of quadratic curvature ( = 3 Gy ). The
calculations show that, for this line, there is no 
advantage to be gained by fractionation. The optimal 
schedule is a large single fraction treatment. There are 
possible advantages achievable by fractionation from the 
point of view of the other line ( 4573 : - 25 Gy )
but these are not significant if fast proliferation is 
assumed. No prediction of a suitable "optimal schedule" 
can be made for Ewing's sarcoma due to the inadequacy of 
the present experimental database.
7.6 DISCUSSION
In this chapter a restricted form of optimal scheduling 
for TBI with bone marrow rescue has been attempted. It was 
seen that the optimal schedules were determined by the 
interaction - between . the numbers and sizes of dose 
fractions, the kinetics of the tumour cell population and 
the temporal distribution of radiation dose as well as the 
intrinsic radiosensitivity of the tumour cells. For the 
radiosensitive neoplasms of leukaemia/lymphoma and, to a 
lesser extent, neuroblastoma optimal treatment schedules 
have an accelerated hyperfractionation form. But it is 
important to note that accelerated hyperfractionation is 
not a sufficient condition for a schedule to be 
therapeutically advantageous. Qualitative statements about
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what sort of schedule is optimal are of little use. It is 
necessary to derive quantitative predictions of what 
actual schedule can be used as the basis for clinical 
testing. Fairly robust predictions can be made by 
introducing additional constraints on the possible 
schedules due to "social" factors ( 9 to 5 working, 5 days 
per week treatment ). It was found that a fractionation 
schedule of 10 fractions of 1.3 - 1.5 Gy, two fractions 
per day, starting Monday, ending Friday was a suitable 
candidate for clinical evaluation and embodies the 
available evidence on the radiation responses of the
tumour cells and lung tissue.
For Ewing's sarcoma the findings of this work were that no
optimal schedule predictions can be made at present due to
the scarcity of experimental data. However the study did 
produce some useful insights. Only one line ( 5838 )
displayed a high degree of quadratic curvature with an
oi/p ratio of 3 Gy. The d/p ratio of the other line ( 4573
) was 25 Gy, which following conventional wisdom ( 
Williams et al, 1985 ) is sufficient proof of the
advantages of hyperfractionation. This analysis shows that 
whether or not hyperfractionation is worthwhile depends on 
the interaction between cell sterilisation by radiation 
and population growth by mitotic division and the
*/p ratio is not, by itself, sufficient information on which 
to base optimal schedule predictions. Absolute
radiosensitivity parameters are necessary to enable this 
interaction to be assessed.
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7.7 EXPERIMENTAL TEST OF THE ADVANTAGES OF 
HYPERFRACTIONATION
An experiment was designed and has been performed to test 
the advantages of an accelerated hyperfractionation
schedule on a tumour line, NB1-G grown as multicellular 
tumour spheroids (MTS). The radiosensitivity parameters 
for this line were estimated as n = 1.18; D0(initial) =
1.47 Gy; D0(final) = 1.04 Gy. This experiment has been
reported ( Wheldon et al, 1987 ). Briefly the LQ model was 
used to calculate a set of isoeffective schedules
of 3 Gy. Multifractionated schedules were given twice 
daily. Two experimental endpoints were used to quantify 
tumour response, regrowth delay and proportion cured. The 
results were as follows :
1/ The lung-isoeffective schedules did not have equal 
effects on the neuroblastoma MTS.
2/ By either endpoint radiation damage to the MTS 
increased with total.dose however it was delivered. This 
meant that schedules consisting of smaller fractions were 
more effective.
This experiment does no more than generally support the 
superiority of moderate hyperfractionation when treating 
radiosensitive cells with a low capacity to repair 
sub—lethal damage. However it does constitute the first 
experimental study of a. normal tissue / tumour 
optimisation and may be a forerunner of more precise 
testing of theoretical predictions.
consisting of from 1 to 8 fractions, using an ratio
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8.0 BIOLOGICALLY TARGETED RADIOTHERAPY
In "the chapter on total body irradiation it was stated 
that the aim of radical treatment of malignant disease is 
to sterili2e every tumour cell. This principle is equally 
valid for biologically targeted radiotherapy. TBI has the 
advantage that all tumour cells in the body, whether they 
are detectable or not, are treated. It suffers from the 
disadvantage that it lacks biological specificity, all 
cells in the body, whether tumour or not being subject to 
irradiation.
Generally, the larger the fractional body volume 
irradiated the less total dose can be given. The possible 
dose which can be given by TBI is, therefore, relatively 
low. Conversely, local radiotherapy has the advantage 
that, when the'tumour cells are restricted to a particular 
limited volume, the radiation dose to other volumes which 
do not contain tumour cells can be reduced or eliminated. 
In this way^much larger doses can usually be given. It has 
the disadvantage that collections of tumour cells which 
are too small to be detected will not be treated at all. 
Biologically targeted radiotherapy ( BTR ) is an attempt 
to combine the good aspects of both systemic and local 
radiotherapy. Ideally, all tumour cells in the body will 
be irradiated by radionuclides carried by some biological 
molecule with an ability to target tumour cells. The 
selectivity of tumour treatment will be achieved both by 
the effects of biological targeting and also the limited 
range of the radiation from the radionuclide. Needleso to
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say the real situation is considerably more complicated 
than this idealized one.
8.1 VEHICLES AND WARHEADS
For successful BTR two distinct requirements are 
neccessary. The first is the ability of the exogenous 
substance to d$ scriminate between target and non-target 
cells and become intimately associated with the target 
cells in some way. The second is the ability to deposit a 
sterilising dose of ionizing radiation in the DNA of the 
target cell nucleus. This duality of function can be 
extended to consider a targeting modality as being 
composed of two distinct parts; a vehicle part, and a 
warhead part. The vehicle consists of a .biological 
molecule with some specificity for the target cell. The 
warhead consists of a radionuclide atom or atoms which 
produce suitable ionizing radiation. For any one cell 
there are two foreseeable ways in which BTR could be 
achieved :
1/ attachment of the radionuclide/vehicle complex to the 
cell surface.
2/ incorporation of the radionuclide/vehicle complex into 
the interior of the cell.
When the vehicle molecule has affinity for some cell 
surface feature, any targeting would be of the first type. 
If the targeting vehicle is a building block precursor 
used, perhaps, in the synthesis of a protein or in the 
replication of DNA, it would lead to targeting of the
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second "type. Before going on to discuss suitable vehicles 
and warheads it is useful to consider how molecules can be 
described as “tumour associated".
8.3 TUMOUR ASSOCIATED MOLECULES
Molecules can be associated with tumour cells in a variety
of ways. In order to classify these ways and their
relevance for biological targeting it is useful to 
consider what it is that distinguishes tumour from
non-tumour cells at the molecular scale. True
tumour-specific targeting can only be possible where there 
are true tumour-specific molecules. This applies in only a 
limited set of circumstances. Where there are no true 
tumour-specific molecles, quantitatively specific 
biological targeting may still be possible.
8.3.1 ONCOGENE ASSOCIATED MOLECULES
Recent advances in the molecular biology of oncogenes have 
revealed some of the relationships between the genetic 
lesions ultimately responsible for the induction and 
promotion of neoplasia and their products via the 
transcription of DNA to RNA and translation of RNA to 
proteins. At present, it is mainly through the processes 
of protein expression that biological targeting may be 
envisaged.
It appears that genetic defects responsible for cancer may 
be due to three main pathways either singly or in 
combination:
1/ Point mutations in cellular proto—oncogenes giving rise
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to aberrant proteins. This has been observed in oncogenes 
of the ras family ( Reddy et al, 1982; Tabin et al, 1982 ) 
2/ Oncogene amplification giving rise to overexpression of 
(possibly normal) proteins e.g. c-myc in lung cancer 
(Little et al, 1983 ), N-myc in neuroblastoma ( e.g.
Brodeur et al, 1984 )
3/ Oncogene translocations possibly involving chromosomal 
abnormalities. Oncogenes may be translocated to another 
part of the genome e.g. in Burkitt’s lymphoma about 90% of 
cases involve the translocation of the c-myc oncogene to 
the regions of the genome coding for immunoglobulin heavy 
chain ( Klein, 1983 ). In these cases proteins may be 
overexpressed by the coding DNA being read too often.
The protein products of activated oncogenes seem to have a 
role in cellular control mechanisms. A variety of oncogene 
products have been identified as cellular growth factors, 
e.g. c-sis ( Waterfield et al, 1983; Doolittle et al, 
1983 ), and growth factor receptors, e.g. c-erb-B (
Downward et al, 1984 ). The products of several oncogenes, 
e.g. src, abl, yes appear to have protein kinase activity, 
especially tyrosine kinase activity ( see Hall, 1986 ).
The genes of the ras family code for GTP-binding proteins 
( McGrath et al, 1984 ) involved in the control of
intracellular levels of the secondary messenger cyclic AMP 
which can lead to the activation of intracellular kinases 
( Hall, 1986 ). Some oncogenes ( e.g. c-myc ) code for 
nuclear proteins which may be involved in DNA 
transcription and cell cycle progression ( Rabbitts et al,
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1985, Campisi et al, 1984 ). It can be conjectured that 
overexpression of these proteins or defects in their 
structure may result in an increase in cellular 
proliferation or a dissociation from homeostatic growth 
control.
Biological targeting of oncogene products may be possible. 
In order to achieve this they would have to be accessible 
to the targeting agent, suggesting that oncogene products 
on the cell surface would offer the best bet, e.g. growth 
factor receptors. The recent study by Chan et al ( 1986 ) 
on the possibility of tumour localisation by targeting the 
c-myc oncogene product seems to contradict this, as c-myc 
codes for a nuclear protein. However this is "the 
exception which proves the rule" as it is only through 
cell death and the consequent release of nuclear contents 
that targeting of the c-myc product is possible. True 
tumour-specificity would only be realistic in cases where 
the oncogene product was an aberrant protein, although it 
is unlikely that proteins differing by only one amino-acid 
could be satisfactorily distinguished. In other cases 
quantitative specificity may be possible where there are 
enhanced levels of expression compared with normal cells. 
The oncogene-associated molecules described above 
constitute one extended set of possible targets for 
therapeutic approaches.
8.3.2 FUNCTION ASSOCIATED MOLECULES
A different type of targeting may be possible with another 
set of tumour associated molecules. Tumour cells may have
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greater or lesser degrees of differentiation depending on 
the status of the initial transformed cell and any further 
evolutionary changes in the descendants. They may still 
retain vestiges of the function which the initial cell 
used to perform. These cells may synthesise molecules ( 
possibly aberrant ) which can be used as "tumour markers". 
The ability of some neuroblastomas and phaeochromocytomas 
to -5ynthesir.e the catecholamines epinephrine and 
nor-epinephrine, and also the synthesis of melanin by some 
malignant melanomas are examples. Biological targeting of 
the process of synthesis may be possible. A radioiodinated 
catecholamine precursor analogue meta-131I-iodo
benzylguanidine ( mIBG ) has been used for both 
scintigraphic imaging and therapy of neuroblastoma and 
phaeochromocytoma ( Horne et al, 1985; Gerrard et al, 1987 
). The basis of this approach is that cells, behaving as 
"assembly lines" for the synthesis of catecholamines will 
preferentially take up mIBG, storing it in neurosecretory 
granules for later use.
Other sorts of "functional" molecules may be expressed on 
the cell surface. Tumour cell surface markers may 
correspond to those of the original transformed cell, but 
they may be expressed to a greater extent or they may be 
altered in some way. A situation where the latter seems to 
be the case is in the expression of a 400 kD mucin 
molecule associated with the human milk fat globule ( HMFG 
) membrane. It has been suggested that the mucin produced 
by breast carcinoma cells may be aberrantly glycosylated (
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Burchel1 et al, 1987 ). A monoclonal antibody SM-3
directed against the protein core of this mucin has been
reported to react with 91% of breast carcinomas but shows 
little or no reactivity with pregnant or lactating breast, 
normal resting breast or benign breast tumours. However 
monoclonal antibodies ( HMFG1, HMFG2 ) directed against 
different epitopes of the complete mucin molecule also 
cross-react with normal breast, Fallopian tube and ovarian 
epithelium ( Ward et al, 1987 ). It may be possible to 
target "functional" cell surface molecules by
radionuclide-conjugated antibodies, in particular 
monoclonal antibodies. Several clinical studies have used 
this method for both diagnosis and therapy ( e.g. Order et 
al, 1980; Carrasquillo et al, 1984; Hammersmith Oncology 
Group and ICRF, 1984 )
To summarize this section, molecules associated with 
tumour cells may be of two main types :
1/ Oncogenes and their products. These may be true tumour 
specific molecules, related to the transcription and
translation of mutated'DNA. This will result in aberrant 
proteins, not found in normal cells. Alternatively, there 
may be quantitative overproduction of certain molecules as 
a result of gene amplification or translocation processes. 
Enhanced levels of expression may therefore occur in 
tumour cells of proteins which also exist in normal cells. 
2/ Molecules related to the differentiation status of the 
original transformed cell and the subsequent evolution of 
the clone. These may be "assembly line" molecules such as
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catecholamines or functional" cell surface markers such 
as mucins.
Both types of tumour associated molecules give rise to the 
possibility of biological targeting.
8.4 PROSPECTS FOR BIOLOGICALLY TARGETED THERAPY
Over the course of evolution vertebrates have developed 
methods of coping with invasion by potentially harmful 
microorganisms. These methods go under the umbrella term 
of the immune system. The feature they all have in common 
is the ability to distinguish foreign molecules from self 
molecules. The functions of the immune system are 
conventionally sub-divided into two general types of 
mechanism:
1/ Humoral antibody responses 
2/ Cell-mediatfed immune responses
Both types of response are mediated by lymphocytes, 
immunoglobulin secreting B-cells for the first type and 
T-cells for the second type. Immunology is a vast subject 
and no attempt will be made here to review it; suffice it 
to say that it is through understanding and modifying both 
components of the immune system that nearly all present 
approaches to biologically targeted therapy are based. The 
main types of biologically specific molecules used so far 
have been whole antibodies or their Fab and F(ab)2 
fragments. This is especially so since 1975 when Kohler 
and Milstein first obtained monoclonal antibodies. Both 
polyclonal and monoclonal intact antibodies may be 
directly cytotoxic through complement lysis. Alternatively
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they may be modified by the addition of a cytotoxic 
warhead . To date these have included the A chain of the 
plant toxin ricin ( Thorpe et al, 1982; Uhr, 1984 ), 
conventional cytotoxic drugs such as methotrexate ( 
Garnett et al, 1983 ) and vindesine ( Rowland et al, 1985 
) and also radionuclides. Only radionuclide-conjugated 
antibodies will be considered further. Together with 
precursor-like molecules such as mIBG they are likely to 
be the main mediators of biologically targeted 
radiotherapy for the immediate future.
8.5 RADIONUCLIDE IMAGING WITH TARGETED MODALITIES
The requirements for imaging and therapy with biologically 
targeted radionuclides are different. Before discussing 
therapeutic approaches further, it will be useful to 
consider the requirements for imaging. The basic mechanism 
of radionuclide imaging is the detection, by a gamma 
camera, of ft7- ray photons emitted,from inside the body. 
From this perspective it is desirable to use a $ -emitting 
radionuclide with a suitable energy for imaging. This 
contrasts with the requirements for therapy, as will be 
discussed later. It has been found when using 
antibody-radionuclide conjugates for imaging that the 
tumour to background discrimination improves as the time 
since administration increases, although the absolute 
lovel of activity in the tumour steadily diminishes ( 
Begent and Bagshawe, 1985 ). This is believed to be caused 
by the prolonged retention of antibody by the tumour 
compared with the faster loss of activity from the
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bloodstream. The optimal times for scanning depend on the 
characteristics of the radionuclide used but, for 131-1, 
are from two to six days following administration ( 
Leichner et al, 1983; Carrasquillo et al, 1984; Riggs et
al, 1988 ). This phenomenon has no counterpart in therapy 
- since this starts immediately after administration. 
Consequently the initial high blood pool concentrations of 
radionuclide seem unavoidable in systemic BTR. A possible 
exception to this may be the use of the
streptavidin-biotin system ( Paganelli et al, 1987 ). 
Another technique used in scanning is computer assisted 
background subtraction ( e.g. Begent and Bagshawe, 1985; 
Chan et al, 1986 ). The blood pool activity can be
electronically removed from the image, thereby improving
the picture quality. Obviously there is no counterpart to 
this in therapeutic applications. These differences 
indicate that success in biologically targeted 
radionuclide diagnosis is not a guarantee of success for 
therapy.
8.6 TUMOUR TARGETS FOR BTR
Tumour targets for BTR may be conveniently divided into 
three categories:
1/ Bulk disease, essentially a primary tumour or a large 
secondary deposit having a diameter greater than 1 cm and 
probably greater than 5 cm.
2/ Disease confined to a specific body region such as the 
peritoneal cavity.
3/ Disease which is widely disseminated and, in general,
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not clinically locatable.
Although these categories can be distinguished it is 
possible for more than one type to be present in a 
patient, possibly all three. The corresponding 
requirements for therapy, however, are likely to differ.
8.6.1 BULK TUMOURS
Bulk disease consists of a mass of viable clonogenic and 
non-clonogenic tumour cells, non-viable and necrotic 
tumour cells, stromal cells, infiltrating lymphocytes and 
macrophages, non-cellular material and blood vessels 
including capillaries. The access of targeted 
radionuclides to bulk disease is provided by diffusion 
through capillary walls. In order to give a high uniform 
dose to a bulk tumour there are, at least, four 
requirements:
1/ Vehicle-warhead specificity is nec essary to provide a 
differential between tumour and normal tissues. It should 
be noted that this broad prerequisite will include not 
only biochemical specificity for tumour associated 
antigens or products but also:
a) firm binding of radionuclide to vehicle to prevent free 
radionuclide from circulating
b) minimizing reticulo—endothelial uptake of non—self 
proteins
c) favourable pharmacokinetics of vehicle-warhead 
distribution.
2/ Vehicle-warhead sensitivity or the ability to target 
all tumour cells is also neccessary. The potential
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problems in this instance can be related to two main 
co-factors as follows:
a) The biological heterogeneity of human tumours by the
time of diagnosis ( Owens et al, 1982 ). This is partly
due to cellular differentiation in less anaplastic tumours 
and also the result of the "genetic instability" of tumour 
cells leading to the continual emergence of mutant clones 
as tumour growth proceedes. Not all tumour cells will 
express a particular antigen ( Edwards, 1985 ) or
synthesize a particular molecule ( Buck et al, 1985 ) even 
if the majority do. The phenomenon of "antigen modulation" 
( Old et al, 1968 ) i.e. suppression of a previously
expressed antigen, will also contribute to the 
heterogeneity of tumour cells.
b/ Another important problem area is likely to be access 
of the vehicle to the tumour cells. Large molecules like
antibodies are likely to diffuse only a short distance ( 
Pimm and Baldwin, 1985; Hagan et al, 1986 ). Problems of 
accessibility may not only be confined to large tumours. 
Restricted access of even small molecules such as 
adriamycin ( Durand, 1981; Kerr et a.1, 1986 ) and
methotrexate ( W e s t  et al, 1980 ) has been observed in 
sub-millimeter diameter tumour spheroids in vitro and may 
be inferred for micrometastases in vivo.
These potential problems highlight another requirement.
3/ The choice of a suitable range of ionising radiation,
either
a/ long-range emissions to exploit cross-fire
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irradiation of tumour cells from radionuclides not 
directly associated with them or
b/ short-range emissions to exploit intimate localisation 
if and when it occurs.
4/ A high level of radionuclide concentration throughout 
the tumour.
The prospects of antibody-targeted radiotherapy for bulk 
disease have been considered by Vaughan and co-workers ( 
Vaughan et al, 1986; 1987 ). These authors used a 
compartmental model to evaluate doses to a bulk tumour and 
the whole body, based on current estimates of tumour 
uptake of antibody-radionuclide conjugates administered 
systemically ( about 0.005% of injected activity per gram 
of tumour ) and their effective half-lives in tumours and 
other body compartments. They calculated that, in order to 
give a "sterilizing” dose of 60 Gy to the tumour, the 
whole body would receive a dose of 17 Gy. Vaughan et al 
pointed out that bone marrow toxicity is the dose-limiting 
effect for BTR, as has been reported by others ( Ettinger 
et al, 1982 ), and that doses of this magnitude are far in 
excess of what would enable marrow recovery. They 
concluded that it was inappropriate to plan therapeutic 
studies using this technique.
This led to a correspondence ( Wheldon and O'Donoghue, 
1986; Epenetos et al, 1986; Begent et al, 1986; Ward et 
al, 1986 ) in which several alternative interpretations 
and therapeutic approaches were described. Vaughan et al 
took a dose of 60 Gy as representing a steriltz-ing dose.
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This may be open to criticism on the grounds that the dose 
required for sterilization depends on tumour size. To a 
first approximation it is directly proportional to the 
logarithm of the number of clonogenic tumour cells. This 
means that smaller tumours will be eradicated at lower 
doses than are required for larger ones. The other 
objection to the figure of 60 Gy is that it is set, not 
because it is the dose required for tumour sterilization, 
but because it corresponds to the tolerance of connective 
tissues for fractionated radiotherapy. Having said this it 
may be acknowledged that 60 Gy is a reasonable figure of 
merit for BTR and doses of this order, or even higher will 
be neccessary for the eradication of bulk tumours. The 
suggestion of bone marrow rescue ( Wheldon and O'Donoghue 
) and its likely consequences will be described in detail 
in the next chapter, suffice it to say here that one would 
anticipate a possible dose escalation. Begent et al 
pointed out that the limited diffusion of 
antibody-radionuclide conjugates from capillaries may be 
similar to that of nutrients and oxygen and that the 
distribution of antibody—radionuclide may correspond to 
the distribution of viable tumour cells. For this reason, 
BTR may be more effective than would be suggested by 
estimates of the mean dose throughout a tumour volume. 
This possibility is supported, to some extent, by the 
appearance of cords of viable tumour cells surrounding 
capillaries with intervening necrotic areas in some human 
tumours ( e.g. Thomlinson and Gray, 1955 ).
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Epenetos et al and Ward et al pointed out that there may
be therapeutic potential in regional administration of 
radiolabelled antibodies. This will be described in the
next section.
8.6.2 REGIONAL DISEASE
Several common cancers, such as cancer of the ovary, 
primary brain neoplasms and malignant serous effusions 
have a propensity for confinement to specific body 
cavities. The advantages of this situation for therapy are 
twofold:
1/ A higher proportion of the administered activity is 
available for binding to tumour.
2/ The accessibility of distant normal organs and tissues
to radionuclide is diminished. Absence of a "first pass" 
encounter with the liver is especially important.
Apart from the limitation to a bounded region of the body, 
regional malignancy may be essentially bulk tumour ( in 
which case most of the discussion of the last section will 
be equally relevant ) or composed of small disease foci — 
micrometastases or single cell suspensions. In the latter 
case the considerations for disseminated malignancy, 
discussed in the next section, will be applicable. 
Candidate neoplasms for regional therapy include ovarian 
carcinoma treated by intraperitoneal infusion ( Epenetos 
et al, 1987 ); liver metastases treated by
intrahepatically administered antibody—radionuclide with 
biodegradable starch microspheres which temporarily block 
the flow of blood creating an artificial regional
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environment; primary malignant melanoma in limbs treated 
by isolated limb perfusion possibly with
antibody-radionuclides; leptomeningeal malignancy deriving 
from medulloblastoma, acute lymphocytic leukaemia, 
lymphoma, melanoma and others, treated by intrathecal or 
intraventricular administration of antibody-radionuclide ( 
Lashford et al, 1988 ). These examples have little in
common apart from the regional aspect. Any other clinical 
conditions where regional confinement, both natural or 
artificial, may be a factor will also be worth considering 
for BTR.
8.6.3 DISSEMINATED MALIGNANT DISEASE
It is in the treatment of disseminated but undetectable 
micrometastases that BTR holds the greatest theoretical 
promise. The reason for this is quite simple. Malignant 
disease less than 1cm in diameter is unlikely to be 
visualiz<zd by imaging procedures. Its existence may be 
inferred by other clinical investigations e.g. serum 
markers, or by experience of the natural course of a 
particular disease. In theory, if disease is locatable, it 
may be treated by local means - surgery or radiotherapy. 
If disease is not localised it must be treated 
systemically by chemotherapeutic drugs and possibly TBI. 
Either way, in this case, it is not so much the disease 
which is being treated as the whole patient. This severely 
restricts the allowable doses. With BTR, as was described 
at the beginning of this chapter, there is the possibility 
of the all-encompassing aspect of systemic treatment
coupled with the spatial specificity of local treatment. 
This is, of course, in the ideal case. In reality, for the 
foreseeable future, BTR will be more like non-uniform TBI 
and, like other forms of cancer therapy, will rely on the 
accumulation of small advantages and differentials in 
order to be a success. Some discussion of the strategic 
aspects of treatment by BTR have been reported ( Wheldon 
et al, 1988 ) and this will be expanded in the next
chapter. For the moment, some comparisons will be drawn 
between disseminated neoplastic disease and bulk tumours. 
Access to small avascular metastatic conglomerations of 
tumour cells is provided by diffusion from the outside. To 
this extent the situation is similar to bulk disease where 
diffusion is from the tumour vasculature. The .levels of 
uptake of targeted radionuclide in microtumours are not 
known. The studies of Moshakis et al, 1981; Menard et al, 
1983 and Hagan et al, 1986 demonstrated that, for specific 
antibody, the radionuclide uptake per gram of tumour was 
inversely proportional to tumour mass. Epenetos et al ( 
1982 ) reported that non-specific antibody uptake varied
directly with tumour sise but was diminished by necrosis. 
Baldwin and Pimm ( 1983 ) also reported tumour growth to 
be accompanied by linear uptake. The latter two studies 
imply a constant or only slowly increasing uptake per gram 
as tumour size decreases. None of these experimental 
systems measured radionuclide uptake in microtumours. The 
balance of the evidence appears to suggest that smaller 
tumours concentrate specific antibody more efficiently.
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Estimates of tumour uptake made for bulk disease may be 
misleadingly low for rnicrometastases.
Micrometastases are probably in an exponential growth 
phase and therefore less likely to harbour quiescent ( GO 
) cells. Consequently, they may be more radiosensitive 
than bulk tumours, although there is no direct clinical 
evidence for this. The requirements for vehicle-warhead 
specificity and sensitivity are the same as for bulk 
tumours.
The ideal range of ionizing radiation will depend on the
dimensions of the collection of tumour cells. Sizeable
microtumours ( 1 mm diameter or greater ) will have 
different range requirements from single freely 
circulating cells. Targeting of single cells calls for a 
radionuclide with a very short range emission, of the 
order of the cell radius. If a long range emitter is used, 
virtually no ionization will occur within the target cell. 
Conversely, given a situation of limited diffusion into a 
sizeable microtumour, a longer range emitter is called 
for. In this case a short range radionuclide could not 
hope to satisfactory 1 / treat tumour cells in the
interior. In the case where both single circulating tumour 
cells and microtumours may be present, no one radionuclide 
is likely to be satisfactory. This may be a reason for
using several radionuclides, having different emissions, 
simultaneously. However, it is difficult to envisage all 
tumour cells being adequately treated by BTR in isolation. 
For curative therapy it may be necessary to combine BTR
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with some other cytotoxic therapy. The combination of BTR 
with external beam TBI is a possibility considered in the 
next chapter.
There have not been any clinical studies of BTR for 
disseminated disease other than in situations where large 
primary tumours were also present. This is mainly due to 
the pattern of development of any new method of cancer 
treatment, where it is first tried out on patients unlucky 
enough to have advanced bulky disease with little hope of 
cure. Although this is unavoidable it should be borne in 
mind that it is in treatment of widely disseminated 
disease where BTR should be most beneficial.
8.7 RADIONUCLIDE WARHEADS FOR BTR
In the previous section it was seen that the requirements 
for a radionuclide warhead are highly dependent on the 
type of tumour- target. In this section radionuclides which 
may be candidates for BTR will be examined. Following Humm 
( 1986 ) radionuclides may be split into five groups,
three of which are only quantitatively independent. These 
groups are:
1/ Alpha sources, e.g. 211 At, 212 Bi
2/ Short range beta sources ( mean range < 200 um ), e.g. 
33 P, 199 Au
3/ Medium range beta sources ( 200 um < mean range < 1 mm 
), e.g. 131 I, 67 Cu, 109 Pd
4/ Long range beta sources ( mean range > 1 mm ), e.g. 32 
P, 90 Y
5/ Electron capture and internal conversion decaying
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sources, e.g. 77 Br, 125 I, 131 Cs
Alpha radiation is a very efficient agent of cell 
sterilisation. The range is short, typically of the order 
of cellular dimensions, 50 - 90 um. This means that one 
would expect only cells directly targeted to be 
sterilised. This implies that oL - emitters may be suitable 
for therapy of single cells. Their potential for therapy 
of substantial microtumours or bulk disease is less 
obvious. Uniform radionuclide distribution throughout the 
tumour mass would be nec essary, otherwise there will be a 
problem relating to tumour cells which escape effective 
targeting.
Astatine - 211 is a halogen. It therefore will be likely
to mimic the chemistry of iodine to some extent. In 
particular it may be possible to replace iodine by 
astatine in mIBG, which would become mAtBG. Astatination 
of antibodies should also be possible. Some investigations 
into the use of astatine labelled monoclonals have been 
reported ( Vaughan et al, 1982; Harrison and Royle, 1984 
). Radiobiologically one would not expect any dose-rate 
effect for o( - emitters, e\-VWr for tumour cell 
sterilisation c>^  also for damage to normal tissues.
Short range beta sources again are likely to be of most 
use in the therapy of single cells or smaller 
micrometastases. Treatment of larger deposits may suffer 
from the heterogeneity of vehicle distribution.
Medium range beta sources include 131 I, the only 
radionuclide used so far in clinical BTR. 131 I also
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produces high energy photons. This has advantages and 
disadvantages. The distribution of radionuclide may be 
visual i'ze.A. by scanning, which enables attempts at 
dosimetry to be made. Conversely, the photon component 
increases the dose throughout the whole body. Medium range 
beta sources like 131 I are of limited use for the therapy 
of single cells as most of the disintegration energy will 
escape. This may increase the cross-fire effect in therapy 
of larger tumours but, in this case, the range is rather 
too short to compensate for the heterogeneity of 
distribution.
Long range beta sources are best suited for BTR of bulk 
tumours and large metastatic deposits. They are not 
appropriate for single cells or small microtumours. 90 Y 
is under investigation as a therapy radionuclide ( 
Hnatowich, 1985; Leichner et al, 1988 ).
Radionuclides such as 77 Br, 125 *1 and 131 Cs decay by 
electron capture or internal conversion causing an inner 
shell vacancy. The subsequent cascade of electronic 
transi tions produce a large amount of X-rays and Auger 
electrons. The Auger electron range is very short ( ~ 1 um 
) and therefore close proximity to the genomic DNA is 
required for cell sterilisation. The compounds 77 Br 
bromodeoxyuridine ( BUDR ) and 125 I - iododeoxyuridine ( 
IUDR ) are pyrimidine analogues and are taken up and used 
in DNA synthesis. They are extremely effective as 
sterilising agents once incorporated into DNA. In the 
future one may speculate on the use of Auger emitters in
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targeting' specific oncogenes, perhaps incorporated in a 
specific gene probe in a genetically engineered virus. 
These approaches are, of course, a long way off.
The spectrum of radionuclides presented above illustrate 
two important points:
1/ No one radionuclide is suitable for all tumour targets. 
Long range beta sources e.g. 90 Y are probably best for 
bulk disease. Medium range beta sources e.g. 131 I may be 
best for sizeable microtumours ( ~ 1 mm diameter ). Short 
range beta sources and alpha emitters may be best for 
single cells and small microtumours ( < 1 mm diameter ). 
The time for Auger electron emitters may not be right yet, 
although these may be useful in the future.
2/ It is likely that there will be a proportion of tumour 
cells which are effectively untargeted. They may pose a 
serious obstacle to cure and it. will be important to 
examine alternative methods of ensuring that they are 
sterilised.
8.8 BTR BIODISTRIBUTION AND DOSIMETRY
The subjects of radionuclide biodistribution and dosimetry 
are intimately connected, one could even say that they are 
aspects of the same thing. For this reason they are 
considered together here.
If monoclonal antibodies and other BTR modalities were, 
truly, "magic bullets", studies of biodistribution and 
dosimetry would be unnecessary. One would simply 
administer enough targeted radionuclide to sterilize all 
tumour cells. However, there are no magic bullets, at
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least, not yet, and the biodistribution and dosimetry of
BTR are of vital importance. For the treatment of
disseminated malignant disease, intravenous or 
intraarterial administration of targeted radionuclide 
seems unavoidable. This means that initially all the
radionuclide is contained in the blood pool. The removal
of radionuclide from the blood pool is brought about by
several mechanisms, including:
1/ Uptake of targeted radionuclide by tumour cells 
2/ Uptake by cross-reacting normal cells
3/ Reticulo-endothelial uptake of non-self protein,
leading to sequestration of radionuclide in the liver and 
spleen.
4/ Excretion of targeted radionuclide, e.g. via the 
urinary tract ( kidney, ureter, bladder ).
Radionuclides in the blood pool will irradiate tissues
through which blood passes i.e. .all tissues. Photon
emission from radionuclides such as 131 I will also
irradiate the whole body by virtue of its long range.
Several remedial measures have been proposed to reduce the 
problems of biodistribution. These include:
1/ Improved physical chemistry and purification techniques 
( Gansow et al, 1986; Meares et al, 1988 ). The ease of 
iodination of antibodies is compromised by the ease of 
deiodination. This is especially important in vivo, where 
it seems to occur primarily in the liver and kidneys (
Carrasquillo et al, 1984 ), but the minimization of
radiolytic products and aggregated proteins before
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administration is very important. Other radionuclides e.g. 
90 Y may be chelated to antibodies ( Hnatowich et al, 1985
). This is a more secure binding and should improve the
situation with respect to in-vivo breakdown.
2/ The identification of more specific tumour markers or 
antigens is a worthwhile goal e.g. SM-3 antigen in breast 
cancer ( Burchell et al, 1987 ). This may reduce the
cross-targeting affinities. However, as has been
described, true tumour-specific molecules may not be 
present in all cases.
3/ The use of chimeric ( Sahagan et al, 1986; Reichman et
al, 1988 ) or human ( Carrasquillo et al, 1987; Yiu et al, 
1987 ) antibodies may help to reduce the immune response 
to foreign proteins.
4/ The use of antibody fragments may help in three 
respects:
a) Reticulo-endothelial uptake of antibody is probably 
facilitated by Fc receptors ( Buraggi et al, 1985 ). The 
use of Fab or F(ab')2 fragments may reduce this, 
b ) Antibody fragments may diffuse further than intact 
antibodies and may therefore improve the intratumour
distribution of radionuclide ( Matsku et al, 1986 ). 
c ) Monovalent antibody fragments ( Fab ) will help to 
reduce the problems of antigenic modulation ( Cobbald and 
Waldmann, 1984 ).
5/ Second antibody techniques may help to accelerate the 
clearance of targeted radionuclide from the blood pool ( 
Begent et al, 1982; Goodwin et al, 1984, Sharkey et al,
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1984 ).
It is difficult to see how these measures will radically 
change the nature of BTR, but they are part of the 
accumulation of small differentials which is the hallmark 
of cancer therapy. For the foreseeable future BTR will be 
equivalent to non-uniform TBI. By analogy with TBI one 
would expect that the introduction of marrow rescue would 
enable an increase in the turnouricidal effect. This will 
be discussed in the next chapter. Meanwhile it would seem 
sensible to adopt the treatment philosophy used in 
radiotherapy. This may be described as "treat to 
tolerance". Adherence to this principle requires that the 
amount of BTR which is given be determined solely by 
consideration of the dose-limiting constraints which are 
imposed by normal organs and tissues. For sytemic 
treatment of minimal residual disease i.e. micrometastases 
and single cells, it is unlikely that tumour doses will be 
directly evaluable. For this case the principle of 
treating to tolerance would appear particularly useful. 
The primary purpose of biodistribution and dosimetric 
studies is the evaluation of doses to normal tissues.
8.8.1 THE MIRD APPROACH TO DOSIMETRY
The quantitative basis for calculation of doses from 
internally distributed radionuclides is the set of 
equations and recommendations of the Medical Internal 
Radiation Dosimetry committee of the Society of Nuclear 
Medicine. These rules have been published as a series of 
pamphlets in the years since 1968 ( Loevinger and Berman,
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19 76 refer to most of the other pamphlets ). The basis of 
the approach is the separation of the relevant variables 
into two main groups:
1/ Processes which involve the temporal distribution of 
radionuclide i.e. biodistribution kinetics 
2/ Other processes, namely physical ( i.e. related to 
radionuclide disintegration ) and spatial ( i.e. related 
to the anatomical distribution of radionuclide )
The MIRD approach amounts to calculating the dose or 
dose-rate produced in a "target organ" due to 
radioactivity in a "source organ", including the special 
case where the target and source organs are the same i.e. 
self-irradiation. Strictly only normal tissue doses can be 
calculated, as the calculations are based on an anatomical 
model of a normal body. The effects of processes 
independent of biodistribution kinetics i.e. spatial 
anatomy and nuclear transformations are summarized in 
tables of "S" values of absorbed dose in a target organ 
per unit cumulated activity of a particular radionuclide 
in a source organ. The S values are arrived at by Monte 
Carlo simulations of the paths of individual ionizing 
particles from radioactive decays. They are, therefore, 
average values over the whole of the target organ based on 
a uniform distribution of radionuclide throughout the
source organ and do not account for local variation. It
seems clear that where this approach is likely to break
down is in self-irradiation processes. This will be
especially pronounced for short range emitters. For these
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cases rnicrodosimetric models will probably be required ( 
Myers, 1987; Humm 1987 )
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9.0 ISOEFFECT AND DOSIMETRIC MODEL STUDIES OF 
BIOLOGICALLY TARGETED RADIOTHERAPY
In this chapter the subject of biologically targeted 
radiotherapy ( BTR ) is considered from the perspectives 
of the LQ isoeffect model and the medical internal 
radiation dosimetry ( MIRD ) approach. Using the LQ model 
the relationships between predicted allowable dose to bone 
marrow and a "late responding" organ as functions of the 
effective radionuclide half-life are investigated. The 
doses to micrometastases from antibody targeted 131-1 and 
90-Y are estimated using the MIRD equations and the models 
of Humm ( 1986 ) and Vaughan et al ( 1987 ).
9.1 ISOEFFECT MODEL STUDIES OF BTR
There is evidence which suggests that haemopoietic 
toxicity is currently the dose-1imiting effect for BTR ( 
Ettinger et al, 1982 ). It is, therefore, important to 
know what dose may be given to the bone marrow. Other 
organs which may be particularly vulnerable are the liver 
( due to sequestration of antibody ) and kidney ( due to 
renal excretion of radiolabel ). As with conventional TBI, 
radiation damage to lung may also be of importance. For 
BTR the dose-rates in these organs may be complex 
functions of time, related to the biodistribution kinetics 
of the vehicle-warhead. The simplest possible case is an 
exponentially decaying dose-rate. This is the only 
situation considered in what follows.
In order to calculate acceptable doses to normal organs
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the extension of the LQ. model to exponentially decaying 
dose-rates ( Dale, 1985 ) will be used.
As described in chapter 3 the biological effect of an 
exponentially decaying radiation exposure of initial 
dose-rate, r0 , and effective decay constant, A ( = In2/T,^ 
; where = effective half-life ) can be expressed as
an ERD where
£RD Rf * 5>
K F  5 I +___!•___ _
D = r./-x
r »-
e R O  - r° rt
(!•»
*/p A
For this biological effect to be equivalent to that 
produced by a fractionated schedule of n fractions of size
E R D  =  ^  ( j  +  (S'2)
Equations 9.1 and 9.2 may be solved for D = r0 to
yield ^
T) - — — -------- ------------------------------- (i.3;
2  >
The first situation to be considered is for haemopoietic 
toxicity. Here the dose-rate of importance is that 
produced in the bone marrow. The single fraction tolerance 
dose taken for the whole body ( without marrow rescue of 
some sort ) is 1 fraction of 2 Gy. The LQ model parameters
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for bone marrow are taken from Thames et al, 1984 as 
o(jp - 10 Gy : T^( repair ) = 0.5 hr ( ^  = 1,4 hr'1 ).
Equation ( 9.3 ) may now be solved to give the predicted
allowable doses for BTR as a function of radionuclide 
effective half-life. These are plotted as the lower curve 
in figure 9.1
The other organs to be considered fall into the
radiobiological category of "late-responders". These are 
likely to assume greater importance when haemopoietic
toxicity is by-passed by the use of marrow rescue. A 
conventionally fractionated schedule which is close to 
tolerance is taken to be 6 fractions of 2 Gy, with the 
assumption of complete repair between fractions. This 
schedule is currently used clinically for TBI when marrow 
rescue is performed ( Clift et al, 1982; Goolden et al, 
1983 ). In the TBI situation the dose limit is set by lung 
tolerance rather than by liver or. kidney, which may be 
able to withstand higher doses. The LQ model parameters 
taken to represent these organs which impose dose 
limitations are taken to be those of a .'"late responding 
organ" ( Dale, 1985 ) and are
tljp - 3 Gy : T^( repair ) = 1. 5 hr ( - 0.46 hf** )
Equation ( 9.3 ) may now be solved to give the predicted
allowable doses as a function of radionuclide effective 
half-life. These are plotted as the upper curve in figure
9.1.
9.2 DISCUSSION OF THE ISOEFFECT MODEL STUDY 
It can be seen from figure 9.1 that there is apparently
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Figure 9.1
The predicted allowable doses as a function of effective 
radionuclide half-life. The logarithmic scale of the 
half-life axis should be noted. The upper curve is for a 
"late responding" organ with an ^  of 3 Gy and a repair 
half-time of 1.5 hours. "Tolerance" for this organ is 
taken to be equivalent to six fractions of 2 Gy. The lower 
curve is for bone marrow with an ofjp of 10 Gy and a repair 
half-time of 0.5 hours. "Tolerance" for bone marrow is 
taken to be equivalent to a single fraction of 2 Gy.
little dose-rate effect for haemopoietic toxicity. This is 
due to a combination of the low repair capacity of 
haemopoietic cells, the low value of tolerance dose and 
also the assumed fast repair kinetic half-time of 30 
minutes. In practice the result of this is that, from the 
point of view of repair, one would not expect any 
significant sparing of bone marrow cells by using a 
radionuclide-carrier combination with an effective 
half-life longer than a few hours.
The dose value represented by the lower curve of figure
9.1 is 2.4 Gy. This corresponds to the ERD i.e. the dose 
assuming all possible repair has been completed. For 
effective radionuclide half-lives tending towards zero 
time, the isoeffective dose tends towards 2.0 Gy, equal to 
the isoeffective single fraction dose. The equivalent dose 
becomes 2.2 Gy ( i.e. the half-way value ) for an 
effective half-life of 0.7 hours.
There is no allowance for repopulation in the LQ 
equations. For this reason the real curve for haemopoietic 
toxicity will diverge from the lower trace in figure 9.1 
having an upward curvature at the long half-life end.
The findings for haemopoietic toxicity contrast with those 
for "late responding" organs. Here there is a marked 
dose-rate effect; 100% in the range of effective 
half-lives shown in figure 9.1. This is due to a 
combination of the higher repair capacities of late 
responding tissues, the higher dose equivalent of the 
tolerance level for these and the slower repair kinetic
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half-time of 1.5 hours which is assumed. Figure 9.1 shows 
that the isoeffective dose for the exponentially decaying
exposure can be lower than the reference fractionated dose
of 12 Gy. This is because the biological effect of the 
fractionated schedule itself embodies a significant degree 
6f sparing ( complete repair being assumed to take place 
between fractions ). Similarly to the case for
haemopoietic toxicity, the isoeffective dose for late 
responders will tend towards the single fraction
equivalent of 6 fractions of 2 Gy ( 6.4 Gy ) as the
effective half-life tends to zero. The isoeffective dose 
as the half-life tends to infinity tends to the ERD value 
of 20 Gy. This means that the theoretical maximum sparing 
factor is 20/6.4 = 3.125. The consequences for BTR are 
that late responders ( kidney, lung, etc ) will be
increasingly spared by using radionuclide-vehicle 
combinations with longer effective.half-lives. They will 
be spared preferentially with respect to bone marrow cells 
and tumours, if tumours behave more like acute than late 
responders. This argument neglects tumour proliferation 
effects, which may remove the relative benefits of longer 
half-lives. For BTR which is limited by marrow tolerance 
it is possible that the doses to organs such as liver,
kidney and lung will be below the levels of clinical
toxicity. If however bone marrow rescue is incorporated 
these organs will probably become dose-limiting and their 
tolerances will determine the amount of activity which can 
be administered.
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9.3 DOSIMETRIC MODEL STUDIES OF BTR
In this section the prospects for treatment of 
micrometastatic disease by BTR are considered. The
conclusions reached are based on purely dosimetric 
reasoning. Use is made of the work of Humm ( 1986 ) and
Vaughan et al ( 1987 ) as well as the standard MIRD
radionuclide dosimetry works ( Berger, 1971; Dillman and 
von der Lage, 1975; Snyder et al, 1975; Loevinger and 
Berman, 1976 ). The strategies of treatment of
micrometastases by antibody-targeted 131-1 and 90-Y will 
be considered.
9.4 ANTIBODY UPTAKE IN MICROMETASTASES
In the course of their analysis, Vaughan et al ( 1987 )
surveyed published data on antibody uptake by human 
tumours. They concluded that uptake, values were mostly 
very low, typically 0.005% of injected activity per gram 
of tumour. These data were mainly on uptake by bulk 
tumours, which are often composed of viable and non-viable 
material. Autoradiographic studies show higher uptake in 
viable regions. It has been suggested ( Begent et al, 1986 
) that viable tumour cells have higher levels of antibody
uptake than would be surmised from the figure of 5E-5/g
which is a gross average for the whole tumour.
This viewpoint is supported by experimental studies on 
uptake of radiolabelled antibody by murine tumours ( 
Moshakis et al, 1981; Menard et al, 1983; Hagan et al, 
1986 ). These studies suggest an increase by about a
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factor of 2 in specific uptake per unit mass as tumour 
size decreases. In the following sections the doses to 
micrometastases will be estimated based on both the 5E-5/g 
suggested by the survey of Vaughan et al ( 1987 ) and also 
on a figure of lE-4/g obtained by incorporating a factor 
of 2 for improved uptake in micrometastases.
9.5 INJECTED ACTIVITIES OF ANTIBODY-TARGETED 131-1
The amount of radionuclide injected will be limited by the 
radiation dose to the bone marrow. The assumption is made 
that the radionuclide distribution is uniform throughout 
the body except in the collections of tumour cells. For 
present purposes the activity in the whole body is assumed 
to clear exponentially according to the formula
Vj x (zyu 0 ± ]  (q.*,)
where W = whole body activity
A o = initial injected activity
c = physical decay constant for 131-1
and m = biological loss rate of activity from the body. 
Vaughan et- al ( 1987. ) in their review of the literature 
suggested that a suitable value of m for antibody-targeted 
131-1 would be 0.23 day-1, corresponding to a biological 
half-life of 3 days.
The whole body radiation dose to a standard man may now be 
calculated using the MIRD scheme. The cumulated whole body 
activity
Cj * . * 2.73xio (jfy.0 ($•£)
Qa + O
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and the whole body dose
p = 5 (5'0
where S is the standard value ( Snyder et al, 1975 ) for 
131-1.
S -  1-UJ H O '"1 Cy / g ’j j  
J> - 2.01 uo~" A0
The predicted allowable dose for bone marrow for an 
effective half-life of 2.19 days is 2.4 Gy ( corresponding 
to a 2 Gy single fraction equivalent dose ) from section
9.2. If the whole body dose must not exceed 2.4 Gy then 
the maximum permissable injected activity may be 
calculated
A -   = ll.fl
Z t l  n/o'16 y
Therefore in order to give a whole body dose of 2.4 Gy 
assuming uniform radionuclide distribution 11.81 GBq ( 319 
mCi ) of antibody-targeted 1311 may be given.
9.6 DOSES TO MICROMETASTASES FROM ANTIBODY-TARGETED 131-1
The dose to tumour cells is due not only to radionuclide 
directly bound but also to irradiation from radionuclides 
elsewhere in the body. This can be expressed as
For 131-1, disintegration energy is released in the form 
of -particles and K-ray photons. The tumour dose may thus
be further divided - ^
D +  ^ ”P L I + P I J ($•?)
wu>v»r -  b o u rx l ncn -fco ow *
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Each of these four components will be evaluated 
individually.
9.6.1 DOSE FROM BOUND BETA ACTIVITY
The model of Vaughan et al ( 1987 ) provides an expression
for the proportion of activity per unit mass of tumour at 
time t after administration as follows
where B0 = the maximum value C(t) would reach if there was 
no loss from the tumour or the whole body
k = biological uptake rate of radiolabelled antibody into 
tumour
1 = biological rate of loss of activity from the tumour
s.
and m = biological rate of loss of activity from the whole 
body, as previously.
From a survey of published data Vaughan et al estimated 
the rate constants for,antibody targeted 131-1 as follows: 
k = 2 day-1 : 1 = m = 0.23 day-1 
It can be shown that the time for maximal uptake
B, is found from equation ( 9.9 .) by setting the maximum 
proportional activity per gram of tumour to be (a) 5 E-5,
or (b) IE-4 for an improved uptake factor of 2. The 
maximum proportional activity per gram Cm is given by
5e k («x|» (- 40 ]
( / ' /f - rvO
0>6<i
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The activity per gram of tumour is given by
= 4 c(t) e 'ct (in)
where c = physical radionuclide decay constant.
The total cumulated activity is given by
Y - J Y<y it ~ a6 k
( ^ + c )  (A+*v + c)
~ Zoz Cr^$ (a.) 
or ^0(4. (J*)
In order to calculate the dose the cumulated activity must 
be multiplied by the equilibrium dose constant. These have 
been tabulated for a large number of radionuclides (
Dillman and von der Lage, 1975 ). The total equilibrium
dose constant for all ^-particles and Auger electrons for
131-1 is m r I
A = 3.0* MO"
P
The product of the cumulated activity and the equilibrium 
dose constant is the absorbed dose for conditions of 
electronic ;equilibrium. This is very far from the real 
situation for micrometastases. Humm ( 1986 ) has published 
values of the absorbed fraction, ^  for small volumes. 
These are shown in Table XIV
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TUMOUR DIAMETER ABSORBED FRACTION (ft )
200 urn 0. 17 
0. 54 
~ 1. 0
1 mm
1 cm
Diameters of micrometastases and associated absorbed 
fractions of equilibrium dose for 131-1 
TABLE XIV
The tumour doses from ^ -activity bound to the tumour can 
now be calculated and are shown in the first line of table 
XV. The figures in brackets are the doses assuming an 
enhanced uptake by a factor of 2 in the two smaller sizes 
of tumour.
This component is considered to be negligible for 
micrometastases of this size.
This component is taken to be the dose to a spherical 
"cold" volume in a continuum of ff -activity at an initial 
concentration of 0.169 MBq gm-1, calculated by assuming 
100% uptake of the administered activity throughout a 70 
kg total body mass. The effective radionuclide decay 
constant in the whole body, is .316 day-1 and the
cumulated activity per gram
The contribution to the "cold" region is found by 
multiplying the equilibrium dose by a factor ( 1- ft) where 
is the absorption factor given in Table XIV ( Rossi and
9.6.2 DOSE FROM BOUND GAMMA ACTIVITY '
9.6.3 DOSE FROM UNBOUND BETA ACTIVITY
A A 66 . 06
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Ellis, 1950 )
o' . - 4- a, 0-“ )/)OA- OftVlWf ^ »
The doses from unbound jj-activity are shown in the third 
line of Table XV
9.6.4 DOSE FROM UNBOUND GAMMA ACTIVITY 
This is the ^-component of the whole body radiation dose. 
The effective photon dose.constant can be calculated by 
multiplying the "S" value by the mass of the reference 
phantom ( 70 kg ) and subtracting the equilibrium beta
dose constant.
Ilf A10
The photon dose is the product of this dose constant and 
the cumulated activity per unit mass. This is shown in the 
fourth line of Table XV
Contribution Tumour diameter
to dose ( Gy ) 200um 1mm 1cm
P
Dbound 1. 05 3. 35 6. 20
(2. 11) (6.69)
Dbound 0 0 0
P
Dnon-bound 1. 17 0.65 ~0
rfnon-bound 0. 98 0. 98 0. 98
Dtumour 3. 20 4. 98 7. 18
(4.26) (8.32)
radiation dose ( Gy ) to micrometastases
varying diameters from 11.81 GBq 131—1 labelled antibody 
assuming a uniform distribution of radionuclide thrc>t£gh£>u.t 
the body. The fractional uptakes in the micrometastases 
are 5 x 10-5/gm and 1 x 10-4/gm in brackets
TABLE XV
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The results show that the doses to micrometastases lie
within the range 3.2 - 8.3 Gy depending on the uptake of 
antibody in the smaller tumours. These doses are low, even 
in comparison with TBI schedules, and it would not be 
expected that they would be curative, even for
micrometastases. To this extent the analysis supports the
conclusions of Vaughan et al that significantly improved
antibody uptake is necessary for tumour sterilization when 
antibody-targeted radiotherapy is used as a treatment 
modality in isolation. Vaughan et al also concluded that 
for BTR of bulk disease 90-Y is a superior warhead to 
131-1. The use of this radionuclide will now be examined 
for treatment of micrometastases.
9.7 INJECTED ACTIVITIES OF ANTIBODY TARGETED 90 Y
Again assuming* the radionuclide distribution is uniform 
throughout the body except in the collections of tumour 
cells, bone marrow will be the dose limiting organ. The 
activity in the body clears exponentially according to the 
formula
\o = /L £a-V>(-Crv+ t->t ]
where W = whole body activity 
A* = initial injected activity
c = physical decay constant for 90-Y = .256 day-1
(half-life = 2.71 days )
and m = biological loss rate of activity from the body. 
Vaughan et al ( 1987 ) suggest that there is no biological
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loss of .90 Y from the body, or effectively that the
physical decay is the dominant mechanism of removal of 
activity ( i.e. m=0 in equation ( 9.4 ) ).
The whole body dose is again calculated using the standard
MIRD method. The cumulated whole body activity
Vj - ^  = 3 . 1 ^  mo Aa (1.13;
C
The whole body dose
T) = Ci s
The "S" factor for 90-Y
S= 2.1 xt6',s Gy/% f^ 
D  - 7.e ft %/<>'“  A a
Again the predicted allowable’ dose for the low LET 
emissions of 90-Y is 2.4 Gy for an effective half-life of 
2.7 days.
46 = 3 - 3 F  Gly,
Therefore in order to give a whole body dose of 2.4 Gy
assuming uniform radionuclide distribution 3.38 GBq ( 91.4
mCi ) of antibody targeted 90 Y may be given.
9.8 DOSES TO MICROMETASTASES FROM ANTIBODY-TARGETED 90-Y
The situation here differs from that for 131-1 as there is 
no photon component in the disintegration of 90 Y. The 
dose to tumour cells may be expressed as
Both components will be evaluated individually
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9.8.1 DOSE FROM BOUND ACTIVITY
The equation for proportional activity per gram is taken 
from the model of Vaughan et al ( 1987 )
C(i) = * jT(A+>v\ it} _ ej^c\p (- (9*0
- /fr - *vO
where the symbols have the same meaning as for 131-1. The 
estimates of the rate constants for 90 Y are
k = 2 day-1. : 1 = m = 0 
Equation ( 9. 9 ) can thus be reduced to
m -  \ 0
The maximal value of C(t) is simply given by
C~ = T5„
1J = S' fifO  ^(a)
I no-** (b) .
It should be noted that this value of B is not the same 
as that used for antibody targeted 131-1. This is because 
Vaughan et al estimated Cm rather than B
Actvity per gram of tumour is given by
X )  4. Cft) _e c* (3 »‘)
The cumulated activity is given by
y = - A* \ k = Sb.dCrKj.s (~)
cCc+'f) „v to
The dose to micrometastases from bound activity is product
of the cumulated activity, the equilibrium dose constant
and the absorbed fraction, ft . From standard tables (
Diliman and von der Lage, 1975 ) the equilibrium dose 
constant may be expressed as
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A  = I. X 1 0 - ’ 6 /  /ti^i
Humrn has published estimates of P  for tumour diameters of 
200 um and 1 mm. The estimate of p  for a tumour diameter 
of 1cm was derived from Berger, 1971 by the following 
method. This MIRD pamphlet deals with absorbed doses from 
point sources of beta activity in small volumes. The
percentile absorption corresponding to a radius value of 
0. 5 cm was scaled by the corresponding ratio of percentile 
absorption to Humms’ factor, pf for the radius value of 0.5 
mm. This gives an estimate of 0. 73 for ft for a 1cm
diameter tumour. The values of ft for these three volume
sizes are shown in Table XVI.
TUMOUR DIAMETER ABSORBED FRACTION ( <f> )
200 um 0.015
1 mm 0.097
• 1 cm 0.73
Diameters of micrometastases and associated absorbed 
fraction of equilibrium dose for 90-Y 
TABLE XVI
The doses to micrometastases from radionuclides bound to 
the tumour cells may now be calculated and are shown in 
the first line of Table XVI/ The figures in brackets are 
doses from bound activity assuming an enhanced uptake by a 
factor of 2.
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*9.8.2 DOSES FROM UNBOUND ACTIVITY
Again this is taken to be the dose to a spherical "cold" 
volume in a continuum of 90—Y activity at an initial 
concentration of 0. 048 MBq grn-1 with an effective 
half-life equal to the physical half-life i.e. 2.7 days. 
The cumulated activity
A  - - 14.31
*
The dose to the cold region is found from
* 4
D  . . = 2? A  h - P )  (?•*)
4m- bouKtf ^
These values are shown in the second line in Table XVII. 
Contribution Tumour diameter
to dose 200um 1mm 1cm
p
Dbound 0. 11 0. 73 ‘ 5. 50
(0.23) (1.46)
Dnon-bound 2. 39 2,19 0. 66
Dtotal 2. 50 2. 92 6. 16
(2.62) (3.65)
radiation dose ( Gy ) to micrometas tases
varying diameters from 3.38 GBq 90-Y labelled antibody 
assuming a uniform distribution of radionuclide throughout 
the body. The fractional uptakes in micrometastases are 5 
x 10-5/gm and 1 x 10-4/gm in brackets
TABLE XVII
The results of this analysis of the predicted doses to 
micrometastases using antibody-targeted 90-Y show that 
they lie within the range 2.5 - 6.2 Gy depending on the 
antibody uptake. For the two smaller tumour sizes the
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majority of the dose is produced by a "cross-fire" effect, 
very little actually corning from bound radionuclide. For 
the 1 cm diameter tumour the estimate of j6 was 0.73. This 
means that 73% of the available energy is absorbed. The 
tumour dose for 100% absorption would be ~ 7.5 Gy. Doses 
of this order are unlikely to be curative. For the largest 
tumour size considered the dosimetric analysis supports 
the contention of Vaughan et al ( 1987 ) as regards the 
necessary improvement in antibody uptake for the clinical 
use of this modality in isolation. However for the two 
smaller tumour sizes an increase in antibody uptake would 
have a small, possibly negligible effect. This is because 
of the highly inefficient absorption of 90-Y energy in 
small volumes. It must be concluded that for tumours of 
this size 90-Y is not an appropriate radionuclide for BTR.
9.9 DISCUSSION
The limitations of this analysis should be borne in mind. 
The compartmental model of Vaughan et al ( 1987 ) is 
simplistic, although this reflects the limited available 
data. In particular the assumption of uniform distribution 
of radionuclide throughout the body is unrealistic. This 
point will be returned to later.
Other radionuclides, apart from iodine and yttrium may 
have been considered, but these two are the most relevant 
at the present stage of development of BTR. The ^ -emitting 
radionuclide 211-At has several theoretical advantages, 
namely extreme localisation of energy deposition and
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highly effective ionizing radiation. However there is no 
information on the effects of antibody targeted 211-At on 
normal tissues and consequently no guide to acceptable 
tolerance dose levels. The above analysis is 
in appropriate for 211-At for another reason which has not 
yet been addressed. This is to do with the problem of 
tumour cells which have escaped targeting, a matter which 
will be discussed further in chapter 10.
For the treatment of micrometastases it is apparent that 
131-1 is better than 90-Y. This finding is in contrast to 
the conclusion of Vaughan et al that 90-Y was superior to 
131-1 as a cytotoxic label for therapy of bulk tumours. 
The reason for this difference is the relatively poorer 
absorption of the p-energy from 90-Y. Although the energy 
from 131-1 is not efficiently absorbed in the smallest 
volume considered ( 200 um diameter ) it is much better
than 90-Y. Consequently, in the next sections on 
strategies incorporating bone marrow rescue, only the use 
of 131-1 as a cytotoxic label will be considered further.
"9.10 THE USE OF BONE MARROW RESCUE
The tumour doses calculated to be achievable by 
administration of antibody-targeted 131-1 are determined 
by the amount of injected activity which is allowed. This, 
in turn, is limited by the predicted allowable whole body 
dose. The whole body dose from BTR is important since 
above 2 Gy equivalent there is a sharply increasing 
incidence of bone marrow toxicity. The conclusions drawn 
from the previous section are that BTR of micrometastases
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does not- seem curative, for the currently achievable 
levels of antibody uptake, so long as the injected 
activity is limited by haematological tolerance. The use 
of bone marrow rescue would remove this obstacle. In this 
section the implications of using this procedure are 
examined for 131-1.
If bone marrow were replaced following BTR, much higher 
activities of radionuclide could be given. Limitation of 
dose would no longer depend on the risk of marrow ablation 
but on damage to other critical organs. The next organ to 
become dose-limiting will depend on the cross-targeting 
affinities of the delivery vehicle and the excretion route 
of the radionuclide. The most vulnerable organs would 
probably be lung ( as for external beam TBI ), liver, 
urinary tract and gastro-intestirial tract. In section 9.1 
the predicted allowable doses to late responding organs 
equivalent to 6 fractions of 2 Gy were calculated using 
the LQ model and are shown in figure 9.1. Assuming the 
effective whole body half-life for antibody targeted 131-1 
remains at 2.19 days, -the predicted allowable dose is 
17.25 Gy to the whole body assuming uniform distribution 
of radionuclide. By the same reasoning as previously the 
injected radionuclide activity to give 17.25 Gy may be 
calculated. This activity is a factor of 7.2 ( i.e.
17.25/2.4 ) higher than the activity required for a 2.4 Gy 
whole body dose. For a 70 kg body weight and assuming 
uniform distribution of radionuclide this proves to be 85 
GBq ( 2.3 Ci ). The doses to micrometastases can also be
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estimated by scaling up the previous doses by a factor of
7.2. These dose values are shown in Table" XVIII
Tumour diameter 
200 um 1 mm 1 cm
Dtotal 23.0-30.7 35.9-59.9 51.7
Estimated radiation doses ( Gy ) to micrometastases of 
varying diameters from an administered activity of 85 GBq 
of 131-1 labelled antibody. These values are arrived at by 
scaling up those in table XV by a factor of 7.2
TABLE XVIII
This analysis suggests that very substantial radiation 
doses could be delivered to micrometastases if BTR were 
combined with marrow rescue. Bearing in mind that the 
smaller a tumour the less dose will be required for 
sterilisation, the achievable doses seem very encouraging. 
However, there would be major obstacles to this treatment 
strategy. The most serious of these are:
1/ The change to BTR plus marrow rescue is potentially a 
large one. As yet there is no clinical experience of such 
a procedure. For this reason caution is to be recommended. 
In the UKCCSG protocol for the mIBG trial for disseminated 
neuroblastoma, storage of autologous marrow is suggested 
as a precautionary measure in case of severe haemopoietic 
depression. This may be the route by which some clinical 
experience of BTR and marrow rescue may be obtained.
2/ So far in the analysis the assumption of uniform
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distribution of radionuclide throughout the body has been 
made. This is an unrealistic assumption. Particular organs 
( e.g. liver, kidney, bladder ) may receive considerably 
higher doses than suggested by the whole body average. The 
effect of this will be to limit the allowable injected 
activity ( and hence tumour dose ) to levels less than 
those of the forgoing analysis. The relative benefits of 
marrow rescue may therefore be rather less than average 
dose values would suggest.
3/ As with chemotherapy there may be "sanctuary sites" 
which are inaccessible to the delivery vehicle. This may 
be a special problem for antibodies which are of higher 
molecular weight than cytotoxic drugs.
4/ The quantities of radionuclide which could 
theoretically be given ( 85 GBq of 131-1 ) would pose very 
serious problems of radiation protection.
5/ It is possible that reinfusion of marrow would have to 
be delayed until dose-rate levels from the radionuclide 
fell to a low level. The time for this to occur would 
obviously depend on the amount of radionuclide injected. 
The longer the interval the greater the risk to the 
patient from immune suppression and prolonged aplasia. 
These points illustrate the potential problems likely to 
exist with single-agent BTR and marrow rescue. They 
suggest that a sudden change from a strategy of BTR 
without marrow rescue ( 2.4 Gy whole body dose ) to BTR 
with marrow rescue ( 17.25 Gy whole body dose ) may be too 
drastic. A more practicable policy may be to combine lower
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levels of BTR with external beam TBI and marrow rescue. It 
will be suggested in the next chapter that this strategy 
is actually the optimal one for the treatment of systemic 
malignant disease. However, for the moment, only the 
dosimetric aspects will be considered.
9.11 COMBINED BTR WITH TBI AND MARROW RESCUE
One way of looking at the rationale for this therapeutic 
strategy is to consider the following: TBI consists of the 
delivery of a uniform dose ( so far as possible ) 
throughout the body. Any non-uniformities are caused by 
physical rather than biological factors ( e.g. the reduced 
density of lung tissue ). Biologically targeted 
radiotherapy entails biological non-uniformity of the dose 
distribution with, hopefully, tumour cells receiving 
higher doses than normal tissues. Without marrow rescue 
the dose from BTR is unable to sterilize even microscopic 
tumours. With marrow rescue we have the problems listed in 
the previous section 9.10. Combination of the uniform 
distribution and high dose of TBI with the 
non-uniformities introduced by BTR could lead to higher 
probabilities of tumour sterilization than could be 
achieved by TBI alone. Normal tissues which receive 
inappropriately high doses from BTR ( e.g. liver, kidney ) 
could be preferentially shielded during TBI.
9.11.1 ISOEFFECT RELATIONSHIPS FOR COMBINATION BTR AND TBI
The amount of radiation damage sustained by an organ or 
tissue can be described using the LQ model as an ERD
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value. When two independent treatments are given the 
combined damage can be expressed by the sum of the ERDs of 
each individual treatment. The following considerations 
are valid only when the fractionated TBI and the BTR are 
sequential ( i.e. non-sirnultaneous ). To describe
simultaneous treatments modified versions of these 
equations would be necessary. These are, however, 
presently unavailable and their derivation is beyond the 
scope of the present work.
The requirement for a sequential combination BTR and TBI 
schedule to be equivalent to a specified "reference" 
toxicity level is
this condition can be written as
If d = dr this may be rewritten as
3 <*(»+ t y /p ) = o
'X «/p *
which is identical to equation 9.1 with n being replaced
by ( nr-n ). The solution for D is
n
The injected activity corresponding to the allowable BTR 
doses may now be calculated from equation 9.18. The doses 
to micrometastases of different sises may also be 
calculated following the methods outlined earlier. This 
has been done as one-by-one the TBI fractions are replaced 
by an "equivalent" amount of BTR. All this information is 
shown in Table XIX
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Treatment strategy Tumour diameter
TBI BTR ( GBq ) 200um 1mm 1cm
6 X 2 - 12. 0 12. 0 12. 0
5 X 2 15. 93 14.3-15.7 16.7-21.2 19. 7
4 X 2 31. 00 15.1-19.2 21.1-29.8 26. 9
3 X 2 45. 34 18.3-22.4 25.1-36.9 33. 6
2 X 2 59. 05 20.0-25.3 28.9-45.6 39. 9
1 X 2 72. 21 21.6-28.1 32.5-52.9 45. 9
- 84. 87 23.0-30.7 35.9-59.9 51. 7
Estimated radiation doses ( Gy ) to micrometastases i
varying diameters from combination strategies ( TBI
targeted 131-1 BTR ) incorporating marrow rescue,
TABLE XIX
9.12 DISCUSSION
In the present stage of development of biologically 
targeted radiotherapy for systemic malignant disease doses 
are limited by bone marrow toxicity. Analysis of the 
situation using the LQ model suggests that there will be 
little or no dose-rate effect on haemopoietie cells. 
Allowable whole body doses are therefore likely to be 
similar to those for external photon irradiation ( i.e. 
around 2 Gy ). With the present reported levels of 
antibody uptake in tumours BTR is unlikely to result in 
curative doses for both bulk disease, as reported by 
Vaughan et al ( 1987 ) and micrometastatic disease, as 
described in this chapter. This is true for both 131-1 and 
90-Y as cytotoxic labels. For micrometastatic disease
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131-1 is a superior therapy radionuclide to 90-Y. This is 
because of better absorption of the disintegration energy. 
Higher levels of BTR rnay be possible if bone marrow rescue 
is incorporated into treatment procedures. This is 
reasonable by analogy with external beam TBI. LQ model 
studies indicate that dose-rate effects due to the 
exponentially decaying low dose-rates from radionuclides 
will be significant in this case. If a uniform 
distribution of radionuclide is assumed, simple 
calculations suggest that single-agent BTR may be curative 
in these circumstances. However, the real situation will 
be rather different and there are good reasons for using a 
combination approach to treatment involving a proportion 
of BTR, a proportion of external beam TBI and bone marrow 
rescue. This has the potential advantage that organs 
receiving high doses from BTR may be shielded during TBI 
treatment. It appears from this .analysis that the 
advantages of the combination BTR/TBI treatments are 
greatest for tumours in the lrnrn - 1cm diameter range. 
While containing large numbers of cancer cells, these 
tumours are below or close to the threshold of clinical 
detectsubility, so not treatable by local modalities, and 
may therefore be important obstacles to cure. If this is 
true the combination approach may have a significant 
impact on patient survival in particular those for whom 
bone marrow rescue is feasible.
9.13 RADIATION PATHOLOGY AND MICRODOSIMETRY
In this chapter doses delivered by BTR and also by
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external beam radiation were assumed to be equally 
effective at the microdosirnetric level. The pathological 
damage to normal organs is related to the pattern of 
distribution of ionisation events. Assays of normal tissue 
damage up till the present have been based on the patterns 
of ionisation produced by external beam radiation. For 
biologically targeted radiotherapy ( BTR ) these patterns 
are quite likely to be different. Myers ( 1987 ) has 
pointed out the need for special microdosirnetric 
approaches to radiation deposition in the bone marrow. 
Other organs like the kidney may also require a dosimetry 
protocol based on the to-be-observed micropathology of BTR 
toxicity. The detailed study of the effects of BTR on 
individual organ systems will be a task for the future.
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10.0 MODEL STUDIES OF OPTIMAL SCHEDULING OF BTR 
10.0.1 THE PROBLEM OF UNTARGETED TUMOUR CELLS
The previous work has been based on largely dosimetric 
reasoning. Combination of BTR with external beam TBI was 
introduced as a method of reducing the problems of 
radionuclide biodistribution and radiation protection. The 
calculated doses to micrometastases are average values. 
This neglects the dosimetric non-uniformities which exist 
at the microscopic level. These will assume greater or 
lesser degrees of importance depending on the range of 
ionization of the radionuclide. For instance, with a long 
range emitter like 90-Y there will be a large amount of 
cross-fire. So much so that, as- was seen in the last 
chapter, most of the dose to micrometastases comes from 
cross-fire from non-bound radionuclide. On the other hand 
for an extremely short range emitter such as 211-At there 
will be little or no cross-fire. Microdosimetric 
fluctuations will ensure that all tumour cells will not 
receive the same dose. In addition to microdosimetry there 
will be other mechanisms in operation which will further 
increase the heterogeneity of absorbed dose in tumour 
cells and consequently the probabilities of sterilisation. 
Several of these mechanisms were discussed in section 
8.6.1. They include:
1/ Differences in protein synthesis between tumour cells ( 
this will be important for delivery vehicles like mIBG )
2/ Differences in antigenic expression between tumour 
cel Is
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3/ Antigenic modulation
The cumulative result of the mechanisms described above 
will be a wide heterogeneity in the probabilities of 
sterilization from one tumour cell to another. The 
possibility exists of some tumour cells receiving 
virtually ho radiation dose at all and being effectively 
untargeted. As a preliminary "thought experiment" it is 
easy to see that in the best case situation ( i.e. where 
all targeted tumour cells are sterilised ) the tumour cell 
population will regrow from those cells which escaped 
targeting. . Using a combination of radionuclides may 
alleviate this to some extent but will not eliminate the 
problem. From this perspective the introduction of an 
element of TBI is an obvious step. It should be noted that 
the rationale presented here is different to that of 
chapter 9. In this case it is to sterilize those tumour 
cells which have escaped targeting.. However, this option 
would only be feasible in the context of bone marrow 
rescue. For BTR limited by haematological toxicity the 
allowable doses are so small that sub-dividing them 
further would be unrealistic. In order to assess the 
consequences of untargeted tumour cells for BTR and 
investigate the question of optimization of combination 
BTR/TBI treatment a mathematical model description of the 
tumour cell population is required.
10.1 A MODEL FOR TUMOUR EFFECTS 
to calculate the effects of BTR, possibly in combination
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with IBI, on tumour cells five assumptions are made:
1/ The radiation survival curve for the tumour cells is 
shoulderless . The surviving fraction of cells is an 
exponential function of dose and the relationship can be 
characterized by one single parameter DO. The value of DO 
used in the numerical examples is 1 Gy. This assumption is 
reasonable for leukaemia/lymphoma and for neuroblastoma ( 
see chapter 5 ) but will be less good for some other 
tumours.
2/ Tumour cells proliferate exponentially with growth 
constant, SJ .
3/ A proportion, ^ , of tumour cells completely escapes 
targeting and receives no dose from BTR. This is a gross 
simplification of the real situation where there will be a 
spectrum of dose-rates applicable to tumour cells in 
different localities. The validity of the assumption will 
also depend on the emission range of the radionuclide 
used.
4/ The dose-rates in the whole body, and by implication 
the dose limiting organ, and also at the tumour cells can 
be described by simple exponential decays, although not 
necessarily at the same rate. This neglects the initial 
"accumulation" phase in tumours described by the analysis 
of Vaughan et al. As a measure of the specificity of the 
BTR the tumour to non-tumour dose-rate ratio ( R ) is 
taken; defined for the purposes of the model as the ratio 
of initial dose-rate at the tumour cells to that in the 
dose-limiting organ. If the allowable dose-rate in the
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The dose-rate at the targeted tumour cells is given by
5/ In combination treatments TBI and BTR are administered 
sequentially. This is due to the requirements of the 
isoeffect model for normal tissue damage as described in 
section 9.9.1. For reasons of mathematical simplicity the 
TBI is assumed to be given first. It will be seen that 
from the point of view of the tumour effects ( though not 
damage to normal tissues ) it is unimportant what order 
these treatments are given in, or even if they are given 
simultaneously.
With these assumptions a general .equation for the effects 
of combination schedules can be constructed.
For convenience the tumour cell population may be split 
into 2 sub-populations. If the original number of viable 
tumour cells is N0 then there is a number = N( which
are untargeted by BTR, effectively receiving zero dose.
receive a uniform dose at a dose-rate of r(t) = Rrftexp( - ^  
t ). The total dose delivered in a time, t for these cells
In the absence of repopulation effects, for the moment, 
the surviving numbers for the 2 sub-populations are
10.1.1 EFFECTS OF BTR
The remaining number of tumour cells ( 1 - tf7 )N.
IS
The total number of viable cells at a time t from the 
start of BTR is
N ®*  to* ^  + (>-<0*4/- ( , -e~'>T ) ] /  (16.3J
10.1.2 THE EFFECTS OF CELLULAR PROLIFERATION
Proliferation is assumed exponential with a growth 
constant, ; ■ When this is included equation 10.3 becomes
d + ([” J"p 0 “ ^ j (10.0
It can be noted that if all the targeted cells are 
sterilised the overall population will regrow according to
M  (t) = o'
10.4 is the final equation for the effects on tumour cells 
of single-agent BTR.
10.1.3 THE EFFECTS OF EXTERNAL BEAM TBI
For mathematical convenience it is assumed that the TBI is 
given first. For times longer than the duration of the TBI 
schedule the surviving number of tumour cells is given by
M(tJ* ^  « \ ( , - 0 « 4 [ .  ^  0 -  e 7 r ( * " r3j ] J  (ID.0
Where d = fraction size of the TBI schedule 
n = number of TBI fractions
X. - duration of the TBI schedule = ( n-1 ) x IT 
Where IT = inter-fraction interval
For times shorter than the duration of the TBI schedule
= tok « +  ( 7 *  '
Where n' = INT ( t/IT ) + 1
INT denoting the integer part of the expression in
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brackets.
The pair of equations 10.6 and 10. 7 describe the time 
course of sterilization of tumour cells for a combination 
BTR/TBI schedule. However, it is more convenient to use 
the log cell kill function
10.2 PARAMETER VALUES USED IN THE CALCULATIONS
A value of 1 Gy was taken for DO, as has been stated 
already. This is appropriate for radiosensitive tumour 
cells such as leukaemia/lymphoma or neuroblastoma. A value 
of 4 days was taken for the tumour cell population
doubling time. The effective half-times for loss and decay 
of radionuclide were taken to be 2.4 days for.both the
dose limiting organ and tumour respectively. This is 
intermediate between the values for antibody targeted 
131-1 and 90-Y values, based on the review of Vaughan et 
al, 1987. In reality these values may be expected to vary, 
depending on factors such as tumour morphology, the
identity of the dose-limiting organ and whether antibody 
fragments or second antibody clearance are used. In this 
model the intensity of BTR is determined solely by the 
tumour to non-tumour ratio, R. For the computer simulation 
this parameter was allowed to vary from 1.0 to 10.0 in 
steps of 1.0. It may be noted that the ratio of effective 
half-lives plays a similar role to the tumour to
non-tumour ratio. This is because the tumour to non-tumour 
dose ratio is directly proportional to the ratio of
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half-times. Variations in the latter ratio may he
simulated approximately by varying the tumour to
non-tumour dose-rate ratio, R. For example the following
situation; tumour:non-turnour = 3, t,, (tumour) = 4 . 8  days, t»/
ft
(organ) = 2.4 days: is approximately equivalent to;
tumour:non-tumour = 6, t^(turnour) = 2 . 4  days, t^(organ) =
2.4 days. The proportion of untargeted tumour cells, > 
was allowed to vary by factors of 10 from 1 to 1 E-10.
10.2.1 SINGLE-AGENT BTR LIMITED BY HAEMOPOIETIC TOXICITY
The allowable whole body dose calculated in section 9.1 to 
be equivalent to a single fraction of 2 Gy ( LQ model:^  = 
10 Gy; Ty^ (repair) = 0 . 5  hour ) was 2.4 Gy. The initial 
dose-rate corresponding to this- dose and an effective 
radionuclide half-life of 2.4 days is 0.69 Gy/day. As 
uniform distribution of radionuclide is assumed this will 
also be the initial dose-rate in the dose-limiting organ.
10.2.2 ALLOWABLE BTR-TBI COMBINATION SCHEDULES
In Section 9.9.1 allowable combination schedules of 
antibody targeted 131-1 BTR and external beam TBI were 
calculated. The criterion was that they were all 
isoeffective to a fractionated schedule of 6 X 2 Gy on the 
basis of the LQ model {'t/p - 3 Gy; T,^  (repair) = 1.5 hrs
). The BTR component was expressed as the injected 
activity in GBq. These values were arrived at by first 
calculating the allowable whole body dose assuming uniform 
distribution of radionuclide. The whole body doses are not 
only applicable to .131-1 but also to any low LET emitting
204
radionuclide with an effective half-life of 2.19 days ( 
the value used in the calculation ). They would not be 
applicable to a high LET emitter like 211-At for which
tolerance doses and isoeffect models are not available.
The effective half-lives for different combinations of 
carrier molecule and radionuclide would be expected to 
vary. As described in 10.2 rather than carry out a 
separate calculation for every value an approximation is 
made. If a value of 2.4 days is chosen this is
intermediate between the effective whole body half-lives 
of antibody targeted 131-1 and 90-Y according to the
review of Vaughan et al. The allowable BTR/TBI doses 
calculated for this half-life would therefore be 
reasonable approximations for both radionuclides. This 
information is shown in table XX along with the 
corresponding -initial whole body dose-rates.
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TBI COMPONENT BTR DOSE ( Cy ) r<) ( Gy/day )
6 X 2
5 X  2 3.24 0.94
4 X 2 6.33 1.83
3 X 2 9.27 2.68
2 X 2  12. 10 3.49
1 X 2  14.81 4. 28
17.43 5.03
Allowed schedules for combined TBI and BTR when bone 
marrow rescue is used. Doses and dose-rates to the whole 
body are shown. The effective radionuclide half-time is 
taken as 2.4 days as described in the text.
TABLE XX
The optimization principle is as follows: a clinically
used external beam TBI schedule ( 6 X 2  Gy ) is taken as 
representing a certain acceptable level of toxicity. This 
toxicity level can be achieved in the various ways 
described above depending on the proportions of BTR and 
TBI. Some of these combinations will produce a greater 
tumour effect than others. The combination schedule 
parameters which maximize the tumour effect, while not 
exceeding the toxicity level of the "reference" TBI 
schedule identify the optimal schedule.
10.3 RESULTS OF COMPUTER SIMULATIONS
10.3.1 SINGLE-AGENT BTR LIMITED BY HAEMOPOIETIC TOXICITY 
The maximum tumour log cell kills, Tmax, as a function of 
( R, ^  ) are plotted in figure 10.1. It can be seen that
206
CD
CN
(S3
CE
00
C£ 
ZD 
Q  
CD ^
CD 
ZZL 
• •
C£ 
ZD 
CN O
53 IS (3 (S3 S3 S IS CS (3
• • • a • • • • a
CD CD r\ CD LO K) CN
Figure 10.1
Maximum log cell kill values produced by single agent BTR 
as a function of the tumour:non-tumour ratio and -log(c/), 
where is the proportion of effectively untargeted tumour
cells.
this quantity increases as the tumour:non-tumour ratio 
increases and as the proportion ^  decreases. Tmax reaches 
a value of around 9 at the limiting values of R = 10 and 
= IE-10.
10.3.2 COMBINED BTR/TBI AND MARROW RESCUE
Figure 10.2 is an illustrative example of the time course 
of the tumour log cell kill function T(t). This is for ( 
R j »/ ) = ( 3,0.01 ), meaning that the initial tumour to 
dose-limiting normal tissue dose-rate ratio is 3 and the 
proportion of untargeted tumour cells is 0.01. The graph 
shows 7 curves, corresponding to the 7 combination 
schedules isoeffective to a fractionated schedule of 6 X 2  
Gy. The combination schedules contain from 0 to 6 
fractions of external beam TBI (. fraction size 2 Gy ). Ib 
may be seen that the schedule with 5 fractions of TBI 
produces a higher peak T value than all the others. This 
schedule is therefore optimal.
This approach may be used to calculate peak T values and 
identify the optimal combination schedules for different 
values of R and ^ . The consequence of this is that the 
optimal schedules can be mapped as a function of ( R ,^ ). 
Figure 10.3 shows the optimal combination schedules of BTR 
and TBI as a function of R and ^ . The optimal schedules 
are indexed by the number of TBI fractions ( out of a 
possible 6 ) which are included in the combination. The 
corresponding quantities of BTR may be derived from table 
XX. In moving from small values of R and -log( 0^ ) to 
larger values, p r o g r e s s i v e l y  more BTR and progressively
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Figure 10.2
The time course of sterilization of tumour cells for 
allowable combinations of TBI and BTR for the case of bone 
marrow rescue. Schedules are indexed by the number of 
fractions of TBI included. This graph is for a 
t umour:non-tumour ratio of 3 and log(c^) = -2. The schedule 
which contains 5 fractions of TBI Is optimal in this case.
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Figure 10.3
Optimal combinations of BTR and TBI in the case of marrow
rescue indexed by the number of TBI fractions.
less TBI make up the optimal schedules. Figure 10.4 shows 
the predicted effects of the optimal schedules on the 
tumour cell population. It is apparent that the Tmax 
values are substantially higher than those shown in figure
9.2 for BTR alone limited by bone marrow toxicity.
10.4 DISCUSSION
The two main parameters which determine the effects of the 
combination schedules on tumour cells are:
R, the tumour to non-tumour ratio, defined as the ratio of 
the initial dose-rate at the tumour cells to that in the 
dose-limiting normal tissue. This parameter can be thought 
of as representative of the specificity of the biological 
targeting.
^ , the proportion of untargeted.tumour cells. This may be 
thought of as representative of the sensitivity of the 
biological targeting. In the model the factor ^  determines 
the proportion of tumour cells which will never be 
sterilised by BTR no matter how intense. In the situation 
where ^ - - 1, i.e. 100% of tumour cells are unaffected by 
BTR it is obvious that external beam TBI alone will be 
optimal. If / =  0 i.e. 100% of tumour cells are effectively 
targeted it follows that BTR alone will be optimal, 
assuming the specificity is high enough. For intermediate 
values of tf' it seems reasonable that some combination of 
BTR and TBI will be optimal. The results of figure 10.3 
are consequently not too surprising. The factor 
ultimately limits the curative potential of BTR. Reduction 
of the surviving fraction of targeted cells to below the
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Maximum log cell kill values produced by the optimal 
BTR/TBI combination schedules as a function of the 
tumour:non-tumour ratio and -log( O' ), where O' is the
proportion of effectively untargeted tumour cells.
overall level of surviving fraction of untargeted cells is 
v/asted therapy or "overkill". In such a case it is better 
to exchange a proportion of BTR for some TBI. The 
"overkill" effect is the main mechanism in determining 
optimal combination schedules. It was seen that for BTR 
limited by bone marrow toxicity potentially curative 
effects were obtained by treatments having not only high 
specificities, as predicted by several authors, but also 
high sensitivities, a necessity which has not received 
much attention to date. When the model was used to examine 
combination strategies with BTR, TBI and marrow rescue it 
was found that treatments incorporating elements of both 
BTR and TBI were usually optimal. The actual amounts of 
BTR and TBI depended on the values of the specificity and 
sensitivity of the BTR.
It is important to recognize that the model studies 
reported here incorporate a high level of approximations 
and simplistic assumptions. In particular uniform 
distributions of radionuclides throughout the body are not 
realistic. -For the tumour cells a simple two state 
dose-rate function is a gross simplification. One would 
expect a far more complex probability distribution of 
dose-rates for the population of tumour cells throughout 
the body? however the possibility of biologically 
untargeted tumour cells seems highly likely. For this 
reason it is anticipated that the tumour model will be of 
most direct relevance to radionuclides with short range 
emissions where the problem of tumour cells escaping
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effective targeting is likely to be most severe. This 
would be for short range beta emitters like 199-Au and 
67-Cu and alpha emitters such as 211-At. However the 
normal tissue isoeffect model will not be directly 
applicable to radionuclides which emit q/particles. In 
order to accomodate these further assumptions about RBE 
values would be necessary. At present the information is 
not available to address this question. However one may 
speculate that optimal schedules for BTR withd -emitters 
will also be mixed. For long range beta emitters like 90-Y 
arid photon emitters like 131-1 it is unlikely that there 
will be any completely untargeted tumour cells, although 
there may be some with low levels of effective targeting. 
It seems likely that mixed schedules will be optimal in 
this case too. It may also be borne in mind that the 
analysis of chapter 9, albeit from a different 
perspective, indicates that combination TBI/BTR treatments 
with marrow rescue would be of benefit here.
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11.0 AREAS FOR FURTHER WORK
The work reported in this thesis draws together several 
strands of radiobiological and clinical study. There are 
many areas where further work is required.
In normal tissue radiobiology it is still not clear what 
are the underlying biological processes responsible for 
distinguishing the response of different organs and 
tissues to radiation. Work is required to elucidate the 
general principles of what is happening. The hypotheses of 
Michalowski ( 1981 ), Zernan and Bedford ( 1984 ) and
Schultheiss et al ( 1987 ) are starting points.
Mathematical studies need to rigorously determine the 
predictions of the different models and design 
experimental tests of these. The radiatioh responses of 
individual organs will have to be studied on an individual 
basis. As yet, theoretical normal tissue radiobiology 
remains confined to an underlying philosophy where cells 
are considered as independent, interactionless, 
self-contained entities. This is essentially unrealistic, 
the intercommunication and interrelationships of cells of 
the same and different lineages via a variety of 
messengers at the heart of organised tissue function. A 
wider expansion of normal tissue radiobiology from a 
cellular to a more integrated approach is warranted.
Ip tumour radiobiology there is a gulf between models like 
the multitarget and the biological processes involved in 
cellular sterilisation. Newer repair models like the LPL 
are more realistic. As in the case of normal tissues,
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current models are unicelJular. Experimental work to 
investigate the role of intercellular factors and 
mathematically to fully integrate these and the processes 
covered by the "4 Rs" is required.
The LQ model suffers from the deficiency that there is, as 
yet, no time factor to take account of proliferation. The 
kinetics of repair need clarification as to whether a 
monoexponential, biexponential or some other sort of 
functional description is most appropriate. The studies 
reported in this work which use the LQ model yield 
conclusions which may have to be revised in the light of 
modifications to the model. Experimental tests of Dale's 
extension of the LQ model to exponentially decaying 
dose-rates may be possible. Animal experiments could be 
designed to compare isoeffect doses for late toxicity 
given as high dose-rate fractions with those given with 
exponentially declining dose-rates.
In Clinical TBI the question of the value of T-cell 
depletion in allogeneic marrow tranplantation must be 
resolved. Are the cell populations responsible for GvHD 
and the antileukaemic effect the same? If not, the role of 
TBI may have to be reconsidered in this context. There is 
still no proof of the benefits of tumour cell purging in 
autologous transplants. Likewise, the role of high dose 
TBI with marrow rescue for disseminated diseases like 
neuroblastoma, Ewing's Sarcoma, small cell carcinoma of 
lung, carcinoma of breast and ovarian carcinoma has not 
been established. Methods of creation and use of
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non-uniform dose distributions may be worth investigating. 
The database of in-vitro radiosensitivities of human 
tumour cells needs expansion. This will determine whether 
extrapolation from the laboratory to the clinic is 
justified. It will also set the scene for the use of 
individual assays of radiation response as a basis for 
clinical decision making. The predicted optimal schedules 
deduced in chapter 7 provide candidates for clinical 
investigation. These investigations may determine whether 
the approach is a useful one.
There is enormous scope for further work on the subject of 
biologically targeted radiotherapy. Improvements in the 
specificity and sensitivity of treatment, design of 
alternative vehicle molecules, use of more appropriate 
radionuclide warheads and targeting of c-onc products, all 
call for a .multidisciplinary programme of research. 
Individualised rnicrodosimetric models of organ systems 
based on patterns of radiation damage may well be 
required. The work reported here suggests that animal 
experiments and clinical investigation of the use of 
marrow rescue in conjunction with BTR should be performed. 
In the future the long term consequences of BTR including 
induction of second maligancy must be evaluated. Single 
photon emission computed tomography ( SPECT ) may be 
required for clinical dosimetry.
Modification of the LQ model for use in BTR should allow 
the calculation of the biological effects of exposure when 
the dose-rate is an arbitrary function of time. This will
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also enable situations involving simultaneous fractionated 
and continuous treatments to be considered. Multicellular 
tumour spheroids provide a realistic in-vitro model for 
the test of dosimetric model predictions in the case of 
micrometastases.
On the subject of optimal scheduling of combined BTR and 
TBI, more realistic model descriptions of the distribution 
of dose-rates to tumour cells are required.
The role of mathematical modelling can only be to 
supplement clinical and experimental investigation. 
However the use of mathematical model studies may lead to 
6therwise unforeseen benefits or suggest new directions 
for clinical investigation. Some of these may prove to be 
false trails; however if a proportion lead to significant 
clinical progress the process may be judged a success.
214
REFERENCES
Adams, G.E., ( 1973 ) Chemical radiosensitisation of
hypoxic cells. British Medical Bulletin. 29, 48-53
Aherne, W and Buck, P. ( 1971 ) The potential cell
population doubling time in neuroblastoma and
nephroblastoma. British Journal of Cancer. 25, 691-696
Aget, H., van Dyk, J. and Leung, P.M.K. ( 1977 )
Utilisaton of a high energy photon beam for total body 
irradiation. Radiology, 123, 745-752
Alper, T. ( Ed ) Cell survival after low doses of 
radiation. ( 1975 ) The Insitute of Physics. John Wiley
and Sons, London.
Alper, T. ( ■ 1979 ) Cellular Radiobiology. Cambridge
University Press, Cambridge.
Alper, T. ( 1980 ) Survival curve models. In Radiation
Biology in Cancer Research. E. Meyn and H.R. Withers ( Eds 
). Raven Press. New York, pp 3-18
Alper, T., Gillies, N.E. and Elkind, M.M. ( 1960 ) The
sigmoid survival curve in radiobiology. Nature, 186, 
1062-1063.
Alper, T., Fowler, J.F., Morgan, R.L., Vonberg, D.D.,
Ellis, F. and Oliver, R. ( 1962 ) The characterisation of
the "Type-C" survival curve. British Journal of Radiology, 
35, 722-723.
Ang, K.K., Xu, F.X., Landuyt, W. and van der Schueren, E.
215
( 1985 ) The kinetics and capacity of repair of sublethal
damage in mouse lip mucosa during fractionated 
irradiations. International Journal of Radiation Oncology, 
Biology and Physics, 11, 1977-1983
Apperley, J.F., Jones, L., Hale, G., Waldmann, H., Hows, 
J., Rombos, Y., Tsatalas, C., Marcus, R.E., Goolden, 
A.W.G., Gordon-Smith, E.G., Catovsky, D., Galton, D.A.G. 
and Goldman, J.M. ( 1986 ) Bone marrow transplantation for 
patients with chronic myeloid leukaemia: T-cell depletion 
with Campath-1 reduces the incidence of
graft-versus-host-disease but may increase risk of 
leukaemic relapse. Bone Marrow Transplantation, 1, 53-56
Applebaum, F.R., Clift, R.A., Buckner, C.D., Stewart, P., 
Storb, R., Sullivan, K.M. and Thomas, E.D. ( 1983 )
Allogeneic marrow transplantation for acute
nonlymphoblastic leukaemia after first relapse. Blood, 61, 
949-953
Arcangeli, G., Friedman, M. and Paoluzi, R. ( 1974 ) A
quantitative study of late radiation effects on normal 
skin and subcutaneous tissues in human beings. British 
Journal of Radiology, 47, 44-50
Baldwin, R.W. and Pimm, M.V. ( 1983 ) Antitumour
monoclonal antibodies for radioimmunodetection of tumours
in drug targeting. Cancer Metastasis Reviews, 2, 89-106
Barendsen, G.W. ( 1982 ) Dose fractionation, dose-rate and 
isoeffect relationships for normal tissue responses. 
International Journal of Radiation Oncology Biology and
216
Physics., 8, 1981-1997
Barkley, H.T. and Fletcher, G.H. ( 1977 ) The significance 
of clinically residual disease present at the end of 
external irradiation of squamous carcinoma of the 
oropharynx. Radiology, 124, 493-495
Barrett, A. ( 1986 ) Germ cell tumours. In Cancer in
Children. P.A. Voute, A. Barrett, H.J.G. Bloom, J. Lemerle 
and M.K. Neidhardt ( Eds ). Springer Verlag. Berlin. pp 
185-196
Barrett, A., Nieholls, J. and Gibson, B. ( 1987 ) Late 
effects of total body irradiation. Radiotherapy and 
Oncology, 9, 131-135
Bates, T.D. and Peters, L.J. ( 1975 ) Danger of the
clinical use • of the USD formula for small fraction 
numbers. British Journal of Radiology, 48, 773
Begent, R.H.J., Green, A.J., Bagshawe, K.D., Jones, B.E., 
Keep, P. A., Searle, F. , Jewkes, R.F. and Barratt, G.M. (
1982 ) Liposomally entrapped second antibody improves
tumour imaging with radiolabelled ( first ) antitumour 
antibody. Lancet, ii, 739-742
Begent, R.H.J. and Bagshawe, K.D. ( 1985 ) Clinical
applications of radioimmunolocalisation. In Monoclonal 
antibodies for cancer detection and therapy. R.W.
Baldwin and V.S. Byers ( Eds ) Academic Press Inc. London 
P P  181-200
Begent, R.H.J., Lederman, J.A., Searle, F. and Bagshawe,
217
K.D. ( 1986 ) Prospects for anti body-targeted radiotherapy 
of cancer. Lancet, ii, 580
Bellamy, A.S., Whelan, R.D.H. and Hill, B.T. ( 1984 )
Studies of variation in inherent sensitivities to 
radiation, 5-fluorouraci1 and methotrexate in a series of 
human and murine tumour cell lines in vitro. International 
Journal of Radiation Oncology Biology and Physics., 10,
87-93
Berger, M.J. ( 1971 ) Distribution of absorbed dose around 
point sources of electrons and beta particles in water and
other media. MIRD pamphlet 7. Journal of Nuclear Medicine,
12, Suppl.5, 5-23
Berry, R.J., Wiernik, G. and Patterson, T.J.S. ( 1974 )
Skin tolerance to fractionated x-irradiation in the pig - 
how good a predictor is the NSD formula? British Journal 
of Radiology, 47, 185-190
Bortin, M. M. , Gale, R.P., Kay, H.E.M., .and Rimm A. A. ( 1983
) Bone marrow transplantation for acute myelogenous 
leukaemia: ' factors associated with early mortality.
Journal of the American Medical Association., 249,
1166-1175
Braby, L.A., Nelson, J.M. and Roesch, W.C. ( 1980 )
Comparison of repair rates determined by split-dose and 
dose-rate methods. Radiation Research, 82, 211-214
Brodeur, G.M., Seeger, R. C. , Schwab, M. , Varmus, H.E. and 
Bishop, J.M. ( 1984 ) Amplification of N-myc in untreated
218
human neuroblastoma correlated with advanced disease 
stage. Science, 224, 1121-1124
Brues, A.M., Weiner, A.E. and Andervont, H.B. ( 1939 ) 
Relation between the latent period and growth rate in 
chemically induced tumours. Proceedings of the Society of
Experimental Biology and Medicine, 42, 374-377
Buck, J. , Bruchelt, G. , Glrgert, R. , Treuner, J. and 
Niethammer, D. ( 1985 ) Specific uptake of m( 125-1)
iodobenzlguanidine in the human neuroblastoma cell line 
SK-N-SH. Cancer Research, 45, 6366-6370
Buki, K.G. and Seppa, H. ( 1985 ) A low Mr chemoattractant 
for vascular endothelial cells. FEBS Letters, 184,. 254-258
Buraggi, G.L., Callegaro, L. , Marianai, G. , Turrin, A., 
Cascinelli, N. , Attili, A., Bombardieri, E., Terno, G., 
Plassio, G. , Dovis, M. , Mazzuca,' N. , Natali, P.G.,
Scassallati, G.A., Rosa, U. and Ferrone, S. ( 1985 )
Imaging with 1-131 labelled monoclonal antibodies to a 
high molecular weight melanoma-associated antigen in 
patients with melanoma: Efficacy of whole immunoglobulin 
and its F(ab’)2 fragments. Cancer Research, 45, 3378-3387
Burchell, J., Gendler, S. , Taylor-Papadimitriou, J., 
Girling, A., Lewis, A. , Millis, R. and Lampert, D. ( 1987 
) Development and characterisation of breast-cancer 
reactive monoclonal antibodies directed to the core 
protein of the human milk mucin. Cancer Re search, 47, 
5476-5482
219
Burchenal, J.H. and Murphy, M.L. ( 1965 ) Long term
survivors in acute leukaemia. Cancer Research, 25, 
1490-1494
Campisi, J., Gray, H.E., Pardee, A.B., Dean, M. and 
Sonenshein, G.E. ( 1984 ) Cycle control of c-rnyc but not 
c-ras expression is lost following chemical 
transformation. Cell, 36, 241-247
Cardozo, B.L. and Hagenbeek, A. ( 1985 ) Interstitial
pneumonitis following bone marrow transplantation: 
pathogenesis and therapeutic considerations. European 
Journal of Cancer and Clinical Oncology, 21, 43-51
Cardozo, B.L., Zoetelief, H. , van Bekkum, D. W. , Zurcher,
C. and Hagenbeek, A. ( 1985 ) Lung damage following bone 
marrow transplantation: 1. The contribution of
irradiation. International Journal of Radiation Oncology 
Biology and Physics., 11, 907-914
Carrasqui1lo, J.A., Krohn, K.A., Beauraier, P., McGuffin, 
R.W., Brown, J.P., Hellstrom, K.E., Hellstrom, I. and 
Larson, S.M. ( 1984 ) Diagnosis of and therapy for solid 
tumours with radiolabelled antibodies and immune 
fragments. Cancer Treatment Reports, 68, 317-328
Carrasquillo, J.A., Steis, R., Bookman, M., Smith, J., del 
Vecchio Reynolds, J. , Perentesis, P., McCabe, R., Haspel, 
M.V. , Hanna, M. , Longo, D. and Larson, S.M. ( 1987 )
Imaging of colon cancer with 1-131 human monoclonal IgM. 
British Journal of Cancer, 56, 514 ( abstract )
220
Chadwick, K.H. and Leenhouts, H.P. ( 1973 ) A molecular
theory of cell survival. Physics in Medicine and Biology, 
18, 78-87
Chan, S.Y.T., Evan, G.I., Ritson, A., Watson, J., Wraight, 
P. and Sikora, K. ( 1986 ) Localisation of lung cancer by 
a radiolabelled monoclonal antibody against the c-rnyc 
oncogene product. British Journal of Cancer, 54, 761-769
Choi, S.I. and Simone, J.V. ( 1976 ) Acute non-lymphocytic 
leukaemia in 171 children. Medical and Paediatric 
Oncology, 2, 119-146
Clift, R.A., Buckner, C.D., Thomas, E.D., Sanders, J.E., 
Stewart, P.S., McGuffin, R., Hersraan, J., Sullivan, K.M., 
Sale, G.E. and Storb, R. ( ' 1982 ) Allogeneic marrow
transplantation for acute lymphoblastic leukaemia in 
remission using fractionated total body irradiation. 
Leukaemia Research, 6, 409-412
Cobbald, S.P. and Waldmann, H. ( 1984 ) Therapeutic
potential of monovalent monoclonal antibodies. Nature 308, 
460
Cohen, L. ( 1987 ) Optimisation of time-dose factors for a 
tumour and multiple associated normal tissues. 
International Journal of Radiation Oncology Biology and 
Physics., 13, 251-258
Cohen, L. and Creditor, M. ( 1983(a) ) Isoeffect tables 
for the tolerance of irradiated normal human tissues. 
International Journal of Radiation Oncology Biology and
221
Physics., 9, 233-241
Cohen, L. and Creditor, M. ( 1983(b) ) Isoeffect tables
and therapeutic ratios for epidermoid cancer and normal 
tissue stroma. International Journal of Radiation Oncology 
Biology and. Physics., 9, 1065-1071
Cole, A., Meyn, R.E., Chen, R., Corry, P.M. and Hittelman, 
W. ( 1.980 ) Mechanisms of cell injury. In Radiation
Biology in Cancer Research. E. Meyn and H.R. Withers ( Eds 
). Raven Press, New York, pp 33-58
Collins, A. ( 1987 ) Cellular responses to ionising
radiation: effects of interupting DNA repair with chemical 
agents. International Journal of Radiation Biology, 51, 
971-983
Curt, G.A., Clendennin, N.J. and Chabner, B.A. ( 1984 )
Drug resistance in cancer. Cancer Treatment Reports, 68, 
87-99
Curtis, S.B. ( 1986 ) Lethal and potentially lethal
lesions induced by radiation - a unified repair model. 
Radiation Research, 106, 252-270
Dale, R.G. ( 1985 ) The application of the
linear-quadratic dose-effect equation to fractionated and 
protracted radiotherapy. British Journal of Radiology, 58, 
515-528
Dale, R.G., Hucskowski, J. and Trott, K.R. ( 1988 )
Possible dose-rate dependence of recovery kinetics as 
deduced from a preliminary analysis of the effects of
222
fractionated irradiations at varying dose rates. British 
Journal of Radiology, 61, 153-157
D'Angio, G.J. and Evans, A.E. ( 1983 ) Cyclic low-dose 
total body irradiation for metastatic neuroblastoma. 
International Journal of Radiation Oncology Biology and 
Physics, 9, 1961-1965
D'Angio, G.J., August, C., Elkins, W. , Evans, A.E., 
Seeger, R., Lenarsky, C., Feig, S., Wells, J., Ramsay, N., 
Kim, T., Woods, W., Krivit, W., Strandjord, S., Coccia, P.
and Novak, L. ( 1985 ) Metastatic neuroblastoma managed by
supralethal therapy and bone marrow reconstitution ( BMRc 
). Results of a four-institution Childrens Cancer Study 
Gtroup pilot study. In Advances in Neuroblastoma Research. 
A.E. Evans, G.J. D'Angio and R.C. Seeger ( Eds ) Alan R. 
Liss Inc. New York, pp 557-563
Danova, M., Wilson, G., Riccardi, A., Mazzini, G., Ucci,
G., Giordano, M. , Bragnatelli, S., Luoni, R., McNally, 
N.J. and Ascari, E. ( 1987 ) In vivo administration of 
bromodeoxyuridine and flow cytometry for cell kinetic 
studies in human malignancies. Haematologica, 72, 115-119
Deacon, J.M., Peckham, M.J. and Steel, G.G. ( 1984 ) The
radioresponsiveness of human tumours and the initial slope 
of the cell survival curve. Radiotherapy and Oncology, 2, 
317-323
Deacon, J.M., Wilson, P.A. and Peckham, M.J. ( 1985(a) )
The radiobiology of human neuroblastoma. Radiotherapy and 
Oncology, 3, 101-109
223
Deacon, J.M., Wilson, P. and Steel, G.G. ( 1985(b) ) 
Radiosensitivity of neuroblastoma. In Advances in 
Neuroblastoma Research. A.E. Evans, G.J. D'Angio and R.C. 
Seeger ( Eds ) Alan R. Liss Inc. New York, pp 525-531
Denekamp, J. ( 1986 ) Cell kinetics and radiation biology. 
International Journal of Radiation Biology, 49, 357-380
Depledge, M.H. and Barrett, A. ( 1982 ) Dose-rate
dependence of lung damage after total body irradiation in 
mice. International Journal of Radiation Biology, 41, 
325-334
Depledge, M.H., Barrett, A. and Powles, R.L. ( 1983 ) Lung 
function after bone marrow grafting. International Journal 
of Radiation Oncology Biology and Physics, 9, 145-151
Dicke, K.A. and Spitser, G. ( 1986 ) Evaluation of the use 
of high-dose cytoreduction with autologous marrow rescue 
in various malignancies. Transplantation, 41, 4-20
Dicke, K.A.*, Jagganath, S., Spitser, G. , Poynton, C. , 
Zander, A., Vellecoo , L. , Reading, C.L., Jehn, LJ.W. and 
Tindle, S. ( 1984 ) The role of autologous bone marrow
transplantation in various malignancies. Seminars in
Hematology, 21, 109-122
Dillman, L.T. and von der Lage, F.C. ( 1975 ) Radionuclide 
decay schemes and nuclear parameters for use in radiation 
dose estimation. MIRD pamphlet 10, Society of Nuclear 
Medicine. New York
224
Dinsrnore, R. , Kirkpatrick, D. , FIomeinberg, N., Gulati,
S., Kapoor, N., Brochstein, J., Shank, B., Reid, A., 
Groshen, S. and O ’Reilly, E.J. ( 19F34 ) Allogeneic bone
marrow transplantation for patients with acute 
nonlyrnphocytic leukaemia. Blood, 63, 649-656
Donaldson, S.S. ( 1986 ) Hodgkin's disease. In Cancer in 
Children. P.A. Voute, A. Barrett, H.J.G. Bloom, J. Lemerle 
and M.K. Neidhardt ( Eds ) Springer Verlag, Berlin, pp 
164-175
Donaldson, S.S. and Hendrickson, M.R. ( 1983 ) Patterns of 
failure in childhood solid tumours: Wilmas tumour,
neuroblastoma and rhabdomyosarcoma. Cancer Treatment 
Symposia, 2, 267-283
Doolittle, R.F., Hunkapiller, M.W., Hood, L.E., Devare, 
S.G., Robbins; K.C., Aaronson, S.A., Antoniades, H.N. ( 
1983 ) simian sarcoma virus one gene, v-sis is derived 
from the gene ( or genes ) encoding a platelet derived 
growth factor. Science, 221, 275
Doughty, D., Lambert, G.D., Hirst, A., Marks, A.M. and 
Plowman, P.N. ( 1987 ) Improved total body irradiation
dosimetry. British Journal of Radiology, 60, 269-278
Douglas, B.G. ( 1982 ) Implications of the quadratic cell 
survival curve and human skin "tolerance doses" on 
fractionation and superfractionation dose selection. 
International Journal of Radiation Oncology Biology and 
Physics, 8, 1135-1142
225
Douglas, B.G. and Fowler, -J.F. ( 1976 ) The effect of
multiple small doses of x-rays on skin reactions in the 
mouse and a basic interpretation. Radiation Research, 66, 
401-426
Downward, J., Yarden, Y., Mayes, E. , Scrace, G. , Totty, 
N. , Stockwell, P., Ullrich, A., Schlessinger, J. and 
Waterfield, M.D. ( 1984 ) Close similarity of epidermal
growth factor receptor and V-erb-B oncogene protein 
sequences. Nature 307, 521-527
Duncan, W. ( 1973 ) The exploitation of the oxygen effect 
in clinical practice. British Medical Bulletin, 29, 33-38
Duncan, W. and Nias, A.H.W. ( 1977 ) Clinical
Radiobiology. Churchill Livingstone. Edinburgh
Durand, R.E. ( 1981 ) Flow cytometry studies of
intracellular adriamycin in multicellular spheroids in 
vitro. Cancer Research 41, 3495-3498
Edwards, P.A.W. ( 1985 ) Heterogeneous expression of cell 
surface antigens in normal epithelia and their tumours 
revealed by monoclonal antibodies. British Journal of 
Cancer, 51, 149-160
Elkind, M.M. ( 1980 ) Cells, targets and molecules in 
radiation biology. In Radiation Biology in Cancer 
Research. E. Meyn and H.R. Withers ( Eds ) Raven Press. 
New York, p p  71-93
Elkind, M.M. ( 1985 ) DNA damage and cell killing: cause 
and effect? Cancer, 56, 2351-2363
226
Elkind, M.M. and Sutton, H. ( 1959 ) X-ray damage and
recovery in mammalian cells in culture. Nature, 184, 
1293-1295
Elkind, M.M. and Sutton, H. ( 1960 ) Radiation response of 
mammalian cells grown in culture. 1 Repair of x-ray damage 
in surviving Chinese hamster cells. Radiation Research, 
13, 556-593
Ellis, F. ( 1969 ) Dose, time and fractionation: a
clinical hypothesis. Clinical Radiology, 20, 1-7
Epenetos, A.A., Nimrnon, C.C. and Arklie, J. ( 1982 )
Detection of human cancer in an animal model using
radiolabelled tumour-associated monoclonal antibodies. 
British Journal of Cancer, 46, 1-8
Epenetos, A.A., Snook, D., Rowlinson, G. and Hooker, G. ( 
1986 ) Prospects for antibody-targeted radiotherapy of 
cancer. Lancet, ii, 579-580
Epenetos, A.A., Munfo, A.J., Stewart, S., Rampling, R., 
Lambert, H.E., McKenzie, C.G., Soutter, P., Rahemtul, A., 
Hooker, G. and Sivolape, G.B. ( 1987 ) Antibody guided 
irradiation of advanced ovarian cancer with 
intraperitoneally administered radiolabelled monoclonal 
antibodies. Journal of Clinical Oncology 5, 1890-1899
Ettinger, D.S., Order, S.E., Wharam, M.D., Parker, M.K.,
Klein, J.L. and Leichner, P.K. ( 1982 ) Phase I-II study 
of isotopic immunoglobulin therapy for primary liver
cancer. Cancer Treatment Reports, 66, 289-297
227
Evans, S.M., Labs, L.M. and Yuhas, J.M. ( 1986 ) Response 
of human neuroblastoma and melanoma multicellular tumour 
spheroids ( MTS ) to single dose irradiation. 
International Journal of Radiation Oncology Biology and 
Physics, 12, 969-973
Falk, S. and Alpert, M. ( 1967 ) Five-year survival of 
patients with Ewing's sarcoma. Surgery Gynaecology and 
Obstetrics, 124, 319-324
Fertil, B. and Malaise, E.P. ( 1981 ) Inherent cellular 
radiosensitivity as a basic concept for human tumour 
radiotherapy. International Journal of Radiation Oncology 
Biology and Physics, 7, 621-629
Fertil, B., Dertinger, H., Courdi, A. and Malaise, E.P. ( 
1984 ) Mean . inactivation dose: A useful concept for 
intercomparison of human cell survival curves. Radiation 
Research, 99, 75-84
Fertil, B. and Malaise, E.P. ( 1985 ) Intrinsic
radiosensitivity of human cell lines is correlated with 
radioresponsiveness of human tumours: analysis of 101
published survival curves. International Journal of 
Radiation Oncology Biology and Physics, 11, 1699-1707
FeCer, A., Cheever, M.A. and Greenberg, P.D. ( 1982 ) 
Treatment of chronic granulocytic leukaemia with 
chemo-radiotherapy and transplantation from identical 
twins. New England Journal of Medicine, 396, 163-168
Field, S.B., Hornsey, S. and Kutsutani, Y. ( 1976 )
2 28
Effects of fractionated irr adiation on mouse lung and a 
phenomenon of slow repair. British Journal of Radiology, 
49, 700-707
Fitzgerald, T.J., McKenna, M., Kase, K., Daugherty, C., 
Rothstein, L. and Greenberger, J.S. ( 1986 ) Effect of
x-irradiation dose-rate on the clonogenic survival of 
human and experimental animal hemopoietic tumour cell 
lines: evidence for heterogeneity. International Journal
of Radiation Oncology Biology and Physics, 12, 69-73
Focht, E.F., Merriam, G.R., Schwartz, M., Velasquez, J.
and McNeil, D. ( 1966 ) A method of radiation cataract
analysis and its uses in experimental fractionation 
studies. Radiology, 87, 465-474
Folkman, J. ( 1976 ) The vascularisation of tumours.
Scientific American 234, 59-73
Forman, S.J., Spruce, W.E., Farbsteiri, M.J., Wolf, J.L.,
Scott, E.P., Nademanee, A.P., Fahey, J.L., Hecht, T.,
Zaica, J.A.,. Rrance, R.A., Findley, D.O. and Bl^me, K.G. (
1983 ) Bone marrow ablation followed by allogeneic marrow 
grafting during first complete remission of acute non 
lymphocytic leukaemia. Blood, 61, 439-442
Fowler, J.F. ( 1983 ) La Ronde - radiation sciences and
medical radiology. Radiotherapy and Oncology, 1, 1-22
Fowler, J.F. ( 1984 ) What next in fractionated
radiotherapy? British Journal of Cancer, 49, Suppl VI,
285-300
229
Fowler, J.F. and Stern, B.E. ( 1963 ) Dose-time
relationships in radiotherapy and the validity of cell 
survival curve models. British Journal of Radiology, 36, 
163-173
Fowler, J.F., Kragt, K., Ellis, R.E., Lindop, P.J. and 
Berry, R.J. ( 1965 ) The effect of divided doses of 15 MeV 
electrons on the skin response of mice. International
Journal of Radiation Biology, 9, 241-252
Friedman, M., Pearlman, W.W. and Turgeon ( 1967 )
Hodgkin's disease, Tumour lethal dose and iso-effect 
recovery curve. American Journal of Radiology, 99, 843-851
Fryer, C.J.H., Fitzpatrick, P.J., Rider, W.D. and Poon, P.
( 1978 ) Radiation pneumonitis: experience following a
large single . dose of radiation. International Journal of 
Radiation Oncology Biology and Physics, 4, 931-936
Gansow, O.A., Brechbiel, M., Atcher, R.W., Scholm, J., 
Simpson, D., Esteban, J. and Colcher, D. ( 1986 )
Synthesis of l-( p-isothiocyanatobenzyl ) DTPA. Antibody 
labelling and tumour imaging studies in comparison with 
DTPA anhydrides and EDTA. British Journal of Cancer, 54, 
531 (abstract)
Garnett, M.C., Embleton, M.J., Jacobs, E. and Baldwin, 
R.W. ( 1985 ) Preparation and properties of a
drug-carrier-antibody conjugate showing selective 
antibody-directed cytotoxicity in vitro. International 
Journal of Cancer, 31, 661-670
230
Gerrard, M., Eden, O.B. and Merrick, M.V., ( 1987 )
Imaging and treatment of disseminated neuroblastoma with 
131-1 meta-iodobensylguanidine. British Journal of
Radiology, 60, 393-395
Glass, A. G. and Fraurneni, J.F. ( 1970 ) Epidemiology of
bone cancer in children. Journal of the National Cancer. 
Institute, 44, 187-199
Glassburn, J.R., Brady, L.W. and Plenk, H.P. ( 1977 )
Hyperbaric oxygen in radiation therapy. Cancer, 39,
751-765
Glorieux, P., Bouffet, E. , Philip, I. , Biron, P.,
Holzarfel, L. , Floret, D., Bouvier, R., Vitrey, D.,
Pinkerton, R., Brunot-Mentiguy, M. and Philip, T. ( 1986 ) 
Metastatic interstitial pneumonitis after autologous bone 
marrow transplantation: a consequence of reinjection of
malignant cells? Cancer, 58, 2136-2139
Goldie, J.N. and Coldmann, A.J. ( 1984 ) The genetic
origin of drug resistance in neoplasms: implications for 
systemic therapy. Cancer Research, 44, 3643-3653
Goldman, J.M. ( 1987 ) Bone marrow transplantation for 
chronic myeloid leukaemia. Hematological Oncology, 5, 
265-279
Goldstone, A.H.( E.B.M.T. Group ) ( 1986 ) EBMT experience
of autologous bone marrow transplantation in non-Hodgkin9s 
lymphoma and Hodgkin’s disease. In Proceedings of the 
Xllth Annual Meeting of the European Cooperative Group for
2 o 1
Bone Marrow Transplantation. A.M. Marrnont, A. Bacigalupo 
and M.T. Van Lint (Eds) Macmillan Press, pp 289-292
Goodhead, D.T. ( 1980 ) Models of radiation inactivation 
and mutagenesis. In Radiation Biology in Cancer Research.
E. Meyn and H.R. Withers ( Eds ) Raven Press, New York, pp 
231-247
Goodwin, D., Meares, C.F. and Diamanti, C. I. ( 1984 ) Use 
of specific tumour antibody for rapid clearance of 
circulating blood background from radiolabelled tumour 
imaging proteins. European Journal of Nuclear Medicine, 9, 
209-215
Goolden, A.W.G., Goldman, J.M. , Karn, _K. C. , Dunn, P. A., 
Baughan, A.S.J., McCarthy, D.M., Worsley, A.M., 
Gordon-Smith , E.C., Samson, D., Catovsky, D. and Galton, 
D.A.Gt ( 1983 .) Fractionation of whole body irradiation 
before bone marrow transplantation for patients with 
leukaemia. British Journal of Radiology, 56, 245-250
Gray, L.H., Conger, A.G., Ebert, M., Hornsey, S. and 
Scott, O.C.A. ( 1953 ) The concentration of oxygen
dissolved in tissues at the time of irradiation as a 
factor in radiotherapy. British Journal of Radiology, 26, 
638-648
Guichard, M., Weichselbaum, R.R., Little, J.B. and 
Malaise, E.P. ( 1984 ) Potentially lethal damage repair as 
a possible determinant of human tumour radiosensitivity. 
Radiotherapy and Oncology, 1, 263-269
232
Habeshaw, T. and Wheldon, T.E. ( 1-984 ) Malignant
melanoma: The role of radiotherapy. Clinics in Oncology,
3, 571-596
Hagan, P.L., Halpern, S.E., Diliman, R.O., Shawler, D.L., 
Johnson, D.E., Chen, A., Krishnan, L., Frinke, J.,
Bartholomew, R.M., David, G.S. and Carlo, D. ( 1986 )
Tumour size: Effect on monoclonal antibody uptake in
tumour models. Journal of Nuclear Medicine, 27, 422-427
Hall, E.J. ( 1978 ) Radiobiology for the Radiologist.
Harper and Row, Hagerstown, Maryland
Hall, A. ( 1986 ) Oncogenes. In Genetic Engineering 5.
P.W.J.Rigby ( Ed ) Academic Press. London, pp 61-116
Hammersmith Oncology Group and Imperial Cancer Research 
Fund ( 1984 ) Antibody guided irradiation of malignant
lesions: Three cases illustrating a new method of
treatment. Lancet, i, 1441-1443
Harrison, A. and Royle, L. ( 1-984 ) Preparation of a 211 
At-IgG conjugate which is stable in vivo. International 
Journal of Applications of Radiation and Isotopes, 35, 
1005-1008
Haynes, R.H. ( 1966 ) The interpretation of microbial
inactivation and recovery phenomena. Radiation Research, 
Suppl 6, 1-29
Helenglass, G., Lakhani, A., Powles, R., Nandi, A.,
Zuiable, A. , Gore, M. , Forgeson, G. , Treleaven, J.,
Milliken, S. and Millar, J. ( 1987 ) Bone marrow
233
transplantation - The Marsden experience. Hematological 
Oncology, 5, 245-254
Hnatowich, D.J., Virzi, F. and Doherty, P.W. ( 1985 )
DTPA-coupled antibodies labelled with yttrium-90. Journal 
of Nuclear Medicine, 26, 503-509
Hopewell, J.W. , Campling, D., Calvo, W. , Reinhold, H.S.,
Wilkinson, J.H., and Yeung, T.K. ( 1986 ) Vascular
irradiation damage: Its cellular basis and likely
consequences. British Journal of Cancer, 53, Suppl VII, 
181-191
Horne, T., Granowska, M., Dicks-Mireau, C., Hawkins, L.A., 
Britton, K.E., Mather, S., Bornanji, J. , Kemshead, J.T.,
Kingston, J. and Malpas, J.S. ( 1985 ) Neuroblastoma
imaged with 123-1 meta-iodo-bensylguanidine and with 123-1 
-labelled monoclonal antibody, UJ13A against neural
tissue. British Journal of Radiology, . 58, 476-480
Huczkowski, J. and Trott, K.R. ( 1984 ) Dose fractionation
effects in low dose rate irradiation of jejunal crypt stem 
cells. International Journal of Radiation Biology, 46, 
293-298
Huczkowski, J. and Trott, K.R. ( 1987 ) Jejunal crypt stem
cells survival after fractionated ^-irradiation performed 
at different dose rates. International Journal of 
Radiation Biology, 51, 131-138
Humm, J.L. ( 1986 ) Dosimetric aspects of radiolabelled
antibodies for tumour therapy. Journal of Nuclear
234
Medicine, 27, 1490-1497
Humrn, J.L. ( 1987 ) A microdos imetric model of
Astatine-211 labelled antibodies for radioimmunotherapy. 
International Journal of Radiation Oncology Biology and 
Physics, 13, 1767-1773
Huvos, A.G. ( 1979 ) Ewing’s sarcoma. In Bone tumours: 
Diagnosis, treatment and prognosis. A.G. Huvos ( Ed )
Saunders, Philadelphia, pp 322-344
Inati, A., Sallan, S.E., Cassady, J.R., Hitchcoek-Bryan,
S., Clavell, L.A., Belli, J.A. and Sollee, N. ( 1983 ) 
Efficacy and morbidity of central nervous system 
"prophylaxis" in childhood acute lymphoblastic leukaemia: 
eight years experience with cranial irradiation and 
intrathecal methotrexate. Blood, 61, 297-303
Johansson, L, Carlsson, J. and Nilsson, K. ( 1982 )
Radiosensitivity of human B-lymphocytic lyphomas in vitro. 
International Journal of Radiation Biology, 41, 411-420
Jurgens, H, Donaldson, S.S. and Gobel, U. ( 1986 ) Ewing's 
sarcoma In Cancer in Children. P.A. Voute, A. Barrett,
H.J.G. Bloom, J. Lemerle and M.K. Neidhardt ( Eds ) 
Springer Verlag, Berlin, pp 300-315
Keane, T.J., van Dyk, J. and Rider, W.D. ( 1981 )
Idiopathic interstitial pneumonia following bone marrow 
transplantation: The relationship with total body
irradiation. International Journal of Radiation Oncology 
Biology and Physics, 7, 1365-1370
235
Kellerer, A.M. and Rossi, H.H. ( 1972 ) The theory of dual 
radiation action. Current Topics in Radiation Research, 8, 
85-158
Kellerer, A.M. and Hug, 0. ( 1972 ) Theory of dose-effect
relationships. In Encyclopedia of Medical Radiology, vol 
2, Springer-Verlag, Berlin, pp 1-42
Kemshead, J.T., Treleaven, J.G., Gibson, F.M., Ugelstaad, 
J., Rembaum, A. and Philip, T. ( 1985a ) Monoclonal
antibodies and magnetic rnicrospheres used for the 
depletion of malignant cells from bone marrow. In Advances 
in Neuroblastoma Research. A.E. Evans, G.J. D ’Angio and 
R.C. Seeger ( Eds ). Alan R. Liss, New York, pp 413-423
Kemshead, J.T., Goldman, A., Jones, D., Pritchard, J., 
Malpas, J.S., Gordon, I., Malone, J.F., Harley, G.D. and 
Breatnach, F. ( 1985b ) Therapeutic application of
radiolabelled rnonclonal antibody UJ13A in children with 
disseminated neuroblastoma - a phase I study. In Advances
in Neuroblastoma Research. A.E. Evans, G.J. D'Angio and
R.C. Seeger ( Eds ). Alan R. Liss, New York, pp 533-544
Kerr, D.J., Wheldon, T.E., Kerr, A.M., Freshney, R.I. and
Kaye, S.B. ( 1986 ) The effect of adriamycin and 4'
deoxydoxorubicin on cell survival of human lung tumour
cells grown in monolayer and as spheroids. British Journal 
of Cancer, 54, 423-429
Kersey, J.H., Ramsay, N.K.C., Kim, T., McGlave, P., 
Krivit, W., Levitt, S., Fillopovieh, A., Woods, W., 
O'Leary, M., Coccia, P. and Nesbit, M.E. ( 1982 )
2 3 6
Allogeneic bone marrow transplantation in acute 
non-lymphoblastic leukaemia: a pilot study. Blood, 60,
400-403
Kimler, B.F., Park, C.H., Yakar, D., and Mies, R.M. ( 1985 
) Radiation response of human normal and leukaemic 
haemopoietic cells assayed by in vitro colony formation. 
International Journal of Radiation Oncology Biology and 
Physics, 11, 809-816
Kinsella, T.J., Mitchell, J.B., McPherson, S., Miser, J., 
Triche, T. and Glastein, E. ( 1984 ) In vitro radiation 
studies on Ewing's sarcoma cell lines and human bone 
marrow: application to the clinical use of total body 
irradiation. Internationa] Journal of Radiation Oncology 
Biology and Physics, 10, 1005-1011
Kirk, J., Gray, W.M. and Watson, E.R. ( 1971 ) Cumulative 
radiation effect - I fractionated treatment regimes. 
Clinical Radiology, 22, 145-155
Kirk, J., Gray, W.M. and Watson, E.R. ( 1972 ) Cumulative 
radiation effect - II continuous radiation therapy - long 
lived sources. Clinical Radiology, 23, 93-105
Kirk, J., Gray, W.M. and Watson, E.R. ( 1973 ) Cumulative 
radiation effect - III continuous radiation therapy - 
short lived sources. Clinical Radiology, 24, 1-11
Kirk, J., Gray, W.M. and Watson, E.R. ( 1975 a )
Cumulative radiation effect - IV normalisation of 
fractionated and continuous therapy - area and volume
237
correction factors . Clinical Radiology, 26, 77-88
Kirk, J., Gray, W.M. and Watson, E.R. ( 1975 b )
Cumulative radiation effect - V time gaps in fractionated 
regimes. Clinical Radiolog;/, 26, 159-176
Klein, G. ( 1983 ) Specific chromosomal translocations and 
the genesis of B-cell derived tumours in mice and men. 
Cell, 32, 311-315
Kohler, G. and Milstein, C. ( 1975 ) Continuous cultures 
of fused cells secreting antibody of predefined 
specificity. Nature, 256, 495-497
Lagrange, J.L., Brassard, N., Cosla, A., Aubanel, D., 
Hery, M. , Bruneton, J.N. and Lalanne, C.M. (• 1987 ) CT 
measurement of lung density: the role of patient position 
and value for total body irradiation. International 
Journal of Radiation Oncology Biology and Physics., 13,
941-944
Larsop, S.M., Carrasquillo, J.A., Krohn, K.A., Brown, 
J.P., McGuffin, R.W., Ferens, J.M., Graham, M.M., Hill. 
L.D., Beaumier, P.L. and Hellstrom, K.E. ( 1983 )
Localisation of 131-1 labelled p97 specific Fab fragments 
in human melanoma as a basis for radiotherapy. Journal of 
Clinical Investigation, 72, 2101-2114
Lashford, L.S., Davies, A.G., Richardson, R.B., Bourne, 
S.P., Bullimore, J.A., Eckert, H., Kemshead, J.T. and 
Coakham, H.B. ( 1988 ) A pilot study of 131-1 monoclonal 
antibodies in the therapy of leptomeningeal tumours.
238
Cancer, 61, 857-868
Laurie, J. , Orr, J.S. and Foster, C. J. ( 1972 ) Repair 
processes and cell survival. British Journal of Radiology, 
45, 362-368
Lebesque, J.V., Stewart, F.A. and Hart, A.A.M. ( 1986 )
Analysis of the rate of expression of radiation-induced 
renal damage and the effects of hyperfractionation. 
Radiotherapy and Oncology, 5, 147-157
Lehnart, S. and Rybka, W.B. ( 1985 ) Dose rate dependence 
of response of mouse lung to irradiation. British Journal 
of Radiology, 58, 745-749
Lehnart, S., Rybka, W.B., Suissa; S. and Giambattisto D. ( 
1986 ) Radiation response of haematopoietic cell lines of
human origin, international Journal of Radiation Biology, 
49, 423-431
Leichner, P.K., Klein, J.L., Siegelman, S.S., Ettinger, 
D.S. and Order, S.E. ( 1983 ) Dosimetry of 131-1 labelled 
antiferritin in hepatoma: Specific activities in the tumor 
and liver. Cancer Treatment Reports, 67, 647-658
Leichner, P.K., Yang, N.C., Frenkel, T.L., Loudenslager, 
D.M., Hawkins, W.G., Klein, J.L. and Order, S.E. ( 1988 )
Dosimetry and treatment planning for 90-Y-labelled 
antiferritin in hepatoma. International Journal of
Radiation Oncology Biology and Physics, 14, 1033-1042
Leung, P.M.K, Rider, W.D., Webb, H.P., Aget, H. and Johns,
H.E. ( 1981 ) Cobalt-60 therapy unit for large field
239
irradiation. International Journal of Radiation Oncology 
Biology and Phy s i cs. , 7, 705-712
Little, C.D., Nau, M.M. , Carney, D.N., Gasdar, A.F. and 
Minna, J.D. ( 1983 ) Amplification and expression of the 
c-rnyc oncogene in human lung cancer cell lines. Nature, 
306, 194
Littman, P., Coccia, P., Bleyer, W. A., Lukens, J., Siegel,
S., Miller, D., Sather, H. and Hammond, D. ( 1987 )
Central nervous system ( CNS ) prophylaxis in children 
with low risk acute lymphoblastic leukaemia ( ALL ). 
International Journal of Radiation Oncology Biology and 
Physics, 13, 1443-1449
Liversage, W.E. ( 1969 ) A general formula for equating 
protracted and acute regimes of radiation. British Journal 
of Radiology, 42, 432-440
Liversage, W.E. ( 1980 ) A comparison of the predictions 
of the CRE, TDF and Liversage formulae with clinical 
experience. British Journal of Radiology, Special Report 
17, 182-189
Loevinger, R. and Berman, M. ( 1976 ) A revised schema for 
calculating the absorbed dose from biologically 
distributed radionuclides. MIRD pamphlet 1 ( revised )
Maciejewski, B., Preuss-Bayer, G. and Trott, K.R. ( 1983 ) 
The influence of the number of fractions and of overall 
treatment time on local control and late complication 
rates in squamous cell carcinomas of the larynx.
240
International Journal of Radiation Oncology Biology and 
Physics, 9, 321-328
Madrazo, A.A. and Churg, J. ( 1976 ) Radiation nephritis - 
chronic changes following moderate doses of radiation.
Laboratory Investigation, 34, 283-290
Mah, K., van Dyk, J., Keane, T. and Poon, P. Y. ( 1987 )
Acute radiation-induced pulmonary damage: a clinical study 
on the response to fractionated radiation therapy. 
International Journal of Radiation Oncology Biology and 
Physics., 13, 179-188
Mahoney, D.H., Gonzales, E.T., Ferry, G.D., Sanjad, S.A., 
Noorden, G.K. and Fernbach, D.J. ( 1981 ) Childhood acute 
leukaemia: a search for occult extramedullary disease prior 
to discontinuation of chemotherapy. Cancer, 48, 1964-1966
Maraninchi, D. , Glu.ckman, E. , Blaise, D. , Guyotat, D. ,
Rio, B., Pico, J.L., Leblond, V. Michallet, M., Dreyfus,
F., Ifrah, N. and Boreligoni, A. ( 1987 ) Impact of T-cell 
depletion on outcome of allogeneic bone-marrow
transplantation for standard-risk leukaemias. Lancet, ii, 
175-178
Marchese, M.J., Zaider, M. and Hall, E.J. ( 1987 ) 
Potentially lethal damage repair in human cells.
Radiotherapy and Oncology, 9, 57-65
Masuda, K., Hunter, N. and Withers, H.R. ( 1980 ) Late 
effect in mouse skin following single and 
multifractionated irradiation. International Journal of
241
Radiation Oncology Biology and Physics., 6, 1539-1544
Matzku, S., Garner, B. , and Tilgen, W. ( 1986 )
Intra-tumoral distribution of labelled antibodies and 
fragments. Autoradiography of tumor-bearing nude mice. 
British Journal of Cancer, 54, 538 (abstract)
McDonald, B., Sharma, P., Mattews, D.E., Shullman, H.W. 
and Thomas, E.D. ( 1985 ) The clinical course of 53
patients with veno-occlusive disease of the liver after 
marrow transplantation. Transplantation, 39, 603-609
McGrath, J.P., Capon, D.J., Goeddel, D.V. and Levinson, 
A.D. ( 1984 ) Comparative biochemical properties of normal 
and activated human ras p21 protein. Nature, 310, ,644-649
Meadows, A.T., Gordon, J., Masari, D. , ■ Littman, P., 
Glasser, K.M. ,■ and Fergusson, J. ( 1981 ) Declines in IQ 
scores and cognitive dysfunctions in children with acute 
lymphoblastic leukaemia ( ALL ) treated with cranial 
irradiation ( RT ). Lancet, ii, 1015-1018
Meares, C.F., Deshpande, S.V., DeNardo, S.J. and Goodwin,
D.A. ( 1988 ) Chelate radiochemistry: cleavable linkers
lead to altered levels of radioactivity in the liver. 
International Journal of Cancer, Suppl.2, 99-102
Menard,S., Miotti, S., Tagliabue, E., Parmi, L., Buraggi,
G.L. and Colnaghi, M.I. ( 1983 ) Tumour
radioimmunolocalisation in a murine system using 
monoclonal antibodies. Tumori, 69, 185-190
Michael, B.D. ( 1985 ) A simple graphical determination of
242
^  /p ratios from reciprocal dose plots. International 
Journal of Radiation Biology 47, 119-120
Michalowski, A. ( 1981 ) Effects of radiation on normal 
tissues: hypothetical mechanisms and limitations of in
situ assays of clonogenicity. Radiation and Environmental 
Biophysics, 19, 157-172 5
Miller, R.J., Langdon, E.A. and Tesler, A. S. ( 1976 ) 
Total body irradiation utilizing’ a single 60-Co source.
International Journal of Radiation Oncology Biology and 
Physics. , 1;- 54.9-552
Moe, P.J. ( 1984 ) Recent advances in the management of
acute lymphocytic leukaemia. Cancer Research, 25, 
1490-1494
Moshakis, V. , Mcllhanney, R.A.J., Raghavan, D. and 
Neville, A.M. ( 1981 ) Localisation of human tumour
xenografts after i.v. administration of radiolabelled 
monoclonal antibodies. British Journal of Cancer, 44, 
91-99
Myers, M.J. ( 1988 ) Dosimetry for radiolabelled
antibodies: macro or micro. International Journal of
Cancer, Suppl 2, 71-73
Nenot, J.C. ( 1987 ) Medical basis for the establishment 
of intervantion levels. British Journal of Radiology, 60, 
1163-1169
Nias, A.H.W. ( 1974 ) The clinical sigificance of cell 
survival curves. In The Biological and Clinical Basis of
243
Radiosensitivity. M. Friedmen ( Ed ) Charles C.Thomas, 
Springfield USA. pp 156-169
Norin, T. and Onyango, J. ( 1977 ) Radiotherapy in
Burkitt’s lymphoma. Conventional or superf ractionated 
regimes. International Journal of Radiation Oncology 
Biology and Physics, 2, 399-406
Ohnuma, N., Kasuga, T., Nojiri, I. and Furuse, T. ( 1977 ) 
Radiosensitivity of the human neuroblastoma cell line ( 
NB-1 ). Gann., 68, 711-712
Old, L.J., Stockert, E., Boyse, E.A. and Kim, J.H. ( 1968 
) Antigenic modulation: loss of TL antigen from cells 
exposed to TL antibody. Journal of Experimental Medicine, 
127, 523-539
Olive, D. and Peeters, M. ( 1986 ) Chemotherapy In Cancer 
in Children. .P.A. Voute, A. Barrett, H.J.G. Bloom, J. 
Lemerle and M.K. Neidhardt ( Eds' ) Springer Verlag. 
Berlin, pp 21-35
Oliver, R. ( 1964 ) A comparison of the effects of acute 
and protracted gamma-radiation on the growth of seedlings 
of vicia faba. Part II Theoretical calculations. 
International Journal of Radiation Biology, 8, 475-488
Order, S.E., Klein, J.L., Etting'er, D. S. , Alderson, P., 
Siegelman, S. and Leichner, P.K. ( 1980 ) Phase I-II study 
of radiolabelled antibody integrated in the treatment of 
primary hepatic malignancies. International Journal of 
Radiation Oncology Biology and Physics, 6, 703-710
244
Orton, C.G. ( 1974 ) Time-dose factors ( TDFs ) in
brachytherapy. British Journal of Radiology, 47, 603-607
Orton, C.G. and Ellis, F. ( 1973 ) A simplification in the 
use of the NSD concept in practical radiotherapy. British 
Journal of Radiology, 46, 529-537
Overgaard, J ( 1986 ) The role of radiotherapy in
recurrent and metastatic malignant melanoma: a clinical
radiobiological study. International Journal of Radiation 
Oncology Biology and Physics., 12, 867-872
Overgaard, Mr. , Bentzen, S.M., Juul-Christensen, J. and 
Hjolland-Madsen, E. ( 1987 ) The value of the NSD formula 
in equation of acute and late radiation complications in 
normal tissue following 2 and 5 fractions per week in 
breast cancer, patients treated with postmastectomy 
irradiation. Radiotherapy and Oncology, 9, 1-12
Owens, A.H., Coffey, S. and Baylin, S.B. Eds ( 1982 ) 
Tumour cell heterogeneity: origins and implications.
Academic Press, New York
Ozawa, K., Miura, Y, Suda, T. , Motoyoshi, K. and Takaku,
F. ( 1983 ) Radiation sensitivity of leukaemic progenitor 
cells in acute nonlymphocytic leukaemia. Cancer Research 
43, 2339-2341
Faganelli, G., Riva, P., Deleide, G. , Clivio, A., 
Chiolerio, F. , Malcovati, M and Siccardi, A.G. ( 1987 ) In 
vivo labelling of biotinylated anti-CEA monoclonal 
antibodies by radioactive avidin. British Journal of
245
Cancer, 56, 514 (abstract)
Painter, R.B., ( 1980 ) The role of DNA damage and repair
in cell killing induced by ionising radiation. In 
Radiation Biology in Cancer Research. E. Meyn and H.R. 
Withers ( Eds ) Raven Press, New York, pp 59-68
Parkins, C.S., Fowler, J.F., Maughan, R.L. and Roper, M.J.
( 1985 ) Repair in mouse lung for up to 20 fractions of 
x-rays or neutrons. British Journal of Radiology, 58, 
225-242
Parkins, C.S. and Fowler, J.F. ( 1985 ) Repair in mouse 
lung of multifraction x-rays and neutrons: extension to 40 
fractions. British Journal of Radiology, 58, 1097-1103
Paterson, R. ( 1948 ) The treatment of malignant disease 
by radium and x-rays. Edward Arnold (Publishers), London
Peres, C.A., Telft, M., Nesbit, M.E., Burgert, E.O., 
Vietti, T.J., Kissane, J., Pritchard, D.J. and Gehan, E.A.
( 1981 ) Radiation therapy in the multimodal management of 
Ewing's sarcoma of bone: report of the intergroup Ewing’s 
sarcoma study. National Cancer Institute Monographs, 56, 
263-271
Peters, L.J., Withers, H.R., Cundiff, J.H. and Dicke, K.A.
( 1979 ) Radiobiological considerations in the use of
total body irradiation for bone marrow transplantation. 
Radiology, 131, 243-247
Peters, L.J. and Withers H.R. ( 1982 ) Critique of
"Radiobiological basis of total body irradiation with
246
different dose rate and fractionation: repair capacity of 
hemopoietic cellsInternational Journal of Radiation 
Oncology Biology and Physics, 8, 1819
Pezner, R.D. and Archarnbeau, J.O. ( 1981 ) Brain tolerance 
unit: a method to estimate risk of radiation brain injury
for various dose schedules. International Journal of 
Radiation Oncology Biology and Physics, 7, 397-402
Pfefferbaum-Levine, B., Copeland, D.R., Fletcher, J.M., 
Ried, H.L., Jaffe, N. and McKinnon, W.R. ( 1984 )
Neurophysiologic assessment of long-term survivors of 
childhood leukaemia. American Journal of Pediatric 
Hematology Oncology, 6, 123-128
Philip, T. , Biron, P., Philip, I., Favrot, M.-, Bernard, 
J.L., Zucker, J.M., Luts, B., Plouvier, E., . Rebattu, P., 
Carton, M., Chauvot, P., Dutou, L., Souillet, G.,
Phillipe, N., Bordigoni, P., Lacrose; M., Clapisson, G.,
Olive, D., Treleaven, J., Kemshead, J.T. and
Brunat-Mentigny, M. ( 1985 ) Autologous bone marrow
transplantation for very bad prognosis neuroblastoma. In
Advances in Neuroblastoma Research. A.E. Evans , G.J. 
D ’Angio and R.C. Seeger ( Eds ) Alan R. Liss. New York pp 
569-586
Philip, T., Biron, P., Philip, I., Favrot, M., Souillet,
G., Frappaz, D., Jaubert, J., Bordigoni, P., Bernard, 
J.L., Laporte, J.P., LeMevel, A., Plouvier, E., 
Marguerite, G., Pinkerton, R., Brigard, C.P., Freycon, F., 
Forster, H.K., Philippe, N. and Brunat-Mentigny, M. ( 1986
247
) Massive' therapy and autologous bone marrow 
transplantation in pediatric and young adults Burkitt's 
lyrnphoma ( 30 courses on 28 patients: a 5-year experience 
). European Journal of Cancer and Clinical Oncology, 22, 
1015-1027
Phillips, R.F. and Higinbotham, N.L. ( 1967 ) The
curability of Ewing's endothelioma of bone in children. 
Journal of Pediatrics, 70, 3.91-397
Phillips, T.L. and Roth, G. ( 1973 ) A quantitative
technique for measuring renal damage after irradiation. 
Radiology, 109, 457-462
Pimm, M.V. and Baldwin, R.W. ( 1985 ) Distribution of IgM 
monoclonal antibody in mice with human tumour xenografts: 
lack of tumour localisation. European Journal of Cancer, 
and Clinical Oncology, 6, 765-768
Potten, C. ( 1986 ) The cellular basis of skin injury
after cytotoxic insult. British Journal of Cancer, 53, 
Suppl.VII pp 47-58
Prentice, H.G., Blacklock, H.A., Janossy, G., Bradstock, 
K.F., Skeggs, D., Goldstein, G. and Hoffbrand, A.V. ( 1982 
) Use of anti-T-cell monoclonal antibody 0KT3 to prevent 
acute graft-versus-host disease in allogeneic bone marrow 
transplantation for acute leukaemia. Lancet, i, 700-703
Prindull, G. ( 1986 ) Minimal residual neoplastic disease 
- concept, pathogenesis and supplementary therapeutic 
possibilities. Cancer Treatment Reviews, 13, 177-194
248
Quast, (J. ( 1987 ) Total body irradiation - review of
treatment techniques in Europe. Radiotherapy and Oncology, 
9, 91-106
Rabbitts, P.H., Watson, J.V., Larnond, A., Forster, A., 
Stinson, M.A., Evan, G., Fischer, W., Atherton, E., 
Sheppard, R. and Rabbitts, T.H. ( 1985 ) Metabolism of 
c-myc gene products; c-myc rnessenger-RNA and protein 
expression in the cell cycle. EMBO Journal, 4, 2009-2015
Ramsay, N.K.C., Kersey, J.H., Robinson, L.L., McGlave, 
P.B., Woods, W.G., Krivit, W., Kim, T.H., Goldman, A.I. 
and Nesbit, M.E. ( 1982 ) A randomised study of the
prvention of acute graft-versus-host disease. New England 
Journal of Medicine, 306, 392-3.97
Razek, A., Perez, C.A., Telft, M., Nesbit, M., Vietti, T., 
Burgert, E.O., Kissane, J., Pritchard, D.J. and Gehan,
E.A. ( 1980 ) Intergroup Ewing’s sarcoma study. Local 
control related to radiation dose, volume and site of 
primary lesion in Ewing's sarcoma. Cancer, 46, 516-521
Reddy, E.P., Reynolds, R.K., Santos, E. and Barbachid, M.
( 1982 ) A point mutation is responsible for the
aquisition of transforming prop erties by the T24 human 
bladder carcinoma oncogene. Nature, 300, 149-152
Regaud, C. ( 1922 ) Influence de la duree de radiation sur 
les effects determines dans le testicle par le radium. 
Cornptes Rendus des seances de la Societe de biologie et de 
ses filliales, 86, 878-890
249
Rhee, J.G., Song, C.W., Kim, T.H. and Levitt, S.H. ( 1985
) Effect of fract ionation and rate of radiation dose on 
human leukaemic cells HL-60. Radiation Reseaerch, 101, 
519-527
Reichman, L., Clark, M., Waldmann, H. and Winter, G. ( 
1988 ) Reshaping human antibodies for therapy. Nature, 
322, 323-327
Riggs, S.J., Green, A.J., Begent, R.H.J. and Bagshawe, D.
( 1988 ) Quantitation in 131-1 radioimmunotherapy using 
SPECT. International Journal of Cancer, Suppl.2, 95-98
Roesch, W.C. ( 1978 ) Models of the radiation sensitivity 
gf mammalian cells. In Proceedings of the third symposium 
on neutron dosimetry in biology and medicine. G. Burger 
and H.G. Ebert ( Eds ) Commission of the Eurpoean
Communities. Luxembourg, pp 1-27
Rofstad, E.K. ( 1986 ) Radiation biology of malignant
melanoma. Acta Radiologica ( Oncol ), 25, 1-10
Rofstad, E.K. and Brustad, T. ( 1987 ) Radioresponsiveness 
of human melanoma xenografts given fractionated 
irradiation in-vivo - relationship to the initial slope of 
the cell survival curves in vitro. Radiotherapy and
Oncology, 9, 45-56
Rossi, H.H. and Ellis, R.H. ( 1950 ) Distributed beta
sources in uniformly absorbing media - I. Nucleonics, 7,
9-25
250
Rowland, G.F., Axton, C.A., Baldwin, R.W., Brown, J.P., 
Corvalan, J.R., Embleton, M.J., Gore, V.A., Hellstrom, I., 
Hellstrom, K.E. and Jacobs, E. ( 1985 ) Anti-tumour
properties of vindesine-monocl on a J antibody conjugates. 
Cancer Immunology and Immunotherapy, 19, 1-7
Rubin, P., Keller, B. and Quick, R. ( 1974 ) The range of 
prescribed tumour lethal dose ( PTLD ) in the treatment 
of different human tumours. In The Biological and Clinical 
Basis of Radiosensitivity. M. Friedman ( Ed ) Charles C. 
Thomas, Springfield USA. pp 435-484
Sahagan, B.G., Dorai, H., Saltzgaber-Muller, J., 
Toneguzzi, F., Guindon, C.A., Lilly, S., McDonald, K. , 
Morrisey, D., Stone, B. and Davis, G. ( 1986 ) Genetically 
engineered murine/human chimeric antibody retains 
specificity for human tumour associated antigens. Journal 
of Immunology, 137, 1066-1074
Sanders, J.E., Buckner, C.D., Sievert, P. and Thomas, E.D.
( 1979 ) Successful treatment of juvenile chronic
granulocytic leukaemia with marrow transplantation.
Pediatrics, 63, 44-46
Sanders, J.E., Thomas, E.D. and Seattle marrow transplant 
group. ( 1981 ) Marrow transplantation for children with 
acute nonlymphoblastic leukaemia in first remission.
Medical and Paediatric Oncology, 9, 423-427
Scalliet, P., Landuyt, W. and van der Schueren, E. ( 1987
) Effect of decreasing the dose rate of irradiation on the 
mouse lip mucosa. Comparison with fractionated
251
irradiations. Radiotherapy and Oncology, 10, 39-47
Schaisson, G. and Castro-Malaspina, H. ( 1986 ) Chronic 
leukaemia. In Cancer in Children. P.A. Voute, A. Barrett, 
H.J.G. Bloom, J. Lemerle and M.K. Neidhardt. Sringer 
Verlag, Berlin, pp 131-136
Schlessinger, H.R., Gerson, J.M., Moorhead, P.S., Maguire,
H. and Hummeler, K. ( 1976 ) Establishment and
characterisation of human neuroblastoma cell lines. Cancer 
Research, 36, 3094-3100
Schultheiss, T.E., Higgins, E.M. and El Mahdi, A.M. ( 1984 
) The latent period in clinical radiation myelopathy. 
International Journal of Radiation Oncology Biology and 
Physics, 10, 1109-1115
Schultheiss, T.E., Zagars, G.K. and Peters, L.J. ( 1987 )
An explanatory hypothesis for early- and late- effect 
parameter values in the LQ model.- Radiotherapy and 
Oncology, 9, 241-248
Schweinle, J.E. and Alperin, J.B. ( 1980 ) Central nervous 
system recurrence ten years after remission of acute
lymphoblastic leukaemia. Cancer, 45, 16-18
Seeger, R.C., Brodeur, G.M., Sather, H., Dalton, A.,
Siegel, S.E., Wong K.Y. and Hammond, D. ( 1985 )
Association of multiple copies of the N-myc oncogene with 
rapid progression of neuroblastomas. New England Journal 
of Medicine, 313, 1111-1116
Seeger, R.C., Rayner, S.A., Banerjee, A., Chung,H., Laung,
W.E., Neustein, H.B., Benedict, W.F. ( 1977 ) Morphology, 
growth, chromosomal pattern and fibrinolytic activity of 
two new human neuroblastoma cell lines. Cancer Research, 
37, 1364-1371
Seshadri, R., Matthews, C. and Morley, A.A. ( 1985 ) 
Radiation sensitivity of human malignant lymphocytes. Acta 
Radiologica ( Oncol ), 24, 411-414
Shank, B. ( 1983 ) Techniques of magna-field irradiation. 
International Journal of Radiation Oncology Biology and 
Physics, 9, 1925-1931
Sharkey, R. M. , Primus, F.J., Goldenberg, D.M. ( 1984 )
Second antibody clearance of radiolabelled antibody in 
cancer radioimmunodetection. Proceedings of the National 
Academy of Sci-ences of the USA, 81, 2843-2846
Shulman, H.M., McDonald, G.B., Matfctews, D., Doney, K.C., 
Kopecky, K.J., Gauvreau, J.M. and Thomas, E.D. ( 1980 ) An 
analysis of hepatic veno-occlusive disease and
centrilobular hepatic degeneration following bone marrow 
transplantation. Gastroenterology, 79, 1178-1191
Singh, K. ( 1978 ) Two regimes with the same TDF but
differing morbidity used in the treatment of stage III 
carcinoma of the cervix. British Journal of Radiology, 51, 
357-362
Snyder, W. S. , Ford, M.R., Warner, G.G. and Watson, S.B. ( 
1975 ) "S" Absorbed dose per unit cumulated activity for
selected radionuclide and organs. MIRD pamphlet 11,
253
Society of Nuclear Medicine. New York
Song, C.W., Kirn, T.H., Khan, F.M., Kersey, J.H. and 
Levitt, S.H. ( 1981 ) Radiobiological basis of total body 
irradiation with different dose-rate and fractionation: 
repair capacity of haernopoietic cells.
International Journal of Radiation Oncology Biology and 
Physics, 7, 1695-1701
Song, C.W., Kim, T.H., Khan, F.M., Kersey, J.H. and 
Levitt, S.H. ( 1982 ) Rebuttal of "Critique of
"Radiobiological basis of total body irradiation with 
different dose-rate and fractionation: repair capacity of 
haernopoietic cells."". International Journal of Radiation 
Oncology Biology and Physics, 10, 1819-1820 . '
Spitser, G., Valdivieso, M., Farha, P. et al ( 1985 ) High 
dose chemotherapy intensification with autologous bone 
marrow support in limited small cell bronchogenic 
carcinoma. In Autologous Bone Marrow Transplantation. 
Proceedings "of the first international symposium. Houston: 
The University of Texas M.D. Anderson Hospital and Tumor 
Institute at Houston. K.A. Dicke, G. Spitser and A.R. 
Zander ( Eds ). pp 155-165
Springmeyer, S.C., Fluornoy, N. , Sullivan, K.M. , Storb, R. 
and Thomas, E.D. ( 1983 ) Pulmonary function changes in 
long-term survivors of allogeneic marrow transplantation. 
In Recent Advances in Bone Marrow Transplantation. R.P. 
Gale ( Ed ) Alan R.Liss, New York, pp 343-353
Steel, G.G. ( 1977 ) Growth Kinetics of Tumours. Clarendon
254
Press, Oxford.
Steel, G.G., Deacon, J.M., Duchesne, G.M., Horwich, A., 
Kelland, L.R. and Peacock, J.H. ( 1987 ) The dose-rate 
effect in human tumour cells. Radiotherapy and Oncology, 
9‘, 299-310
Stephens, T.C. and Steel, G.G. ( 1980 ) Regeneration of 
tumours after cytotoxic treatment. In Radiation Biology in 
Cancer Research. E. Meyn and H.R. Withers ( Eds ) Raven 
Press, New York, pp 385-395
Stephens, T.C., Eady, J.J., Peacock, J.H. and Steel, G.G.
( 1987 ) Split-dose and low dose-rate recovery in four 
experimental tumour systems. International Journal of 
Radiation Biology., 52, 157-170 .
Stewart, F.A., Soranson, J.A., Alpen, E.L., Williams, M.V. 
and Denekamp, J. ( 1984 ) Radiation-induced renal damage: 
the effects of hyperfractionation. Radiation Research, 98, 
407-420
Stewart, F.A. , Oussoren, Y., Luts, A., Begg, A.C., Dewit, 
L., Lebesque, J. and Bartelink, H. ( 1987 ) Repair of
sublethal radiation injury after multiple small doses in 
mouse kidney: an estimate of flexure dose. International 
Journal of Radiation Oncology Biology and Physics, 13, 
765-772
Stoffel, T.J., Nesbit, M.E. and Levitt, S.H. ( 1975 )
Extrarnedullary involvement of the testes in childhood 
leukaemia. Cancer, 35, 1203-1211
255
Strandqvist, M. ( 1944 ) Studien uber die kumulative
wirkung der Rontgenstrahlen bei f raktioAierung. Acta
Radiologica. Suppl.55
Suit, H.D., Lindberg, R.D. and Fletcher, G.H. ( 1965 )
Prognostic significance of extent of tumour regression at 
completion of radiation therapy. Radiology, 84, 1100-1103
Sullivan, K.M. and Parkman, R. ( 1983 ) The
pathophysiology and treatment of graft-versus-host
disease. Clinical Haematology, 12, 775-789
Szekely, J.G. and Lobreau, A.U. ( 1985 ) High
radiosensitivity of the M0LT-4 leukaemic cell line. 
International Journal of Radiation Biology. , 48, 2-77-284
Tabin, C.J., Bradley, S.M., Bargmann, C.I., Weinberg,
R.A., Papageorge, A.G., Scolnick, E.M., Dhar, R., Lowy,
D.R. and Chang, E.H. ( 1982 ) Mechanism of activation of a 
human oncogene. Nature, 300, 143-149
Tarbell, N., Guinan, E., Niermeyer, C., Cotran, R.,
Sallan, S. and Weinstein, H. ( 1987a ) Late onset of renal
dysfunction in survivors of bone marrow transplantation. 
International Journal of Radiation Oncology Biology and 
Physics, 13, Suppl 1. pp 100 ( Astract )
Tarbell, N.J., Amato, D.A., Down, J.D. , Mauch, P. and 
Heilman, S. ( 1987b ) Fractionation and dose-rate effects 
in mice: A model for bone marrow transplantation in man.
International Journal of Radiation Oncology Biology and 
Physics, 13, 1065-1069
256
Teoule, R. ( 1987 ) Radiate on-induced DMA damage and its 
repair. International Journal of Radiation Biology, 51, 
573-589
Thames, H.D. ( 1985 ) An "incomplete repair” model for
survival after fractionated and continuous irradiations. 
International, Journal of Radiation Biology, 47, 319-339
Thames, H.D., Withers, H.D., Peters, L.J. and Fletcher,
G.H. ( 1982 ) Changes in early and late radiation
responses with altered dose fractionation: implications 
for dose survival relationships. International Journal of 
Radiation Oncology Biology and Physics, 8, 219-226
Thames, H.D., Peters, L.J., Withers, H.R. and Fletcher,
G.H. ( 1983 ) Accelerated fractionation vs
hyperfractionation: rationales for several treatments per
day. International Journal of Radiation Oncology Biology 
and Physics, 9, 127-138
Thames, H.D., Withers, H.R. and Peters, L.J. ( 1984 )
Tissue repair capacity and repair kinetics deduced from 
multifractionated or continuous irradiation regimens with 
incomplete repair. British Journal of Cancer, 49, 
Suppl.VI, 263-269
Thames, H.D., Brock, W.A., Bock, S.P. and Dixon, D.O. (
1986 ) Effect of dose per fraction on the division
potential of lethally irradiated plateau-phase CHO cells 
exposed to isoeffective fractionation regimens. British 
Journal of Cancer, 53, Suppl.VII, 376-381
257
Thierf elder, S., Hof frnan-Fezer, G., Rodt, H. , Doxiadis,
I., Eulits, M. and Kumrner, U. ( 1.981 ) Anti lymphocytic
antibodies and marrow transplantation. Transplantation, 
35, 249-254
Thomas, E.D., Storb, R., Clift, R.A., Fefer, A., Johnson,
F.L., Nieman, P.E., Lerner, K.G., Glucksberg, H. and
Buckner, C.D. ( 1975 ) Bone-rnarrow transplantation. New 
England Journal of Medicine, 292, 832-843 and 895-902
Thomas, E.D., Sanders, J.E., Fluornoy, N., Johnson, F.L.,
Buckner, C.D., Clift, R.A., Fefer, A., Goodell, B.W.,
Storb, R. and Weiden, P.L. ( 1983a ) Marrow
transplantation for patients with acute lymphoblastic 
leukaemia: a long term follow-up. Blood, 62, 1139-1141
Thomas, E.D., Applebaum, F.R., Buckner, C.D.', Clift, R.A., 
Deeg, H.J., Fefer, A., Sanders, J.E., Singer, J., Stewart, 
P., Sullivan, K.M., Storb, R. and Witherspoon, R.P. (
1983b ) Marrow transplantation for acute nonlymphocytic 
leukaemia. - In Recent Advances in Bone Marrow 
Transplantation. R.P. Gale ( Ed ) Alan R.Liss, New York. 
PP 61-70
Thomas, P.R. , Perez, C.A., Neff, J.R. , Nesbit, M.E. and 
Evans, R.G. ( 1984 ) The management of Ewing's sarcoma: 
role of radiotherapy in local tumour control. Cancer 
Treatment Reports, 68, 703-710
Thomlinson, R.H. and Gray, L.H. ( 1955 ) The histological 
structure of human lung cancers and the possible 
implications for radiotherapy. British Journal of Cancer,
258
9, 539-549
Thomlinson, R.H., Dische, S., Gray, A.J. and Errington, 
L.M. ( 1979 .) Clinical testing of radiosenstiser
RO-07-0582 3. Response of humours. Clinical Radiology, 27, 
167-174
Thompson, R.B. ( 1977 ) Disorders of the Blood. Churchill 
Livingstone, Edinburgh.
Thomson, A.E.R., Vaughan-Smith, S., Peel, W.E. and
Wetherley-Mein, G. ( 1985 ) The intrinsic radiosensitivity 
of lymphocytes in chronic lymphocytic leukaemia, 
quantitatively determined independently of cell death rate 
factors. International Journal of Radiation Biology, 48, 
943-961
Thorpe, P. E. , . Mason, D. W. , Brown, A.N.F., Sirnmonds, S.J., 
Ross, W.C.J., Cumber, A.J. and Forrester, J.A. ( 1982 )
Selective killing of malignant cells in a leukaemic rat 
bone marrow .using an antibody-ricin conjugate. Nature, 
297, 594-598
Tobias, C.A. , Blakely, E.A. , Ngo, F.Q.H. and Yang, T.C.H.
( 1980 ) The repair-misrepair model of cell survival. In
Radiation Biology in Cancer Research. E. Meyn and H.R. 
Withers ( Eds ) Raven Press, New York, pp 195-230
Tournade, M.F., Lemerle, J., Sarrasin, D. and Valayer, J.
( 1986 ) Tumours of the kidney. In Cancer in Children.
P.A. Voute, A. Barrett, H.J.G. Bloom, J. Lemerle and M.K. 
Neidhardt (Eds). Springer Verlag, Berlin, pp 252-264
259
Travis, E.L., Vojnovic, B., Davies, E.E. and Hirst, D.G. ( 
1979 ) A plethysmographic method for measuring function in 
locally irradiated mouse lung. British Journal of 
Radiology, 52, 67-74
Travis, E.L., Parkins, C.S., Down, J.D., Fowler, J.F. and 
Thames, H.D. ( 1983 ) Repair of mouse lung between
multiple small doses of x-rays. Radiation Research, 94, 
326-339
Travis, E.L. and Tucker, S.L. ( 1986 ) The relationship 
between functional assays of radiation response in the 
lung and target cell depletion. British Journal of Cancer, 
53, Suppl. VII, 304-319 . •
Travis, E.L., Peters, L.J., McNeil, J., Thames, H.D. and 
Karolis, C. ( 1986 ) Effect of dose rate on total body
irradiation: lethality and pathological findings.
Radiotherapy and Oncology, 4, 341-351
Treleaven, J., Gibson, F., Ugelstaad, J, Rembaum, A.,
Philip, T., Caine, G. and Kemshead, J.T. ( 1984 ) Removal 
of neuroblastoma cells from bone marrow with monoclonal 
antibodies conjugated to magnetic microspheres. Lancet, 
ii, 70-73
Treuner, J. , Feurg, U. , Niethamrner, D. , Muller-Schaunberg, 
W., Meinke, J., Eibach, E., Dopper, R., Klingbul, T. and
Grumbech, S.T. ( 1984 ) Scintigraphic imaging of
neuroblastoma with 131-1 meta-iodobensylguanidine. Lancet, 
i, 333-335
260
Trigg, M.E., Billing, R. , Sondel, P.M., Exten, R., Hong,
R. , Bozdech, M.J., Horowitz, S. D. , Finlay, J.L., Moen, R. ,
Longo, W., Erikson, C. and Peterson, A. ( 1985 ) Clinical 
trial depleting T-lymphocytes from donor marrow for- 
matched and mismatched allogeneic bone marrow transplants. 
Cancer Treatment Reports, 69, 377-386
Trott, K.R. and Kummermehr, J. ( 1985 ) What is known 
about tumour proliferation rates to choose between
accelerated fractionation or hyperfractionation.
Radiotherapy and Oncology, 3, 1-9
Tsoi, M.S., Storb, R., Santos, E. and Thomas, E.D. ( 1983
) Anti-host cytotoxic cells in patients with acute
graft-versus-host disease after HLA-identica'l marrow
grafting. Transplantation Proceedings, 15, 1484-1486
Tsuda, T., Obara, M., Hirano, H., Gotoh, S., Kubomura, S., 
Higashi, K., Kuroiwa, A., Nakagawara, A., Nagahara, N. and 
Shimizu, K. ( 1987 ) Analysis of N-myc amplification in
relation to disease stage and histological types in human 
neuroblastomas. Cancer, 60, 820-826
Turesson, I. and Notter, G. ( 1979 a ) The response of pig 
skin to single and fractionated high dose-rate and 
continuous low dose-rate 137-CsJ -irradiation. - I: 
Experimental design and results.
International Journal of Radiation Oncology Biology and 
Physics, 5, 835-844
Turesson, I. and Notter, G. ( 1979 b ) The response of
261
pi# skin to sin#l.e and f raok.i ona ked high dose-rate and 
continuous low dose-rate 137-Cs ^-irradiation. - III:
Re-evaluation of the CRE system and the TDF system
according to the present findings.
International Journal of Radiation Oncology Biology and 
Physics, 5, 1773-1779
Turesson, I. and Notter, G. ( 1988 ) Accelerated versus 
conventional fractionation. Acta Oncologica, 27, 169-179
Uhr, J.W. ( 1984 ) Immunotoxins: harnessing natures
poisons. Journal of Immunology, 133, i-x
United Nations Scientific Cornittee on the Effects of
Atomic Radiation ( UNSCEAR ) ( 1982 ) Report to the
General Assembly with annexes. Ionising Radiation: Sources 
and biological effects. United Nations. New York
Vallera, D.A. , Soderling, C.C.B.,. Carlson, G.J and 
Kersey, J.H. ( 1981 ) Bone marrow transplantation across 
major histocompatibility barriers in mice.
Transplantation, 31, 218-222
van der Kogel, A.J. and Barendsen, G.W. ( 1974 ) Late
effects of spinal cord irradiation with 300 kV x-rays and
15 Mev neutrons. British Journal of Radiology, 47, 393-398
van Dyk, J. ( 1987 ) Dosimetry for total body irradiation. 
Radiotherapy and Oncology, 9, 107-118
van Dyk, J., Keane, T.J., Kan, S., Rider, W.D. and Fryer, 
C.J.H. ( 1981 ) Radiation pneumonitis following large
single dose irradiation: a re-evaluation based on absolute
262
dose to lung. International Journal of Radiation Oncology
Biology and Physics, 7, 461-467
Vaughan, A.T.M., Bateman, W.J. and Fisher, D.R. ( 1982 )
The in vivo fate of 211-At labelled monoclonal antibody 
with known specificity in a murine system. International 
Journal of Radiation Oncology Biology and Physics, 8, 
1943-1946
Vaughan, A.T.M., Bradwell, A.R., Dykes, P. and Anderson, 
P. ( 1986 ) Illusions of cell killing using radiolabelled 
antibodies. Lancet, i, 1492-1493
Vaughan, A.T.M., Anderson, P., Dykes, P. and Bradwell, 
A.R. ( 1987 ) Limitations to killing of tumours using
radiolabelled antibodies. British Journal -of Radiology, 
60, 567-578
Vegnesa, V., Withers, H.R. , Thames, H.D. and Mason, K. ( 
1985 ) Multifraction radiation response of mouse lung. 
International Journal of Radiation Biology, 47, 413-422
Verdonck, L.F., Dekker, A.W., Vendrick, P.J., van Kemper, 
M.L., Schornagel, J.H., Rosenberg-Arska, M. and de Gast,
G.C. ( 1987 )Intensive cytoreductive therapy followed by
autologous bone marrow transplantation for patients with 
hematologic malignancies or solid tumours. Cancer, 60, 
289-295
Voute, P.A., de Kraker, J. and Burgers, J.M.V. ( 1986 )
Tumours of the sympathetic nervous system - neuroblastoma, 
ganglioneuroma and phaeochromocytoma. In Cancer in
263
Children. P.A. Voute, A. Barrebt, H.J.G. Bloom, J. Lemerle 
and M.K. Neidhardt (Eds). Springer Verlag, Berlin. pp 
238-251
Walker, G, Daniel, M. and Makes, G. ( 1984 ) Proliferative 
response of human venous endothelial cells to medium
conditioned by human tumour cells. Cell Biology 
International Reports, 8, 731-738
Wara, W.M. , Phillips, T. C. , Marg'olis, L.W. and Smith, V. ( 
1973 ) Radiation pneumonitis: a new approach to the
derivation of time-dose factors. Cancer, 32, 547-552
Ward, B.G., Mather, S.J., Shepherd, J.H., Britton, K.E., 
Granowska, M. and Slevin, M.L. ( 1986 ) Prospects for
antibody-targeted radiotherapy, .of cancer. Lancet, ii, 
580-581
Ward, B.G., Lowe, D.G. and Shepherd, J.H. ( 1987 )
Patterns of expression of a tumour associated antigen, 
defined by the monoclonal antibody HMFG2, in human 
epithelial overian carcinaom: comparison with expression 
of the HMFG1, AUA1 and F36/22 antigens. Cancer, 60, 
787-793
Ward, J.F. ( 1986 ) Mechanisms of DNA repair and their 
potential modification for radiotherapy. International 
Journal of Radiation Oncology Biology and Physics, 12, 
1027-1032
Waterfield, M.D., Scrace, G.T., Whittle, N., Stroobant, P, 
Johnson, A., Wasteson, A., Westermark, B., Heldin, C.H.,
264
Huang, J.S. and Deuel, T.F. ( 1983 ) Platelet derived
growth factor is structurally related to the putative 
transforming protein p28 sis of simian sarcoma virus.
Nature, 304, 35-39
Watson, E.R., Hainan, K.E., Dische, S., Saunders, M.I., 
Cade, I.S., McEwan, J.B., Wiernik, G., Perrins, D.J.D. and 
Sutherland, I. ( 1978 ) Hyperbaric oxygen and
radiotherapy: a Medical Research Council trial in
carcinoma of the cervix. British Journal of Radiology, 51, 
879-887
Weichselbaum, R.R., Nove, B.S. and Little, J.B. ( 1980 )
X-ray sensitivity of human tumour cells in vitro.
International Journal of Radiation Oncology Biology and 
Physics, 6, 437-440
Weichselbaum, R.R., Greenberger, J.S., Schmidt, A.,
Karpas, A., Moloney, W.C. and Little, J.B. ( 1981 ) In
vitro radiosensitivity of human leukaemia cell lines.
Radiology, 139, 485-487
Weichselbaum, R.R. and Little, J.B., ( 1982 a ) The
differential response of human tumours to fractionated
radiation may be due to a post-irradiation repair process.
British Journal of Cancer, 46, 532-537
Weichselbaum, R.R. and Little, J.B. ( 1982 b ) Resistance
in some human tumour cells conferred in vitro by repair of 
potentially lethal x-ray damage. Radiology, 145, 511-513
Weichselbaum, R.R., Schmidt, A. and Little, J.B. ( 1982 )
265
Cei.JuJ.ar repair factors influenoing radiocurabil ity of 
human malignant tumours. British Journal of Cancer, 45, 
10-16
Weiden, P.L., Fluornoy, N., Thomas, E.D., Prentice, R., 
Fefer, A., Buckner, C.D. and Storb, R. ( 1979 )
Antileukaemic effect of graft-versus-host disease in human 
recipients of allogeneic marrow grafts. New England 
Journal of Medicine, 300, 1068-1073
Weiden, P.L. , Fluornoy, N., Sanders, J.E., Sullivan, K.M. 
and Thomas, E.D.( 1981 ) Antileukaemic effect of
graft-versus-host disease contributes to improved survival 
after allogeneic marrow transplantation. Transplantation 
Proceedings, 13, 248-251
West, G.W., Weischelbaum, R.R. and Little, J.B. ( 1980 )
Limited penetration of methotrexate into human 
osteosarcoma spheroids as a proposed model for solid 
tumour resistance to adjuvant chemotherapy. Cancer 
Research, 40, 3665-3668
Wheldon, T.E., Michalowski, A.S. and Kirk, J. ( 1982 ) The 
effect of irradiation on function in self-renewing normal 
tissues with differing proliferative organisation. British 
Journal of Radiology, 55, 759-766
Wheldon, T.E., Livingstone, A., Wilson, L., O ’Donoghue, J. 
and Gregor, A. ( 1985a ) The radiosensitivity of human
neuroblastoma cells estimated from regrowth curves of 
multicellular tumour spheroids. British Journal of 
Radiology, 58, 661-664
266
Wheldon, T.E., O'Donoghue, J. and Gregor ( 1985b ) Optimal 
scheduling of total body irradiation in the treatment of 
Ewing's sarcoma. International Journal of Radiation 
Oncology Biology and Physics, 11, 1569-1570
Wheldon, T.E. and Michalowski, A.S. ( 1986 ) Alternative
models for the proliferative structure of normal tissues 
and their response to irradiation. British Journal of 
Cancer, 53, Suppl. VII, 383-385
Wheldon, T.E. and O'Donoghue, J.A. ( 1986 ) Prospects for 
antibody-targeted radiotherapy of cancer. Lancet, ii, 579
Wheldon, T.E., Wilson, L., Livingstone, A., Russell, J. , 
O'Donoghue, J. and Gregor, A. ( 1986 ) Radiation studies 
on multice'l lular tumour spheroids derived from human 
neuroblastoma: absence of sparing effect of dose
fractionation. European Journal of .Cancer and Clinical 
Oncology, 22, 563-566
Wheldon, TiE., Berry, I., O'Donoghue, J.A., Gregor, A., 
Hann, I.M., Livingstone, A., Russell, J. and Wilson, L. ( 
1987 ) The effect on human neuroblastoma spheroids of
fractionated radiation regimes calculated to be equivalent 
to late responding normal tissues. European Journal of 
Cancer and Clinical Oncology, 23, 855-860
Wheldon, T.E., O'Donoghue, J.A., Hilditch, T.E. and 
Barrett, A. ( 1988 ) Strategies for systemic radiotherapy 
of mi crornetastases using antibody-targeted 131-1.
Radiotherapy and Oncology, 11, 133-142
267
Wheldon, T.E. and Amin, A.E. ( 1968 ) The linear-quadratic 
mode1. British Journa1 of Rad i o1ogy, 61, 700-702
White, A. and Hornsey, S. ( 1978 ) Radiation damage to the 
rat spinal cord: the effect of single and fractionated 
doses of x-rays. British Journal of Radiology, 51, 515-523
Williams, M.V. and Denekamp, J. ( 1983 ) Sequential
functional testing of radiation-induced renal damage in 
the mouse. Radiation Research, 94, 305-317
Williams, M.V., Denekamp, J. and Fowler, J.F. ( 1985 ) A 
review of iX /jg ratios for experimental tumours: 
implications for clinical studies of altered 
fractionation. International Journal of Radiation Oncology 
Biology and Physics, 11, 87-96
Willoughby, M. L.N. ( 1986 ) Acute non-lymphoblastic
leukaemia. In Cancer in Children. P.'A. Voute, A. Barrett,
H.J.G. Bloom, J. Lemerle and M.K. Neidhardt (Eds). 
Springer Verlag, Berlin, p p  119-130
Wilson, G.D., McNally, N.J., Dische, S. and Bennett, M.B.
( 1988 ) Cell proliferation in human tumours measured by 
in-vivo labelling with bromodeoxyuridine. British Journal 
of Radiology, 61, 419-422
Winsor, C.P. ( 1932 ) The Gomperts curve as a growth 
curve. Proceedings of the National Academy of Sciences of 
the USA, 18, 1-7
Winston, B.M. , Ellis, F. and Hall, E.J. ( 1969 ) The
2 6 8
Oxford NSD calculator for clinical use. Clinical
Rad i o1ogy, 20, 8-11
Withers, H.R. and Elkind, M.M. ( 1970 ) Microcolony 
survival assay for cells of mouse intestinal mucosa 
exposed to radiations. International Journal of Radiation 
Biology, 17, 261-267
Withers, H.R., Peters, L.J. and Kogelnik, H.D. ( 1980 ) 
the pathobiology of late effects of radiation. In 
Radiation Biology in Cancer Research. E. Meyn and H.R. 
Withers ( Eds ) Raven Press, New York, pp 439-448
Withers, H.R., Thames, H.D. and Peters, L.J. ( 1983 ) A
new isoeffect curve for change in dose per fraction. 
Radiotherapy and Oncology, 1, 187-191
Woods, W.G., Dehner, L.P., Nesbit, M.E., Krivitt, W., 
Coccia, P.F., Ramsay, N.K.C., Kim, T.H. and Kersey, J.H. ( 
1980 ) Fatal veno-occlusive disease of the liver following 
high dose chemotherapy, irradiation and bone marrow 
transplantation. American Journal of Medicine, 68, 285-290
Yiu, C.Y., Baker, L. and Clark, C.G. ( 1987 ) Human
monoclonal antibodies to colonic antigens. British Journal 
of Cancer, 56, 512 ( abstract )
Young, J.L. and Miller, R.W. ( 1975 ) Incidence of
malignant tumours in US children. Journal of Pediatrics, 
86, 254-258
Yunis, E.J., Awdeh, Z., Kaum, D. and Alper, C.A. ( 1983 ) 
The MHC in human bone marrow allotransplantation. Clinical
269
Haematology, 12, 641-680
Zeman, E.M. and Bedford, J.S. ( 1984 ) Changes in early 
and late effects with dose-per-fraction: alpha, beta, 
redistribution and repair. International Journal of
Radiation Oncology Biology and Physics, 10, 1039-1047
270
PUBLISHED PAPERS ARISING FROM THESIS
1. Wheldon, T.E., O'Donoghue, J. and Gregor, A. ( 1985 ) 
Optimal scheduling of total body irradiation in the 
treatment of Ewing's Sarcoma. International Journal of 
Radiation Oncology Biology and Physics, (letter), 11, 
1569-1570
2. O'Donoghue, J.A. ( 1986 ) Agreement of quadratic and 
CRE models in predicting the late effects of continuous 
low dose-rate radiotherapy. British Journal of Radiology, 
(letter), 59, 193-194
3. Wheldon, T.E., O'Donoghue, J. , Gregor, A., Livingstone, 
A. and Wilson, L. ( 1986 ) Radiobiological . considerations 
in the treatment of neuroblastoma by total body 
irradiation. Radiotherapy and Oncology, 6, 317-326
4. O'Donoghue, J.A. ( 1986 ) Fractionated versus low
dose-rate total body irradiation : Radiobiological
considerations in the selection of regimes. Radiotherapy 
and Oncology 7, 241-247
5. Wheldon, T.E. and O'Donoghue, J.A. ( 1986 ) Prospects 
for antibody-targeted radiotherapy of cancer. Lancet 
(letter), (ii ), 579
6. O'Donoghue, J.A., Wheldon, T.E. and Gregor, A. ( 1987 ) 
The implications of in-vitro radiation survival curves for 
the optimal scheduling of total body irradiation with bone 
marrow rescue in the treatment of leukaemia. British 
Journal of Radiology, 60, 279-283
271
7. Wheldon, T.E., Berry, I., O ’Donoghue, J.A., Gregor, A., 
Harm, I.M., Livingstone, A. and Wilson, L. ( 1987 ) The
effects on human neuroblastoma spheroids of fractionated 
radiation regimes calculated to be equivalent for damage 
to late responding normal organs. European Journal of 
Cancer and Clinical Oncology, 23, 855-860
8. Wheldon, T.E., O ’Donoghue, J.A. and Gregor, A. ( 1987 ) 
Radiobiological rationale for hyperfractionation in the 
radiotherapy of neuroblastoma. International Journal of 
Radiation Oncology Biology and Physics, 13, 1430 (letter)
9. O ’Donoghue, J.A. and Wheldon, T.E. ( 1988 ) Predicted 
allowable doses to normal organs for biologically targeted 
radiotherapy. British Journal of Radiology, 61,‘264-266
10. Wheldon, T.E., O ’Donoghue, J.A., Hilditch, T.E. and 
Barrett, A. ( 1988 ) Strategies for systemic radiothrapy 
of micrometastases using antibody-targeted 131-1. 
Radiotherapy and Oncology, 11, 133-142
11. 0 ’Donoghue, J.A. ( 1988 ) The linear-quadratic model. 
British Journal of Radiology, 61, 700 (letter)
